{"title": "PDF", "author": "PDF", "url": "www.irsjd.org/media/upload/domain_3/pdf/irsjd-2021-memoria_1658309472.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "id": "PDF", "license": "PDF", "body": "PDF", "comments": "PDF", "commentsbody": "PDF", "raw_text": "PDF", "text": "2021ANNUAL  \nSCIENTIFIC REPORTAll images property of  Institut de Recerca \nSant Joan de D\u00e9u, Parc Sanitari Sant \nJoan de D\u00e9u & Institut de Neuroci\u00e8ncies \u00b7 \nUniversitat de BarcelonaSanta Rosa, 39-57\n08950 Esplugues de Llobregat \u00b7 Barcelona\nT. 936 00 97 51\ninfo@irsjd.org\nwww.irsjd.org\nThe cover has been designed by  \nAndrea Casanueva and Giselle Esparza  \nof the Escola d\u2019Art Pau Gargallo within  \nthe Talent Creatiu i Empresa program3 INSTITUT  DE RECERCA  \nIndex\n1  FOREWORD  4\nGov\nernance and structures  5\nGlobal number\ns 2021  7\nGlobal number\ns 2015-2021  8\nInstitutional awar\nds 9\n2  STAFF  10\nResear\nch staff  11\n3  PROJEC\nTS AND CLINICAL \nTRIALS  1\n2\nNew projects  13\nActive pr\nojects  13\nNew clinic\nal trials and \nobservational studies  14\nActive clinic\nal trials and \nobservational studies  14\n4  SCIENTIFIC \nPRODUCTION \nAND RESULTS  15\nScientific public\nations  16\nHighest impact f\nactor journals  17\nPat\nents, utility models  \nand spin-offs  28\nDoctor\nal Theses  30\n5  CORE \nFACILITIES  33\n6\n  TRAINING,\n \nCOMMUNICATION AND \nPARTICIPATION  3\n5\nSeminars  36\nT\nraining programme  37\nCommunication and public \nengagement  38\nNe\nws 39\n7\n  SCIENTIFIC \nACTIVITY  41\n7.1. Medicine and pediatric \nscience ar\nea 42\n7.1.1.  Neur\noscience  42\nApplied resear\nch in \nneuromuscular diseases  43\nPediatric neur\nometabolism: \nneural communication \nmechanisms and \npersonalized therapies  43\nNeonatal br\nain 45Neuropsy chology  45\nCognitiv\ne neuroscience  46\nAttention, P\nerception and \nLanguage Acquisition (APAL)  47\nResearch in child and adol\nescent \nmental health  48\n7.1.2.  Adaptive r\nesponse, \nmetabolism and \nimmunobiology  50\nMet\nabolic endocrinology  51\nMetabolic diseases of paediatric \norigin  51\nMol\necular biology and gene \nregulation of adipose tissue \nand its pathologies  52\nNeonatol\nogy research group  53\nPharmacol\nogical targets in \ninflammation and metabolic \ndiseases  54\nStudy of diseases due t\no immune \ndysfunction in pediatrics \n(GEMDIP)  54\nInf\nectious diseases  \nand microbiome  55\nGut microbiot\na 56\nEnvironment and c\nomplications in \npregnancy  57\nCar\ndiovascular diseases in \ndevelopment  58\nImmune and r\nespiratory \ndysfunction in the critical child  59\nAll\nergic diseases in childhood and \nadolescence  60\n7.1.3.  Paediatric c\nancer  61\nTr\nanslational genomics  62\nSarc\nomas and histiocytosis  62\nTherapy de\nvelopment in pediatric \noncology  63\nP\naediatric leukaemia and \nhaematopoiesis  64\nMol\necular pharmacology and \nexperimental therapies  65\nPaediatric c\nancer epigenetics  66\n7.1.4.  Precision medicine  \nin r\nare diseases  67\nMetabolic and mit\nochondrial \nmedicine  68\nNeur\nogenetics and molecular \nmedicine  69\nHuman mol\necular genetics I  70\nHuman molecular genetics II  71\nGenomics for the diagnosis of \nr\nare diseases  72Diagnostic and ther apeutic  \nimaging  72\n7.1.5.  Applied clinical r\nesearch  73\nInfluence of the envir\nonment on \nchild and adolescent welfare  74\nHospital dentis\ntry and periodontal \nmedicine  74\nP\naediatric ophthalmology  75\nResearch in nur\nsing 75\n7.2. Mental health ar\nea 77\n7.2.1.  Mental health and society  77\nEpidemiology of ment\nal disorders \nand aging  78\nHealth technol\nogy assessment \nin primary care and mental \nhealth (PRISMA)  78\nPsy\nchological research group on \nfibromyalgia and chronic pain \n(AGORA group)  79\n7.2.2.  Scientific bases and \napproach t\no mental disorders  81\nEtiopathogenesis and tr\neatment \nof severe mental disorders \n(MERITT)  82\nCer\nebral imprints of gender, \ndevelopment and pathology  82\n7.3. Tr\nansversal program  84\n7.3.1.  Health technol\nogies \nand innovation  84\nMedical t\nechnologies: \nbioinformatics and \nbiomedical signals  85\nMedical t\nechnologies:  \ncomputer graphics: serious \ngames and gamification  85\nMedical t\nechnologies: \nbiomaterials and tissue \nengineering  86\nMedic\nal technologies:  \nanalysis for rehabilitation  86\nMedical t\nechnologies: \ninstrumentation and eHealth  87\nMedical t\nechnologies:  \nrobotics and vision  87\nMedical t\nechnologies:  \nbiomechanics  88\nP\natients engagement in research  89\nInnov\nation in health technologies  901 \nFOREWORD\nGovernance and structures\nGlobal numbers 2021\nGlobal numbers 2015-2021\nInstitutional awards5 ANNUAL SCIENTIFIC REPORT 2021 \u00b7  INSTITUT  DE RECERCA  \n FOREWORD\nGovernance  \nand structures\nDr. Manuel del Castillo Rey \nGeneral Manager, SJD Barcelona \nChildren\u2019s Hospital \nDr. Joan Gu\u00e0rdia Olmos\nUniversitat de Barcelona \nDr. Jordi Garcia Fernandez\nVice-Rector for Research, Universitat \nde Barcelona \nDr. Jordi Berenguer Sau\nVice-rector for Knowledge Transfer \nand Innovation, Universitat Polit\u00e8cnica \nde Catalunya \nDr. Climent Molins Borrell\nVocal, Vicerector de Transfer\u00e8ncia, \nInnovaci\u00f3 i Emprenedoria de la \nUniversitat Polit\u00e8cnica de Catalunya. \nMr. Enric Mangas i Monge \nDirector, Parc Sanitari Sant Joan de \nD\u00e9u \nDr. Jaume P\u00e9rez Payarols \nDirector of Innovation and Research, \nSJD Barcelona Children\u2019s Hospital \nDr. Josep Maria Haro Abad \nDirector of Research, Innovation  \nand Teaching, Parc Sanitari Sant Joan \nde D\u00e9u \nDr. Francesc Palau Mart\u00ednez \nDirector, Institut de Recerca  \nSant Joan de D\u00e9u \nMr. Emili Bargall\u00f3 Angerri \nDirector, Fundaci\u00f3 de Recerca  \nSant Joan de D\u00e9u Dr. Francesc Palau Mart\u00ednez Director\nInstitut de Recerca Sant Joan de D\u00e9u \nDr. Rafael Artuch Iriberri \nDeputy director, Institut de Recerca \nSant Joan de D\u00e9u \nDr. Jaume P\u00e9rez Payarols \nDirector of Innovation and Research, \nSJD Barcelona Children\u2019s Hospital \nDr. Alexandre Perera Lluna \nDirector, Centre de Recerca en \nEnginyeria Biom\u00e8dica (CREB). \nUniversitat Polit\u00e8cnica de Catalunya \nDr. Mar\u00e7al Pastor-Anglada \nDirector, Institut de Biomedicina - \nUniversitat de Barcelona (IBUB) \nDr. Carles Escera i Mic\u00f3 \nDelegate, Institut de Neuroci\u00e8ncies - \nUniversitat de Barcelona (UBNeuro) \nDr. Josep M. Haro Abad \nDirector of Research, Innovation and \nTeaching, Parc Sanitari Sant Joan  \nde D\u00e9u \nMr. Emili Bargall\u00f3 Angerri \nDirector, Fundaci\u00f3 de Recerca  \nSant Joan de D\u00e9u \nMs. J\u00falia Ribot Ballabriga \nScientic Manager, Institut de Recerca \nSant Joan de D\u00e9u Dr. Montserrat Vendrell i Rius \nPartner. Alta Life Sciences (President) \nDr. Antonio L. Andreu \nScientific director. European \ninfrastructure for translational \nmedicine (EATRIS) \nDra. Maria A. Blasco \nDirector. Centro Nacional de \nInvestigaciones Oncol\u00f3gicas (CNIO) \nDr. Jordi Cam\u00ed i Morell \nDirector. Parc de Reserca Biom\u00e8dica \nde Barcelona & Fundaci\u00f3 Pasqual \nMaragall \nDra. Marisol Montolio \nScientific director. Duchenne Parent \nProject, Spain \nDr. Michael B. King \nLondon\u2019s Global University. Division  \nof Psychiatry \nDr. Carlos Rodr\u00edguez-Galindo \nExecutive vice-president. St. Jude \nChildren\u2019s Research \nDra. Maithe Tauber \nHospital Paediatric endocrinologist. \nInstitut des Sciences du Cerveau,  \nde la Cognition et du Comportement \nde Toulouse (ISC3T) Board of trustees Executive Committee Institut  \nde Recerca Sant Joan de D\u00e9uScientic Advisory Council 6 ANNUAL SCIENTIFIC REPORT 2021 \u00b7  INSTITUT  DE RECERCA  \n FOREWORD\nPresident \nDr. Rafael Artuch Iriberri\nVocals\nDra. Esther Camprod\u00f3n Rosanas\nDr. Carles Escera Mic\u00f3\nDra. Maria Dolores G\u00f3mez Roig\nDra. Lourdes Ib\u00e1\u00f1ez Toda \nDr. Josep Jim\u00e9nez Chillar\u00f3n\nDra. Cinzia Lavarino\nDr. \u00c1ngel Montero Carcaboso\nDra. Carmen Mu\u00f1oz Almagro\nDr. Francesc Palau Mart\u00ednez\nDr. Mar\u00e7al Pastor Anglada\nDra. Al\u00edcia Casals Gelp\u00ed\nDra. Cecilia Jim\u00e9nez-Mallebrera\nDr. Cristian Launes Montana\nDr. Oriol Mart\u00edn Sol\u00e9\nDra. Alexandra Avgustinova\nDra. Marta Camprub\u00ed Camprub\u00ed  \nDra. Roser Pue\nyo Benito\nSecretary\nMs. J\u00falia Ribot BallabrigaResearch commission\n7 ANNUAL SCIENTIFIC REPORT 2021 \u00b7  INSTITUT  DE RECERCA  \n FOREWORD\nGlobal numbers \n2021\n720\nRESEARCH STAFF\n 59 Group leader\n 280  Staff researcher\n 78 Postdoc - associate researcher\n 120  PhD student\n 183  Assistant researcher & Technician506\nPROJECTS\n 87 Competitive autonomic projects\n 236  Competitive national projects\n 58 Competitive international projects\n 10 Non competitive autonomic projects\n 100  Non competitive national projects\n 15 Non competitive international projects\n645\nPUBLICATIONS\nArticles & reviews published in scholarly \njournals indexed in the ISI Web of Science\n 3581  Impact Factor\n 64%  Publications in first quartile\n 5.55  Mean impact factor\n 52%  Articles with main contributing authors13\nBUDGET *\n 68%  Private\n 32%  Public321\nCLINICAL TRIALS  \n& OBSERVATIONAL STUDIES\n 26 Phase I\n 70 Phase II\n 115  Phase III\n 8 Phase IV\n 11 Other clinical trial \n 91 Observational studies\n* Thousand of euros8 ANNUAL SCIENTIFIC REPORT 2021 \u00b7  INSTITUT  DE RECERCA  \n FOREWORD\nGlobal numbers  \n2015-2021\nRESEARCH STAFF\nBUDGET *321 2015\n483 2016\n552 2017\n514 2018\n594 2019\n688 2020\n720 2020\n2015 5.2\n2016 6.5\n2017 7.9\n2018 9.2CLINICAL TRIALS  \n& OBSERVATIONAL STUDIES\n2015 132\n2016 124\n2017 140\n2018 147\n2019 222\n2020 231\n2021 321PROJECTS\n2015 251\n2016 303\n2017 360\n2018 378\n2019 470\n2020 486\n2021 506\nPUBLICATIONS\n2015 302 (1138 IF)\n2017 401 (1909 IF)\n2018 443 (2287 IF)\n2019 469 (2260 IF)\n2020 590 (2652 IF)\n2021 645 (3581 IF)2016 376 (1442 IF)2019 10.9\n2020 12\n2021 13\n* Thousand of euros9 ANNUAL SCIENTIFIC REPORT 2021 \u00b7  INSTITUT  DE RECERCA  \n FOREWORD\nInstitutional \nawards\nHRS4R Human Resources Strategy \nfor Researchers \nhttps://www.irsjd.org/en/research/\nhrs4r-hr-excellence-research/ \nFundaci\u00f3 de Recerca Sant Joan de \nD\u00e9u is awarded with the logo \u201cHR \nExcellence in research\u201d since 2018. \nThus, it has acquired a commitment to \nimplement the European Charter for \nResearchers and the Code of Conduct \nfor the Recruitment of Researchers \n(Charter & Code) in their policies and \npractices. The Institut de Recerca Sant Joan \nde D\u00e9u (IRSJD) has been recognized \nby the board of trustees of the \nInstitution for Research Centers in \nCatalonia (CERCA) as a CERCA centre \nin 2020\nThis award involves the development \nof a frontier research aimed at the \nscientific and economic impact and \nthe improvement of the social and \nindividual wellbeing.\nThe CERCA institute focuses its \nactions on the contribution to the \ninternational presence of research \ncentres from Catalonia and to \npromote the cooperation and scientific \nexchange with the top centres and \nuniversities worldwide. Moreover, it \npromotes the adoption of joint policies \nin research management, scientific \ndevelopment and knowledge transfer. \nAlso, it works in order to increase \nand ease knowledge transfer in the \nbusiness sector and general public, \npromoting the involvement of these \nagents in the field of research.HRS4R award CERCA\n1 FOREWORD\nGovernance and structures\nGlobal numbers 2020\nGlobal numbers 2020-2015\nInstitutional awards\n2 \nSTAFF\nResearch staff11 ANNUAL SCIENTIFIC REPORT 2021 \u00b7  INSTITUT  DE RECERCA  \n STAFF\nResearch  \nstaff\n720\n240 men (33%)\n31 men (53%)\n115 men (41%)\n31 men (26%)24 men (31%)\n40 men (22%)59 GROUP LEADER\n280 STAFF RESEARCHER\n120 PhD STUDENT78 POSTDOC ASSOCIATE RESEARCHER\n183 TECHNICIAN AND ASISTANT RESEARCHERS479 women (67%)\n28 women (47%)\n165 women (59%)\n89 women (74%)54 women (69%)\n143 women (78%)\n1 FOREWORD\nGovernance and structures\nGlobal numbers 2020\nGlobal numbers 2020-2015\nInstitutional awards\n3 \nPROJECTS \nAND CLINICAL \nTRIALS\nNew projects\nActive projects\nNew clinical trials and observational studies\nActive clinical trials and observational studies13 ANNUAL SCIENTIFIC REPORT 2021 \u00b7  INSTITUT  DE RECERCA  \n PROJECTS AND  \nCLINICAL TRIALS\nNew  \nprojectsActive  \nprojects\n145\n116 comptetitive\n19 comptetitive\n64 comptetitive\n33 comptetitive23 INTERNATIONAL\n86 NATIONAL\n36 AUTONOMIC29 non comptetitive\n4 non comptetitive\n22 non comptetitive\n3 non comptetitive506\n381 comptetitive\n58 comptetitive\n236 comptetitive\n87 comptetitive73 INTERNATIONAL\n336 NATIONAL\n97 AUTONOMIC125 non comptetitive\n15 non comptetitive\n100 non comptetitive\n10 non comptetitive\n14 ANNUAL SCIENTIFIC REPORT 2021 \u00b7  INSTITUT  DE RECERCA  \n PROJECTS AND  \nCLINICAL TRIALS\nNew clinical trials \nand observational \nstudiesActive clinical trials \nand observational \nstudies\n60\nCLINICAL TRIALS AND OBSERVATIONAL STUDIES  \nBY RESEARCH AREA\n12NEUROLOGY  \n(11 clinical trials & 1 observational study)\n12ONCOLOGY \n(12 clinical trials)\n5DERMATOLOGY \n(5 clinical trials)\n4CLINICAL HAEMATOLOGY  \n(3 clinical trials & 1 observational study)\n4ALLERGY AND CLINICAL IMMUNOLOGY  \n(2 clinical trials & 2 observational studies)\n7GASTROENTEROLOGY, HEPATOLOGY AND NUTRITION  \n(5 clinical trials & 2 observational studies)\n3EMERGENCY ROOM AND INTERNAL MEDICINE  \n(3 clinical trials)\n1NEPHROLOGY \n(1 clinical trial)\n2ORTHOPAEDICS AND TRAUMATOLOGY  \n(1 clinical trial & 1 observational study)\n1PSYCHIATRY AND PSYCHOLOGY  \n(1 clinical trial)\n2PNEUMOLOGY \n(2 clinical trials)\n5RHEUMATOLOGY  \n(5 clinical trials)\n2INTENSIVE CARE UNIT\n(2 clinical trials)\n7INFECTIOUS DISEASES  \n(7 clinical trials)\n1NURSERY \n(1 observational study)\n230\nCLINICAL TRIALS AND OBSERVATIONAL STUDIES  \nBY RESEARCH AREA\n3PAEDIATRICS  \n(2 clinical trials & 1 observational study)\n63NEUROLOGY  \n(48 clinical trials & 15 observational studies)\n16CLINICAL HAEMATOLOGY \n(8 clinical trials & 8 observational studies)\n12EMERGENCY ROOM AND INTERNAL MEDICINE\n(9 clinial trials & 3 observational studies)\n20DERMATOLOGY\n(17 clinical trials & 3 observational studies)\n13ALLERGY AND CLINICAL IMMUNOLOGY\n(6 clinical trials & 7 observational studies)\n11GASTROENTEROLOGY, HEPATOLOGY AND NUTRITION\n(6 clinical trials & 5 observational studies)\n8GYNAECOLOGY AND OBSTETRICS\n(3 clinical trials & 5 observational studies)\n5NEONATOLOGY\n(5 clinical trials)\n3ANAESTHESIA\n(3 observational studies)\n8NEPHROLOGY\n(4 clinical trials & 4 observational studies)\n6PSYCHIATRY AND PSYCHOLOGY\n(5 clinical trials & 1 observational study)\n5ORTHOPAEDICS AND TRAUMATOLOGY\n(21 clinical trial & 3 observational studies)\n6PNEUMOLOGY\n(4 clinical trials & 2 observational studies)\n3OPHTHALMOLOGY\n(2 clinical trials & 1 observational sutdy)\n26RHEUMATOLOGY\n(20 clinical trials & 6 observational studies)\n4CARDIOLOGY\n(3 clinical trials & 1 observational study)\n2REHABILITATION AND PHYSICAL MEDICINE\n(2 clinial trials)\n14ENDOCRINOLOGY\n(4 clincal trials & 10 observational studies)\n3DIGESTIVE MEDICINE\n(1 clinical trial & 2 observational studies)\n24INFECTIOUS DISEASES\n(21 clinical traials & 3 observational studies)\n5INTENSIVE CARE UNIT\n(5 clinical trials)\nPhase IOther type\nPhase IV\nPhase II\nPhase III923\n14\n32\nPhase IOther type\nPhase IV\nPhase II\nPhase III26 118\n70\n115Clinical Trials by Type Clinical Trials by Type1 FOREWORD\nGovernance and structures\nGlobal numbers 2020\nGlobal numbers 2020-2015\nInstitutional awards\n4 \nSCIENTIFIC \nPRODUCTION  \nAND RESULTS\nScientific publications\nHighest impact factor journals\nPatents, utility models and spin-offs\nDoctoral Theses16 ANNUAL SCIENTIFIC REPORT 2021 \u00b7  INSTITUT  DE RECERCA  \nSCIENTIFIC PRODUCTION  \nAND RESULTS\nScientific \npublications\nOutput Total IF Mean IF %Q1 %D1\nArticle 662 3440 5.5 64% 22%\nEditorial material 7 25 3.6 0% 0%\nLetter 22 173 7.9 68% 21%\nReview 23 141 6.1 83% 0%\nOthers 40 365 9.1 72% 25%\nTotal 714 4143 5.8 64% 14%\n17 ANNUAL SCIENTIFIC REPORT 2021 \u00b7  INSTITUT  DE RECERCA  \nSCIENTIFIC PRODUCTION  \nAND RESULTS\nHighest impact \nfactor journals\nJournal Total articles IF\nNATURE MEDICINE 1 53,440\nLANCET ONCOLOGY 1 41,316\nEUROPEAN HEART JOURNAL 1 29,983\nCIRCULATION 1 29,690\nLANCET PSYCHIATRY 1 26,481\nLANCET INFECTIOUS DISEASES 1 25,071\nLANCET DIGITAL HEALTH 1 24,519\nJOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY 1 24,093\nLANCET PUBLIC HEALTH 1 21,648\nJAMA PSYCHIATRY 1 21,596\nLANCET HAEMATOL 1 18,959\nADVANCED FUNCTIONAL MATERIALS 2 18,808\nSCIENCE TRANSLATIONAL MEDICINE 2 17,992\nCIRCULATION RESEARCH 1 17,367\nACTA NEUROPATHOLOGICA 2 17,088\nNATURE COMMUNICATIONS 8 14,919\nJOURNAL OF CLINICAL INVESTIGATION 1 14,808\nBIOACTIVE MATERIALS 1 14,593\nJOURNAL OF EXPERIMENTAL MEDICINE 1 14,307\nJOURNAL FOR IMMUNOTHERAPY OF CANCER 1 13,751\nNATURE METABOLISM 1 13,511\nNATURE PROTOCOLS 1 13,491\nALLERGY 1 13,146\nCLIN PSYCHOL REV 1 12,792\nNEURO-ONCOLOGY 1 12,300\nOPHTHALMOLOGY 2 12,079\nTRENDS IN MOLECULAR MEDICINE 1 11,951\nTHERANOSTICS 1 11,556\nMOLECULAR THERAPY 2 11,454\nCLINICAL GASTROENTEROLOGY AND HEPATOLOGY 1 11,382ORIGINALS ARTICLES IN FIST DECIL\nNumber of orginal articles in first decil journals: 13518 ANNUAL SCIENTIFIC REPORT 2021 \u00b7  INSTITUT  DE RECERCA  \nSCIENTIFIC PRODUCTION  \nAND RESULTS\nJournal Total articles IF\nLANCET CHILD & ADOLESCENT HEALTH 2 11,288\nADDITIVE MANUFACTURING 2 10,998\nARTHRITIS & RHEUMATOLOGY 2 10,995\nAGE AGEING 2 10,668\nJ NANOBIOTECHNOL 2 10,435\nANNALS OF NEUROLOGY 1 10,422\nMOVEMENT DISORDERS 1 10,338\nAMERICAN JOURNAL OF HEMATOLOGY 1 10,047\nNEUROLOGY 2 9,910\nONCOGENE 1 9,867\nBRITISH JOURNAL OF PSYCHIATRY 1 9,319\nCLINICAL INFECTIOUS DISEASES 5 9,079\nNEUROSCIENCE AND BIOBEHAVIORAL REVIEWS 1 8,989\nGENETICS IN MEDICINE 2 8,822\nBMC MEDICINE 1 8,775\nADV NUTR 1 8,701\nMETABOLISM-CLINICAL AND EXPERIMENTAL 1 8,697\nAMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY 1 8,661\nCLINICAL CHEMISTRY 1 8,327\nJOURNAL OF NEUROINFLAMMATION 1 8,322\nCAN MED ASSOC J 1 8,262\nENVIRON POLLUT 1 8,071\nJOURNAL OF MATERIALS SCIENCE & TECHNOLOGY 1 8,067\nPLOS BIOLOGY 1 8,029\nJOURNAL OF PATHOLOGY 1 7,996\nMODERN PATHOLOGY 1 7,842\nPSYCHOLOGICAL MEDICINE 1 7,723\nOBSTET GYNECOL 1 7,661\nJOURNAL OF MEDICINAL CHEMISTRY 1 7,446\nULTRASOUND IN OBSTETRICS & GYNECOLOGY 3 7,299\nINTERNATIONAL JOURNAL OF EPIDEMIOLOGY 1 7,196Highest impact \nfactor journals19 ANNUAL SCIENTIFIC REPORT 2021 \u00b7  INSTITUT  DE RECERCA  \nSCIENTIFIC PRODUCTION  \nAND RESULTS\nJournal Total articles IF\nJOURNAL OF SPORT AND HEALTH SCIENCE 1 7,179\nPEDIATRICS 2 7,125\nANALYTICAL CHEMISTRY 2 6,986\nINT J BIOL MACROMOL 1 6,953\nBIOINFORMATICS 1 6,937\nEPIDEMIOLOGY AND PSYCHIATRIC SCIENCES 4 6,892\nPLOS PATHOG 1 6,823\nOSTEOARTHR CARTILAGE 1 6,576\nNEUROIMAGE 1 6,556\nBJOG-INT J OBSTET GY 1 6,531\nBIOMEDICINE & PHARMACOTHERAPY 1 6,530\nDEPRESSION AND ANXIETY 3 6,505\nDEV COGN NEUROS-NETH 1 6,464\nINTERNATIONAL JOURNAL OF BEHAVIORAL NUTRITION AND PHYSICAL ACTIVITY 2 6,457\nPEDIATRIC ALLERGY AND IMMUNOLOGY 2 6,377\nANTIOXIDANTS 2 6,312\nEUROSURVEILLANCE 1 6,307\nTRAVEL MEDICINE AND INFECTIOUS DISEASE 1 6,211\nJ INTERPERS VIOLENCE 1 6,144\nJOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL \nSCIENCES1 6,053\nBMJ GLOBAL HEALTH 2 5,558\nJOURNAL OF MEDICAL INTERNET RESEARCH 2 5,428\nMED SCI SPORT EXER 1 5,411\nBRITISH JOURNAL OF GENERAL PRACTICE 1 5,386\nAUTISM RESEARCH 1 5,216\nDEVELOPMENTAL SCIENCE 1 5,131\nEUROPEAN CHILD & ADOLESCENT PSYCHIATRY 2 4,785\nJOURNAL OF PEDIATRICS 6 4,406\nNEONATOLOGY 1 4,035\nARCH PHYS MED REHAB 1 3,966\nJOURNAL OF ADVANCED NURSING 1 3,187Highest impact \nfactor journals20 ANNUAL SCIENTIFIC REPORT 2021 \u00b7  INSTITUT  DE RECERCA  \nSCIENTIFIC PRODUCTION  \nAND RESULTS\nOriginal article Journal IF Program\nRives S. CAR T cells in CNS-relapsed leukaemia: one step forward. \nLANCET HAEMATOL. 2021;8(10):675-676. IF:18,959. (Q1).LANCET HAEMATOL 18,959 Paediatric Cancer\nRib\u00f3 S, S\u00e1nchez D, Mart\u00ednez L, Garc\u00eda I, Ramon M, Tondo M et al. \nIncreasing breast milk betaine modulates Akkermansia abundance \nin mammalian neonates  and improves long-term metabolic health. \nSCI TRANSL MED. 2021;13(587):322IF:17,992. (Q1).SCIENCE  \nTRANSLATIONAL \nMEDICINE17,992 Adaptive Response, \nMetabolism and \nImmunobiology\nDemontis D, Walters RK, Rajagopal VM, Waldman ID, Grove J, Als TD \net al. Risk variants and polygenic architecture of disruptive behavior \ndisorders in the  context of attention-deficit/hyperactivity disorder. \nNat Commun. 2021;12(1):576-576. IF:14,919. (Q1).NATURE \nCOMMUNICATIONS14,919 Precission Medicine \nin Rare Diseases\nEsteve A, Anton J, Pino RM, S\u00e1nchez J, Fumad\u00f3 V, Fortuny C et al. \nSimilarities and differences between the immunopathogenesis of \nCOVID-19-related  pediatric multisystem inflammatory syndrome \nand Kawasaki disease. J CLIN INVEST. 2021;131(6):1-28. IF:14,808. \n(Q1).JOURNAL OF CLINICAL \nINVESTIGATION14,808 Neuroscience\nEsteve A, Anton J, Pino RM, S\u00e1nchez J, Fumad\u00f3 V, Fortuny C et al. \nSimilarities and differences between the immunopathogenesis of \nCOVID-19-related  pediatric multisystem inflammatory syndrome \nand Kawasaki disease. J CLIN INVEST. 2021;131(6):1-28. IF:14,808. \n(Q1).JOURNAL OF CLINICAL \nINVESTIGATION14,808 Adaptive Response, \nMetabolism and \nImmunobiology\nGarc\u00eda C, C\u00f3rdoba LC, Buxadera J, Marquina A, Jim\u00e9nez E, Ginebra \nMP et al. Zn-Mg and Zn-Cu alloys for stenting applications: From \nnanoscale mechanical  characterization to in vitro degradation and \nbiocompatibility. Bioact Mater. 2021;6(12):4430-4446. IF:14,593. (Q1).BIOACTIVE MATERIALS 14,593 Health Technologies \nand Innovation\nRuperez CH, Ferrer G, Cervera A, Florit L, Guitart M, Garrabou \nG et al. Meteorin-like/Meteorin-\u00df protects heart against cardiac \ndysfunction. J Exp Med. 2021;218(5):20201206IF:14,307. (Q1).JOURNAL OF \nEXPERIMENTAL  \nMEDICINE14,307 Adaptive Response, \nMetabolism and \nImmunobiology\nTornin J, Labay C, Tampieri F, Ginebra MP, Canal C. Evaluation of \nthe effects of cold atmospheric plasma and plasma-treated liquids \nin  cancer cell cultures. Nat Protoc. 2021;16(6):2826-2850. IF:13,491. \n(Q1).NATURE PROTOCOLS 13,491 Health Technologies \nand Innovation\nPfaar O, Agache I, Bonini M, Brough HA, Chivato T, Del Giacco SR \net al. COVID-19 pandemic and allergen immunotherapy-an EAACI \nsurvey. Allergy. 2021;76(11):3504-3516. IF:13,146. (Q1).ALLERGY 13,146 Adaptive Response, \nMetabolism and \nImmunobiology\nPalomer FX, Aguilar D, Garc\u00eda R, Nistal JF, Vazquez M. Sirtuins: \nTo Be or Not To Be in Diabetic Cardiomyopathy. Trends Mol Med. \n2021;27(6):554-571. IF:11,951. (Q1).TRENDS IN MOLECULAR \nMEDICINE11,951 Adaptive Response, \nMetabolism and \nImmunobiology\nVictor C, Schieber R, Raymond Y, S\u00e9gry B, Sabat\u00e9 R, \nKolandaivelu K et al. Solvent-cast direct-writing as a fabrication \nstrategy for radiopaque stents. Additive Manufacturing. \n2021;48(B):102392IF:10,998. (Q1).ADDITIVE \nMANUFACTURING10,998 Health Technologies \nand InnovationOriginals articles D1 with IRSJD main contribution: 82Highest impact \nfactor journals21 ANNUAL SCIENTIFIC REPORT 2021 \u00b7  INSTITUT  DE RECERCA  \nSCIENTIFIC PRODUCTION  \nAND RESULTS\nOriginal article Journal IF Program\nRaymond Y, Thorel E, Liversain M, Riveiro A, Pou J, Ginebra M. \n3D printing non-cylindrical strands: Morphological and structural \nimplications. Additive Manufacturing. 2021;46IF:10,998. (Q1).ADDITIVE \nMANUFACTURING10,998 Health Technologies \nand Innovation\nSmith L, Shin JI, Ghayda RA, Hijaz A, Sheyn D, Pope R et al. \nPhysical multimorbidity and incident urinary incontinence among \ncommunity-dwelling  adults aged =50 years: findings from a \nprospective analysis of the Irish  Longitudinal Study on Ageing. Age \nAgeing. 2021;50(6):2038-2046. IF:10,668. (Q1).AGE AGEING 10,668 Mental Health and \nSociety\nFelez M, Haro JM, Stubbs B, Smith L, Koyanagi A. Moving more, \nageing happy: findings from six low- and middle-income countries. \nAge Ageing. 2021;50(2):488-497. IF:10,668. (Q1).AGE AGEING 10,668 Mental Health and \nSociety\nTristan A, Borr\u00e0s E, Molero M, Wassenberg T, Peters T, Verbeek MM \net al. Novel Protein Biomarkers of Monoamine Metabolism Defects \nCorrelate with Disease  Severity. Mov Disord. 2021;36(3):690-703. \nIF:10,338. (Q1).MOVEMENT  \nDISORDERS10,338 Precission Medicine \nin Rare Diseases\nTristan A, Borr\u00e0s E, Molero M, Wassenberg T, Peters T, Verbeek MM \net al. Novel Protein Biomarkers of Monoamine Metabolism Defects \nCorrelate with Disease  Severity. Mov Disord. 2021;36(3):690-703. \nIF:10,338. (Q1).MOVEMENT  \nDISORDERS10,338 Neuroscience\nOliver L, Martin H, Reyes L, Noureddine F, Ada Cavalcanti E, \nGinebra MP et al. An Engineered Biomimetic Peptide Regulates Cell \nBehavior by Synergistic Integrin and  Growth Factor Signaling. ADV \nHEALTHC MATER. 2021;10(7)IF:9,933. (Q1).ADVANCED  \nHEALTHCARE  \nMATERIALS9,933 Health Technologies \nand Innovation\nNatera D, Foley AR, Dom\u00ednguez C, Ortez CI, Jain M, Mebrahtu A \net al. Association of Initial Maximal Motor Ability With Long-term \nFunctional Outcome in  Patients With COL6-Related Dystrophies. \nNeurology. 2021;96(10):1413-1424. IF:9,910. (Q1).NEUROLOGY 9,910 Neuroscience\nCrovetto F, F\u00e0tima B, Llurba E, Pascal R, Larroya M, Trilla C et \nal. Impact of Severe Acute Respiratory Syndrome Coronavirus 2 \nInfection on Pregnancy Outcomes: A Population-based Study. Clin \nInfect Dis. 2021;73(10):1768-1775. IF:9,079. (Q1).CLINICAL INFECTIOUS \nDISEASES9,079 Neuroscience\nBrotons P, Launes C, Buetas E, Fumad\u00f3 V, Henares D, Fern\u00e1ndez \nde Sevilla M et al. Susceptibility to Severe Acute Respiratory \nSyndrome Coronavirus 2 Infection Among  Children and Adults: \nA Seroprevalence Study of Family Households in the Barcelona  \nMetropolitan Region, Spain. Clin Infect Dis. 2021;72(12):1-8. IF:9,079. \n(Q1).CLINICAL INFECTIOUS \nDISEASES9,079 Neuroscience\nGarc\u00eda L, L\u00d3pez M, Gonc\u00c9 A, Fortuny C, Salazar L, Valenzuela BI \net al. Cardiac Remodeling and Hypertension in HIV-Uninfected \nInfants Exposed in utero to  Antiretroviral Therapy. Clin Infect Dis. \n2021;73(4):586-593. IF:9,079. (Q1).CLINICAL INFECTIOUS \nDISEASES9,079 Adaptive Response, \nMetabolism and \nImmunobiology\nCrovetto F, F\u00e0tima B, Llurba E, Pascal R, Larroya M, Trilla C et \nal. Impact of Severe Acute Respiratory Syndrome Coronavirus 2 \nInfection on Pregnancy Outcomes: A Population-based Study. Clin \nInfect Dis. 2021;73(10):1768-1775. IF:9,079. (Q1).CLINICAL INFECTIOUS \nDISEASES9,079 Adaptive Response, \nMetabolism and \nImmunobiologyHighest impact \nfactor journals22 ANNUAL SCIENTIFIC REPORT 2021 \u00b7  INSTITUT  DE RECERCA  \nSCIENTIFIC PRODUCTION  \nAND RESULTS\nOriginal article Journal IF Program\nBrotons P, Launes C, Buetas E, Fumad\u00f3 V, Henares D, Fern\u00e1ndez \nde Sevilla M et al. Susceptibility to Severe Acute Respiratory \nSyndrome Coronavirus 2 Infection Among  Children and Adults: \nA Seroprevalence Study of Family Households in the Barcelona  \nMetropolitan Region, Spain. Clin Infect Dis. 2021;72(12):1-8. IF:9,079. \n(Q1).CLINICAL INFECTIOUS \nDISEASES9,079 Adaptive Response, \nMetabolism and \nImmunobiology\nSerra M, Radua J, Soriano C, G\u00f3mez A, Porta D, Marta R et al. \nStructural brain correlates in major depression, anxiety disorders \nand  post-traumatic stress disorder: A voxel-based morphometry \nmeta-analysis. Neurosci Biobehav Rev. 2021;129:269-281. IF:8,989. \n(Q1).NEUROSCIENCE  \nAND BIOBEHAVIORAL \nREVIEWS8,989 Neuroscience\nDoba\u00f1o C, Alonso S, Fern\u00e1ndez de Sevilla M, Vidal M, Jim\u00e9nez A, \nPons G et al. Antibody conversion rates to SARS-CoV-2 in saliva from \nchildren attending summer  schools in Barcelona, Spain. BMC Med. \n2021;19(1):309-309. IF:8,775. (Q1).BMC MEDICINE 8,775 Neuroscience\nDoba\u00f1o C, Alonso S, Fern\u00e1ndez de Sevilla M, Vidal M, Jim\u00e9nez A, \nPons G et al. Antibody conversion rates to SARS-CoV-2 in saliva from \nchildren attending summer  schools in Barcelona, Spain. BMC Med. \n2021;19(1):309-309. IF:8,775. (Q1).BMC MEDICINE 8,775 Adaptive Response, \nMetabolism and \nImmunobiology\nDoba\u00f1o C, Alonso S, Fern\u00e1ndez de Sevilla M, Vidal M, Jim\u00e9nez A, \nPons G et al. Antibody conversion rates to SARS-CoV-2 in saliva from \nchildren attending summer  schools in Barcelona, Spain. BMC Med. \n2021;19(1):309-309. IF:8,775. (Q1).BMC MEDICINE 8,775 Health Technologies \nand Innovation\nZarei M, Aguilar D, Palomer FX, Vazquez M. Revealing the role of \nperoxisome proliferator-activated receptor \u00df/d in nonalcoholic  fatty \nliver disease. METABOLISM. 2021;114:154342-154342. IF:8,697. (Q1).METABOLISM-CLINICAL \nAND EXPERIMENTAL8,697 Adaptive Response, \nMetabolism and \nImmunobiology\nPeguero A, Herraiz I, Perales A, Melchor JC, Melchor I, Marcos \nB et al. Placental growth factor testing in the management \nof late preterm preeclampsia  without severe features: a \nmulticenter, randomized, controlled trial. Am J Obstet Gynecol. \n2021;225(3):308IF:8,661. (Q1).AMERICAN JOURNAL  \nOF OBSTETRICS  \nAND GYNECOLOGY8,661 Adaptive Response, \nMetabolism and \nImmunobiology\nTrifunov S, Paredes AJ, Badosa MC, Codina A, Montoya C, Ruiz E \net al. Circulating Cell-Free Mitochondrial DNA in Cerebrospinal \nFluid as a Biomarker for  Mitochondrial Diseases. Clin Chem. \n2021;67(8):1113-1121. IF:8,327. (Q1).CLINICAL CHEMISTRY 8,327 Paediatric Cancer\nTrifunov S, Paredes AJ, Badosa MC, Codina A, Montoya C, Ruiz E \net al. Circulating Cell-Free Mitochondrial DNA in Cerebrospinal \nFluid as a Biomarker for  Mitochondrial Diseases. Clin Chem. \n2021;67(8):1113-1121. IF:8,327. (Q1).CLINICAL CHEMISTRY 8,327 Precission Medicine \nin Rare Diseases\nTrifunov S, Paredes AJ, Badosa MC, Codina A, Montoya C, Ruiz E \net al. Circulating Cell-Free Mitochondrial DNA in Cerebrospinal \nFluid as a Biomarker for  Mitochondrial Diseases. Clin Chem. \n2021;67(8):1113-1121. IF:8,327. (Q1).CLINICAL CHEMISTRY 8,327 NeuroscienceHighest impact \nfactor journals23 ANNUAL SCIENTIFIC REPORT 2021 \u00b7  INSTITUT  DE RECERCA  \nSCIENTIFIC PRODUCTION  \nAND RESULTS\nOriginal article Journal IF Program\nAfia AB, Vila \u00c8, MacDowell KS, Ormazabal A, Leza JC, Haro JM \net al. Kynurenine pathway in post-mortem prefrontal cortex and \ncerebellum in  schizophrenia: relationship with monoamines and \nsymptomatology. J Neuroinflammation. 2021;18(1):198-198. IF:8,322. \n(Q1).JOURNAL OF \nNEUROINFLAMMATION8,322 Mental Health and \nSociety\nAfia AB, Vila \u00c8, MacDowell KS, Ormazabal A, Leza JC, Haro JM \net al. Kynurenine pathway in post-mortem prefrontal cortex and \ncerebellum in  schizophrenia: relationship with monoamines and \nsymptomatology. J Neuroinflammation. 2021;18(1):198-198. IF:8,322. \n(Q1).JOURNAL OF \nNEUROINFLAMMATION8,322 Scientific base and \napproach to mental \ndisorders\nAfia AB, Vila \u00c8, MacDowell KS, Ormazabal A, Leza JC, Haro JM \net al. Kynurenine pathway in post-mortem prefrontal cortex and \ncerebellum in  schizophrenia: relationship with monoamines and \nsymptomatology. J Neuroinflammation. 2021;18(1):198-198. IF:8,322. \n(Q1).JOURNAL OF \nNEUROINFLAMMATION8,322 Precission Medicine \nin Rare Diseases\nFern\u00e1ndez D, Gin\u00e9 I, Liu I, Yucel R, Nai M, Morena M et al. Are \nenvironmental pollution and biodiversity levels associated to the \nspread and  mortality of COVID-19? A four-month global analysis. \nEnviron Pollut. 2021;271:116326-116326. IF:8,071. (Q1).ENVIRON POLLUT 8,071 Mental Health and \nSociety\nRodriguez A, Punset M, Calero JA, Javier F, Rup\u00e9rez E, Manero JM. \nPowder metallurgy with space holder for porous titanium implants: \nA review. J Mater Sci Technol. 2021;76:129-149. IF:8,067. (Q1).JOURNAL OF  \nMATERIALS SCIENCE  \n& TECHNOLOGY8,067 Health Technologies \nand Innovation\nFerrer G, Guitart M, Ruperez CH, MATIAS R, F\u00e0tima B, Villarroya F \net al. The protective effect of fibroblast growth factor-21 in alcoholic \ncardiomyopathy: a  role in protecting cardiac mitochondrial function. \nJ Pathol. 2021;253(2):198-208. IF:7,996. (Q1).JOURNAL OF  \nPATHOLOGY7,996 Adaptive Response, \nMetabolism and \nImmunobiology\nJacob L, Smith L, McDermott D, Haro JM, Stickley A, Koyanagi A. \nRelationship between sexual orientation and psychotic experiences \nin the general  population in England. Psychol Med. 2021;51(1):138-\n146. IF:7,723. (Q1).PSYCHOLOGICAL \nMEDICINE7,723 Mental Health and \nSociety\nGonzalez E, Grau L, Ferrero SI, Hernandez A, Rebollo M, G\u00f3mez M \net al. Pessary for Management of Cervical Varices Complicating \nPregnancy. Obstet Gynecol. 2021;138(3):482-486. IF:7,661. (Q1).OBSTET GYNECOL 7,661 Precission Medicine \nin Rare Diseases\nGonzalez E, Grau L, Ferrero SI, Hernandez A, Rebollo M, G\u00f3mez M \net al. Pessary for Management of Cervical Varices Complicating \nPregnancy. Obstet Gynecol. 2021;138(3):482-486. IF:7,661. (Q1).OBSTET GYNECOL 7,661 Adaptive Response, \nMetabolism and \nImmunobiology\nBasurto D, Fuenzalida J, Martinez RJ, Russo FM, Pertierra A, \nMartinez JM et al. Intrapulmonary artery Doppler to predict \nmortality and morbidity in fetuses with  mild or moderate left-\nsided congenital diaphragmatic hernia. Ultrasound Obstet Gynecol. \n2021;58(4):590-596. IF:7,299. (Q1).ULTRASOUND IN \nOBSTETRICS & \nGYNECOLOGY7,299 Adaptive Response, \nMetabolism and \nImmunobiologyHighest impact \nfactor journals24 ANNUAL SCIENTIFIC REPORT 2021 \u00b7  INSTITUT  DE RECERCA  \nSCIENTIFIC PRODUCTION  \nAND RESULTS\nOriginal article Journal IF Program\nMeler E, Mazarico E, Eixarch E, Gonzalez A, Peguero A, Martinez J et \nal. Ten-year experience of protocol-based management of small-\nfor-gestational-age  fetuses: perinatal outcome in late-pregnancy \ncases diagnosed after 32 weeks. Ultrasound Obstet Gynecol. \n2021;57(1):62-69. IF:7,299. (Q1).ULTRASOUND IN \nOBSTETRICS & \nGYNECOLOGY7,299 Adaptive Response, \nMetabolism and \nImmunobiology\nS\u00e1nchez A, Forero CG, Wu YT, Gin\u00e9 I, Prina M, De La Fuente J et \nal. Development of a common scale for measuring healthy ageing \nacross the world: results  from the ATHLOS consortium. INT J \nEPIDEMIOL. 2021;50(3):880-892. IF:7,196. (Q1).INTERNATIONAL \nJOURNAL OF \nEPIDEMIOLOGY7,196 Mental Health and \nSociety\nBarranco M, Sol\u00e0 P, Picart S, Kanaan S, Fonollosa J, Perera A. \nmWISE: An Algorithm for Context-Based Annotation of Liquid \nChromatography-Mass  Spectrometry Features through Diffusion in \nGraphs. Anal Chem. 2021;93(31):10772-10778. IF:6,986. (Q1).ANALYTICAL  \nCHEMISTRY6,986 Health Technologies \nand Innovation\nTampieri F, Ginebra MP, Canal C. Quantification of Plasma-Produced \nHydroxyl Radicals in Solution and their Dependence  on the pH. Anal \nChem. 2021;93(8):3666-3670. IF:6,986. (Q1).ANALYTICAL  \nCHEMISTRY6,986 Health Technologies \nand Innovation\nBabeli I, Puiggal\u00ed A, Roa JJ, Ginebra MP, Jos\u00e9 M, Alem\u00e1n C. \nHybrid conducting alginate-based hydrogel for hydrogen peroxide \ndetection from  enzymatic oxidation of lactate. Int J Biol Macromol. \n2021;193(Pt B):1237-1248. IF:6,953. (Q1).INT J BIOL MACROMOL 6,953 Health Technologies \nand Innovation\nPicart S, Thompson WK, Buil A, Perera A. The effect of statistical \nnormalization on network propagation scores. Bioinformatics. \n2021;37(6):845-852. IF:6,937. (Q1).BIOINFORMATICS 6,937 Health Technologies \nand Innovation\nAyuso JL, Morillo D, Haro JM, Olaya B, Lara E, Maria M. Changes in \ndepression and suicidal ideation under severe lockdown restrictions  \nduring the first wave of the COVID-19 pandemic in Spain: a \nlongitudinal study in the  general population. Epidemiol Psychiatr \nSci. 2021;30:1-27. IF:6,892. (Q1).EPIDEMIOLOGY  \nAND PSYCHIATRIC \nSCIENCES6,892 Mental Health and \nSociety\nCabello M, Rico LA, Martinez JC, S\u00e1nchez A, Caballero FF, Borges \nG et al. The role of ageing in the wish to be dead: disentangling age, \nperiod and cohort  effects in suicide ideation in European population. \nEpidemiol Psychiatr Sci. 2021;30IF:6,892. (Q1).EPIDEMIOLOGY  \nAND PSYCHIATRIC \nSCIENCES6,892 Mental Health and \nSociety\nJacob L, Kostev K. Osteoarthritis and the incidence of fracture in the \nUnited Kingdom: a retrospective  cohort study of 258,696 patients. \nOsteoarthritis Cartilage. 2021;29(2):215-221. IF:6,576. (Q1).OSTEOARTHR  \nCARTILAGE6,576 Mental Health and \nSociety\nGorina N, Kurkela J, H\u00e4m\u00e4l\u00e4inen J, Astikainen P, Escera C. Neural \ngenerators of the frequency-following response elicited to stimuli of \nlow and  high frequency: A magnetoencephalographic (MEG) study. \nNeuroimage. 2021;231:117866-117866. IF:6,556. (Q1).NEUROIMAGE 6,556 Neuroscience\nPeguero A, Fernandez L, Mazarico E, Benitez L, Gonzalez A, Youssef \nL et al. Added prognostic value of longitudinal changes of angiogenic \nfactors in early-onset  severe pre-eclampsia: a prospective cohort \nstudy. BJOG. 2021;128(2):158-165. IF:6,531. (Q1).BJOG-INT  \nJ OBSTET GY6,531 Adaptive Response, \nMetabolism and \nImmunobiologyHighest impact \nfactor journals25 ANNUAL SCIENTIFIC REPORT 2021 \u00b7  INSTITUT  DE RECERCA  \nSCIENTIFIC PRODUCTION  \nAND RESULTS\nOriginal article Journal IF Program\nParedes AJ, Cesar S, Montero R, Latre C, Genov\u00e9s J, Martorell \nL et al. Plasma idebenone monitoring in Friedreich's ataxia \npatients during a long-term  follow-up. Biomed Pharmacother. \n2021;143:112143-112143. IF:6,530. (Q1).BIOMEDICINE & \nPHARMACOTHERAPY6,530 Precission Medicine \nin Rare Diseases\nParedes AJ, Cesar S, Montero R, Latre C, Genov\u00e9s J, Martorell \nL et al. Plasma idebenone monitoring in Friedreich's ataxia \npatients during a long-term  follow-up. Biomed Pharmacother. \n2021;143:112143-112143. IF:6,530. (Q1).BIOMEDICINE & \nPHARMACOTHERAPY6,530 Neuroscience\nParedes AJ, Cesar S, Montero R, Latre C, Genov\u00e9s J, Martorell \nL et al. Plasma idebenone monitoring in Friedreich's ataxia \npatients during a long-term  follow-up. Biomed Pharmacother. \n2021;143:112143-112143. IF:6,530. (Q1).BIOMEDICINE & \nPHARMACOTHERAPY6,530 Adaptive Response, \nMetabolism and \nImmunobiology\nCollado C, Navarro M, Adri\u00e1n A, L\u00f3pez Y, Garcia J, Montero \nJ. Effectiveness of mindfulness-based stress reduction and \nattachment-based compassion  therapy for the treatment \nof depressive, anxious, and adjustment disorders in mental  \nhealth settings: A randomized controlled trial. Depress Anxiety. \n2021;38(11):1138-1151. IF:6,505. (Q1).DEPRESSION AND \nANXIETY6,505 Mental Health and \nSociety\nSmith L, Il J, McDermott D, Jacob L, Barnett Y, L\u00f3pez GF et al. \nAssociation between food insecurity and depression among older \nadults from low- and  middle-income countries. Depress Anxiety. \n2021;38(4):439-446. IF:6,505. (Q1).DEPRESSION AND \nANXIETY6,505 Mental Health and \nSociety\nFelez M, Bort J, Ma R, Romano E, Faires M, Stubbs B et al. Light-\nintensity physical activity and mental ill health: a systematic review \nof  observational studies in the general population. Int J Behav Nutr \nPhys Act. 2021;18(1):123-123. IF:6,457. (Q1).INTERNATIONAL \nJOURNAL OF  \nBEHAVIORAL NUTRITION \nAND PHYSICAL ACTIVITY6,457 Mental Health and \nSociety\nAznar I, Zabaleta E, Casajuana M, S\u00e1nchez A, Parody E, Bol\u00edbar B et \nal. Cost-effectiveness analysis of a multiple health behaviour change \nintervention in  people aged between 45 and 75 years: a cluster \nrandomized controlled trial in  primary care (EIRA study). Int J Behav \nNutr Phys Act. 2021;18(1):88-88. IF:6,457. (Q1).INTERNATIONAL \nJOURNAL OF  \nBEHAVIORAL NUTRITION \nAND PHYSICAL ACTIVITY6,457 Mental Health and \nSociety\nGarc\u00eda A, Buendia M, Dey\u00e0 A, Lozano J, Serrano M, Van Den A RYM \net al. Novel PGM3 compound heterozygous variants with IgE-related \ndermatitis, lymphopenia,  without syndromic features. Pediatr \nAllergy Immunol. 2021;32(3):566-575. IF:6,377. (Q1).PEDIATRIC ALLERGY  \nAND IMMUNOLOGY6,377 Precission Medicine \nin Rare Diseases\nGarc\u00eda A, Buendia M, Dey\u00e0 A, Lozano J, Serrano M, Van Den A RYM \net al. Novel PGM3 compound heterozygous variants with IgE-related \ndermatitis, lymphopenia,  without syndromic features. Pediatr \nAllergy Immunol. 2021;32(3):566-575. IF:6,377. (Q1).PEDIATRIC ALLERGY  \nAND IMMUNOLOGY6,377 Adaptive Response, \nMetabolism and \nImmunobiology\nGarc\u00eda R, Gavalda A, Villarroya F, Marfany G, Mirra S. \nOverexpression of CERKL Protects Retinal Pigment Epithelium \nMitochondria from  Oxidative Stress Effects. Antioxidants (Basel). \n2021;10(12):2018IF:6,312. (Q1).ANTIOXIDANTS 6,312 Precission Medicine \nin Rare DiseasesHighest impact \nfactor journals26 ANNUAL SCIENTIFIC REPORT 2021 \u00b7  INSTITUT  DE RECERCA  \nSCIENTIFIC PRODUCTION  \nAND RESULTS\nOriginal article Journal IF Program\nGarc\u00eda R, Gavalda A, Villarroya F, Marfany G, Mirra S. \nOverexpression of CERKL Protects Retinal Pigment Epithelium \nMitochondria from  Oxidative Stress Effects. Antioxidants (Basel). \n2021;10(12):2018IF:6,312. (Q1).ANTIOXIDANTS 6,312 Adaptive Response, \nMetabolism and \nImmunobiology\nDur\u00e1n Fern\u00e1ndez C, Rodr\u00edguez J, L\u00f3pez M, Hadley S, Cavia M, Mu\u00f1iz \nP et al. Effects of Hypothermia and Allopurinol on Oxidative Status \nin a Rat Model of Hypoxic  Ischemic Encephalopathy. Antioxidants \n(Basel). 2021;10(10):1523IF:6,312. (Q1).ANTIOXIDANTS 6,312 Adaptive Response, \nMetabolism and \nImmunobiology\nLamonja N, Dacosta R, L\u00f3pez J, Prades L, Roig F, Castells A \net al. Sex-Specific Protective Effects of APOE e2 on Cognitive \nPerformance. J Gerontol A Biol Sci Med Sci. 2021;76(1):41-49. \nIF:6,053. (Q1).JOURNALS OF \nGERONTOLOGY SERIES \nA-BIOLOGICAL SCIENCES \nAND MEDICAL SCIENCES6,053 Neuroscience\nMartinez A, Bekele D, Sabariego C, Rodr\u00edguez \u00c1, Vorstenbosch \nE, Rico LA et al. The Structural and Intercultural Competence for \nEpidemiological Studies (SICES)  guidelines: a 22-item checklist. \nBMJ Glob Health. 2021;6(4)IF:5,558. (Q1).BMJ GLOBAL HEALTH 5,558 Mental Health and \nSociety\nSantini ZI, Koyanagi A, Stewart S, Perry BD, Marmot M, Koushede \nV. Cumulative risk of compromised physical, mental and social \nhealth in adulthood due  to family conflict and financial strain \nduring childhood: a retrospective analysis  based on survey data \nrepresentative of 19 European countries. BMJ Glob Health. 2021;6(3)\nIF:5,558. (Q1).BMJ GLOBAL HEALTH 5,558 Mental Health and \nSociety\nTyrovolas S, Gin\u00e9 I, Fern\u00e1ndez D, Morena M, Koyanagi A, Janko M et \nal. Estimating the COVID-19 Spread Through Real-time Population \nMobility Patterns:  Surveillance in Low- and Middle-Income \nCountries. J Med Internet Res. 2021;23(6)IF:5,428. (Q1).JOURNAL OF MEDICAL \nINTERNET RESEARCH5,428 Mental Health and \nSociety\nCastells A, Roig F, Lamonja N, Tor\u00e1n P, Pera G, Montero P et al. Sex \nMatters in the Association between Physical Activity and Fitness with \nCognition. Med Sci Sports Exerc. 2021;53(6):1252-1259. IF:5,411. \n(Q1).MED SCI SPORT EXER 5,411 Neuroscience\nPijuan J, Ortigoza JD, Juan Jairo Ortiz G, Alcal\u00e1 A, Calvo MJ, \nCubells M et al. PLXNA2 and LRRC40 as candidate genes in autism \nspectrum disorder. AUTISM RES. 2021;14(6):1088-1100. IF:5,216. \n(Q1).AUTISM RESEARCH 5,216 Precission Medicine \nin Rare Diseases\nFran\u00e7ois C, Rodriguez A, Teixid\u00f3 M, Agut T, Bosch L. Attenuated \nbrain responses to speech sounds in moderate preterm infants at \nterm age. Dev Sci. 2021;24(1):12990IF:5,131. (Q1).DEVELOPMENTAL \nSCIENCE5,131 Neuroscience\nCalderon M, Vila R, Dolz M, Butjosa A, Barajas A, del Cacho N et al. \nDepressive symptoms and their relationship with negative and other \npsychotic  symptoms in early onset psychosis. Eur Child Adolesc \nPsychiatry. 2021;30(9):1383-1390. IF:4,785. (Q1).EUROPEAN CHILD  \n& ADOLESCENT \nPSYCHIATRY4,785 Mental Health and \nSociety\nCalderon M, Vila R, Dolz M, Butjosa A, Barajas A, del Cacho N et al. \nDepressive symptoms and their relationship with negative and other \npsychotic  symptoms in early onset psychosis. Eur Child Adolesc \nPsychiatry. 2021;30(9):1383-1390. IF:4,785. (Q1).EUROPEAN CHILD  \n& ADOLESCENT \nPSYCHIATRY4,785 Scientific base and \napproach to mental \ndisordersHighest impact \nfactor journals27 ANNUAL SCIENTIFIC REPORT 2021 \u00b7  INSTITUT  DE RECERCA  \nSCIENTIFIC PRODUCTION  \nAND RESULTS\nOriginal article Journal IF Program\nZer\u00f3n MF, Carpio TV, Estrella G, D\u00edez A, Cambras T, Alda JA et al. \nADHD subtypes are associated differently with circadian rhythms of \nmotor activity,  sleep disturbances, and body mass index in children \nand adolescents: a case-control  study. Eur Child Adolesc Psychiatry. \n2021;30(12):1917-1927. IF:4,785. (Q1).EUROPEAN CHILD  \n& ADOLESCENT \nPSYCHIATRY4,785 Neuroscience\nCalderon M, Vila R, Dolz M, Butjosa A, Barajas A, del Cacho N et al. \nDepressive symptoms and their relationship with negative and other \npsychotic  symptoms in early onset psychosis. Eur Child Adolesc \nPsychiatry. 2021;30(9):1383-1390. IF:4,785. (Q1).EUROPEAN CHILD  \n& ADOLESCENT \nPSYCHIATRY4,785 Neuroscience\nGarc\u00eda A, Arnaez J, Arca G, Agut T, Alarcon A, Mart\u00edn A et al. \nDevelopment, Reliability, and Testing of a New Rating Scale for \nNeonatal  Encephalopathy. J Pediatr. 2021;235:83-91. IF:4,406. (Q1).JOURNAL OF  \nPEDIATRICS4,406 Neuroscience\nIglesias I, Beardsall K. Strict glycemic control in very low birthweight \ninfants using continuous glucose  monitoring reduces dysglycemic. J \nPediatr. 2021;238:338-342. IF:4,406. (Q1).JOURNAL OF  \nPEDIATRICS4,406 Adaptive Response, \nMetabolism and \nImmunobiology\nMart\u00ednez A, Baquero F, Santiago B, Fortuny C, M\u00e9ndez A, Del Rosal \nT et al. Interferon-Gamma Release Assays Differentiate between \nMycobacterium avium Complex  and Tuberculous Lymphadenitis in \nChildren. J Pediatr. 2021;236:211IF:4,406. (Q1).JOURNAL OF  \nPEDIATRICS4,406 Adaptive Response, \nMetabolism and \nImmunobiology\nAldecoa V, Velilla M, Teresa M, Balcells C, Herranz A, Sin M et al. \nLung Ultrasound in Bronchopulmonary Dysplasia: Patterns and \nPredictors in Very  Preterm Infants. Neonatology. 2021;118(5):537-\n545. IF:4,035. (Q1).NEONATOLOGY 4,035 Neuroscience\nAldecoa V, Velilla M, Teresa M, Balcells C, Herranz A, Sin M et al. \nLung Ultrasound in Bronchopulmonary Dysplasia: Patterns and \nPredictors in Very  Preterm Infants. Neonatology. 2021;118(5):537-\n545. IF:4,035. (Q1).NEONATOLOGY 4,035 Adaptive Response, \nMetabolism and \nImmunobiology\nJacob L, L\u00f3pez GF, Kostev K, Schnitzler A, Haro JM, Koyanagi A et \nal. Sexual Orientation and Functional Limitations: Cross-sectional \nAnalyses From the  Adult Psychiatric Morbidity Survey. Arch Phys \nMed Rehabil. 2021;102(11):2117-2124. IF:3,966. (Q1).ARCH PHYS MED  \nREHAB3,966 Mental Health and \nSocietyHighest impact \nfactor journals28 ANNUAL SCIENTIFIC REPORT 2021 \u00b7  INSTITUT  DE RECERCA  \nSCIENTIFIC PRODUCTION  \nAND RESULTS\nPatents,  \nutility models  \nand spin-offs\nElemento de fijaci\u00f3n de dispositivos a \nnivel craneal para neonatos\nCountry: Spain\nNumber: EP3368044\nInventors: Nuria Carrera Blesa \nPropietors: Hospital Sant Joan de D\u00e9u \nBarcelona\nPeptidic Conjugates of SN38 useful in \nthe treatment of cancer\nDate: 15/01/2021 \nCountry: PCT\nNumber: PCT/EP2021/076546\nInventors: Macare S\u00e1nchez Navarro, \nMeritxell Teixid\u00f3 Tur\u00e0, Nagore \nGen\u00e9 Olaciregui and Angel Montero \nCarcaboso\nPropietors: Hospital Sant Joan de D\u00e9u \nBarcelona, Fundaci\u00f3 Privada Institut \nde Recerca Biom\u00e8dica de Barcelona \nand Universitat de Barcelona\nV\u00e1lvula para respiradores (PEEP) \nCountry: Germany and Europe\nNumber: 2021042107265100DE and \nEP213823131\nInventors: Enric Palau Forte, Arnau \nValls Esteve, Mart\u00ed Pons Odena, \nCarlos Alaez Vasconcellos, Lluis Font \nVizcarra, Adrian Berm\u00fadez Castel, \nXoel Pena P\u00e9rez, Marc Murcia Laguna\nPropietors: Hospital Sant Joan de D\u00e9u \nBarcelona\nTratamiento de la enfermedad de \nCharcot-Marie-Tooth\nCountry: Spain \nNumber: P202130576\nInventors: Jose Manuel Cuerza \nMarcos, Cristina Nuevo Tapioles, \nFrancesc Palau Mart\u00ednez, Jorgina \nSatrutegui Gil-Delgado\nPropietors: Hospital Sant Joan de D\u00e9u \nBarcelona, Fundaci\u00f3n General de la \nUniversidad Aut\u00f3noma de Madrid and \nCentro de Investigaci\u00f3n Biom\u00e9dica en \nRed (CIBER)\nV\u00e1lvula para dispositivos de \nventilaci\u00f3n (VENTURI) \nCountry: Europe\nNumber: EP21165556Inventors: Francis de Zegher and \nLourdes Ib\u00e1\u00f1ez \nPropietors: Hospital Sant Joan de D\u00e9u \nBarcelona and University Leuven Kath\nTreatment of hepatic and or visceral \nfat excess\nCountry: Spain \nNumber: P2021382313\nInventors: Lluis Font Vizcarra, \nArnau Valls Esteve, Carlos Alaez \nVasconcellos and Mart\u00ed Pons \nPropietors: Hospital Sant Joan de D\u00e9u \nBarcelona\nGD2 Administration regimen\nCountry: Europe\nNumber: EP21383131\nInventors: Jaume Mora Graupera, Nai-\nKong Cheung, Modak Shakeel, Vignesh \nRajah and Claus J Moller SanPedro\nPropietors: Y-mAbs Therapeutics, Inc\nBetaine for prevention of obesity\nCountry: Europe \nNumber: EP3621605\nInventors: Josep Jim\u00e9nez Chillaron, \nCarles Ler\u00edn and Marta Ram\u00f3n \nPropietors: Hospital Sant Joan de D\u00e9u \nBarcelona\nTreatment of hepatic steatosis \nrelated oligo-ovulation\nCountry: Europa, Australia and Rusia\nNumber: EP3368044, AU2016344737 \nand RU2745606\nInventors: Francis de Zegher and \nLourdes Ib\u00e1\u00f1ez \nPropietors: Hospital Sant Joan de D\u00e9u \nBarcelona and University Leuven Kath\nA medical ventilator system and a \nmethod for predicting transient states \nof a ventilated patient upon changes in \nmechanical ventilator settings\nCountry: Spain\nNumber: EP21382381.8\nInventors: L. Serna, M.A. Ma\u00f1anas, A. \nHern\u00e1ndez\nPropietors: Universitat Polit\u00e8cnica \nde Catalunya and Universidad de \nAntioquiaEphion Health S.l.\n2021 \u00b7 https://ephion.health/\nCo-funders: Eurecat, Hospital Sant \nJoan de D\u00e9u and The Collider\nEphion Health is the platform to \ndevelop and deploy clinical measures \nfor patient mobility. They assist the \ncomplete parametrization of mobility \nfor serval diseases and conditions, to \ncreat a positive impact on the patient\u2019s \ndiagnosis, treatment and quality of \nlife. Ephion\u2019s technology allows to save \ntime and resources in clinical care and \nclinical trials.\nGate2Brain\n2020 \u00b7 https://gate2brain.com/\nCo-funders: Universidad de Barcelona \n(UB), Hospital Sant Joan de D\u00e9u \n(HSJD) \nGate2Brain is a biotech company \nfocused on the development of \ntherapeutics that efficiently cross \nbiological barriers such as the blood-\nbrain barrier. We pursue our goals \nusing a radically innovative peptide-\nbased patented technology platform.\nOMADRE \n2019 \u00b7 https://www.omadre.com/ \nDr. Jaume P\u00e9rez Payarols (IRSJD) \nThe company Omadre was created \nto provide hospitals with the tools \nrequired for the efficient management \nof mother\u2019s milk, increasing the safety \nof existing processes in this way. \nABLE Human Motion\n2018 \u00b7  https://www.ablehumanmotion.\ncom/\nCo-funders: Dr. Alfons Carnicero, Dr. \nAlex Garc\u00eda & Dr. Josep Maria Font \n(IRSJD)\nABLE Human Motion is a medical \ndevice spin-off from Universitat \nPolit\u00e8cnica de Catalunya (UPC) that \nis developing and will commercialize \nrobotic exoskeletons to enhance \nmobility and independence of people \nwith lower-limb paralysis. We have New patents, license \nagreements and utility modelsPortfolio of spin-offs 29 ANNUAL SCIENTIFIC REPORT 2021 \u00b7  INSTITUT  DE RECERCA  \nSCIENTIFIC PRODUCTION  \nAND RESULTS\ncreated ABLE, the first lightweight, \neasy-to-use and affordable \nexoskeleton that allows walking \nagain after a spinal cord injury. It \nhelps palliating health complications \nwhile boosting self-confidence and \nindependence.\nDBGEN Ocular Genomics \n2018 \u00b7 https://dbgen.com/ \nCo-funders: Dr. Roser Gonz\u00e0lez-\nDuarte and Dr. Gemma Marfany \n(IRSJD)\nDBGen is a company focused on the \ngenetic diagnosis of hereditary eye \ndisorders, providing the highest level \nof quality, diagnostic effectiveness \nand close contact with patients, \nophthalmologists, and enterprises \nin need of its services. At DBGen, \nwe offer high-quality, reliable and \naccessible genetic diagnosis, allowing \nthe clinical diagnosis to be assured \nand guidance to be provided to the \npatient with respect to emerging \ntherapies for genetic disorders \nof the eyes. Genetic diagnosis is \nindispensable to identify family \nmembers possessing a genetic defect, \npermitting the most suitable advice to \nbe given in each case.\nCEBIOTEX\n2012 \u00b7 http://www.cebiotex.com/ \nDr. Joan Bertran Llavina (CEO) & Dr. \nAngel Montero (IRSJD) \nCebiotex has developed and \ncharacterised at preclinical level, in \nvitro and in vivo, nonwoven nanofiber \nmembranes for the local release \nof active ingredients in the local \ntreatment of the surgical site after \ntumour excision surgery. The purpose \nof the local release of drugs is to \nachieve high concentrations of active \ningredients in the area where the \nrelease device is placed, avoiding \nsystemic toxicity and increasing the \neffectiveness of the drug against possible tumoral remnants. The \nactivity of Cebiotex is based on the \ninteraction of researchers from two \nCatalan institutions: the Polytechnic \nUniversity of Catalonia (UPC) and Sant \nJoan de D\u00e9uBarcelona Children\u2019s \nHospital (HSJD).\nBCN Innova \n2008 \u00b7 http://www.bcninnova.com/ \nDr. Joan Prat (IRSJD) \nBCN Innova, a spin-off company \nof Sant Joan de D\u00e9u-Barcelona \nChildren\u2019s Hospital, has developed a \ndevice (GazeLab) that substantially \nimproves the diagnosis and treatment \nof strabismus, reducing the number \nof second operations that are now \nperformed to achieve the expected \nresults. GazeLab offers two main \nbenefits: 1. It allows objective \nexploration on a revolutionary level of \nprecision, with much better results \nthan the subjective-measurement \nmodel that has prevailed until now. \n2. It provides a 50% reduction in \nthe number of second operations, \nobviating those which are surgically \nunnecessary.\nPatents,  \nutility models \nand spin-offs30 ANNUAL SCIENTIFIC REPORT 2021 \u00b7  INSTITUT  DE RECERCA  \nSCIENTIFIC PRODUCTION  \nAND RESULTS\nDoctoral Theses\nThesis author Title University Thesis directors Month  \nof lectureEuropean \nmention\nEliana Carolina Gon\u00e7alves Combined therapies for \nneuroblastoma based on \nthe activation of the calcium \nsensing receptorUniversitat \nde BarcelonaCinzia Lavarino and Silvia \nMateoJanuary\nMaria Julieta Gonzalez Avances en el estudio de la \nfenilcetonuriaUniversitat \nde BarcelonaJaume Campistol and \nRafael ArtuchFebruary\nElena Borrego Dom\u00e8nech La funci\u00f3 de CERKL a la retina: \ngeneraci\u00f3 d\u2019un model de ratol\u00ed i \nan\u00e0lisi de la seva implicaci\u00f3 en \nla resposta a estr\u00e8s oxidatiuUniversitat \nde BarcelonaGemma Marfany February\n\u00c8lia Vidal Development of metallic \nfunctionalized biomaterials \nwith low elastic modulus for \northopedic applicationsUniversitat \nPolit\u00e8cnica \nde CatalunyaDaniel Rodr\u00edguez and \nElisa Rup\u00e9rezFebruary\nN\u00faria Mart\u00ednez-Gil Role of Wnt pathway genes \nin complex and monogenic \nphenotypes of low and high \nbone massUniversitat \nde BarcelonaSusanna Balcells and \nDaniel GrinbergMarch\nMontserrat Bou Papel de la microbiota \nintestinal en el tratamiento del \ns\u00edndrome de Prader-WilliUniversitat \nde BarcelonaCarles Lerin and Marta \nRamonApril\nMarta Batllori Investigaci\u00f3 en biomarcadors \nde l'estat de la dopamina i \nla serotonina en pacients \nneuropedi\u00e0tricsUniversitat \nde BarcelonaMarta Molero and Aida \nOrmazabalApril\nAnu Shivalikanjli Shared and specific genetic \nbasis of autism spectrum \ndisorders and ADHDUniversitat \nde BarcelonaBru Cormand and No\u00e8lia \nFern\u00e0ndezMarch\nAm\u00e9rica Vera Montecinos Proteomic profil\u00b7le in \npostmortem brain in chronic \nschizophreniaUniversitat \nde BarcelonaBelen Ramos March\nJordina Tor Riesgo de psicosis en poblaci\u00f3n \ninfanto-juvenil: caracter\u00edsticas \ncl\u00ednicas y cognitivesUniversitat \nde BarcelonaLuis San Molina and \nAnna SintesMarch\nAm\u00e9rica Vera Montecinos Proteomic profil\u00b7le in \npostmortem brain in chronic \nschizophreniaUniversitat \nde BarcelonaBel\u00e9n Ramos March\nIvet Bay\u00e9s Mar\u00edn Estudio de enfermedades \ncr\u00f3nicas de salud y \nfuncionamiento en personas de \nmediana edad y mayores desde \nuna perspectiva epidemiol\u00f3gicaUniversitat \nde BarcelonaBeatriz Olaya and Josep \nMaria HaroMay31 ANNUAL SCIENTIFIC REPORT 2021 \u00b7  INSTITUT  DE RECERCA  \nSCIENTIFIC PRODUCTION  \nAND RESULTS\nThesis author Title University Thesis directors Month  \nof lectureEuropean \nmention\nCarme Nolla Colomer An\u00e0lisi de patrons funcionals i \nestructurals en la regulaci\u00f3 del \ncalci en les c\u00e8l\u00b7lules card\u00edaquesUniversitat \nPolit\u00e8cnica \nde CatalunyaRa\u00fcl Ben\u00edtez and Leif \nHove MadsenMay\nLaura Almeida Modelo de s\u00edndrome alcoh\u00f3lico \nfetal en rat\u00f3n seg\u00fan dos \npatrones de consumo humano y \nel papel de la epigalocatequina \ngalato en su prevenci\u00f3n. \nestudio de biodisponibilidad de \nla epigalocatequina galato en \nhumanosUniversitat \nde BarcelonaV Andreu (buscar) and \nMaria Dolores G\u00f3mez \nRoigJune\nSilvia Sim\u00f3 Implementaci\u00f3 i resultats \nd'un programa d\u2019optimitzaci\u00f3 \nd\u2019\u00fas d\u2019antimicrobians (PROA) \npedi\u00e0tric a un hospital infantil \nde tercer nivellUniversitat \nde BarcelonaAntoni Noguera June\nSara Bobillo Utilidad de los biomarcadores \nen la respuesta \ninflamatoria sist\u00e9mica y \nen la implementaci\u00f3n de \nalgoritmos de manejo de \nla antibioticoterapia en los \npacientes cr\u00edticos pedi\u00e1tricosUniversitat \nde BarcelonaIolanda Jordan and \nFrancisco Jose CambraJune\nJoaquim Minguela Surface characterization and \ncell instructive properties of \nsuperficially modified dental \nzirconiaUniversitat \nPolit\u00e8cnica \nde CatalunyaCarles Mas-Moruno and \nJoan-Josep RoaJuly\nBernardo S\u00e1nchez \nFern\u00e1ndezDiferencias de g\u00e9nero en el \nadolescente con conducta \nsuicidaUniversitat \nAut\u00f2noma  \nde CatalunyaFrancisco Villar Cabeza, \nMar Vila Grifoll, Mar and \nAnna Sintes Est\u00e9vezJuly\nEster Ant\u00f3n Galido Genetic and functional analyses \nof Autism Spectrum Disorder \nand ADHDUniversitat \nde BarcelonaBru Cormand and No\u00e8lia \nFern\u00e0ndezSeptember\nDavid Aguilar-Recarte GDF15, a novel regulator of the \nAMPK-mediated antidiabetic \nactions of PPARbeta/delta and \nmetforminUniversitat \nde BarcelonaManuel V\u00e1zquez Carrera September\nSantiago Raymond Biomimetic Bone Grafts: from \nthe lab to the clinicUniversitat \nPolit\u00e8cnica \nde CatalunyaMaria Pau Ginebra September\nJoanna M. Konka 3D-Printed Biomimetic Bone Universitat \nPolit\u00e8cnica \nde CatalunyaMaria Pau Ginebra and \nMontserrat Espa\u00f1olOctoberDoctoral Theses32 ANNUAL SCIENTIFIC REPORT 2021 \u00b7  INSTITUT  DE RECERCA  \nSCIENTIFIC PRODUCTION  \nAND RESULTS\nThesis author Title University Thesis directors Month  \nof lectureEuropean \nmention\nAlejandro Delgado Angl\u00e9s Experimental and human \nstudies on aging of adipose \ntissues: role of ParkinUniversitat \nde BarcelonaFrancesc Villarroya and \nJoan VillarroyaOctober\nDiego Torres Desarrollo de un nuevo proceso \nbasado en la inyecci\u00f3n 3D \nde tintas con carga met\u00e1lica \npara fabricar pr\u00f3tesis porosas \nde titanio bioactivas y con \npropiedades antibacterianasUniversitat \nPolit\u00e8cnica \nde CatalunyaJos\u00e9 Mar\u00eda Manero, Elisa \nRup\u00e9rez and Jos\u00e9 A. \nCalero (AMES).October\nAnnaHuguet Miguel Influencia de un programa \nde mindfulness sobre los \ns\u00edntomas nucleares, las \nfunciones ejecutivas y el eje \nhipot\u00e1lamo-hip\u00f3fisis-adrenal \n(HPA), en ni\u00f1os recientemente \ndiagnosticados de Trastorno \npor D\u00e9ficit de Atenci\u00f3n e \nHiperactividad (TDAH). Un \nestudio aleatorizadoUniversitat \nde BarcelonaJos\u00e9 \u00c1ngel Alda October\nLaura Castilla-Vallmanya Combining exome sequencing \nand functional studies to \nidentify causal genes of ultra-\nrare neurodevelopmental \ndisordersUnveritat de \nBarcelonaSusanna Balcells and \nRoser UrreiztiNovember\nMarley Vega Development and Applications \nof Neuromusculoskeletal \nModeling Software for \nPersonalized Treatment Design Rice  \nUniversity \n(Houtson \u00b7 \nUSA)Josep Maria Font \nand B.J. Fregly (Rice \nUniversity)November\nNatalia Diaz Garrido Modulation of intestinal \nimmune responses by \nmicrobiota-derived extracelular \nvesiclesUniversitat \nde BarcelonaLaura Baldom\u00e0 and \nJosefa BadiaNovember\nEstela Prada Target Therapy in \nRhabdomyosarcoma: \nDiscovering new targets and \nopportunitiesUniversitat \nde BarcelonaJaume Mora and \nInmaculada Hern\u00e1ndez \n(IRB Barcelona)November\nLaia Villalta Macia Emotional dysregulation, \npsychiatric disorders and \ntrauma in adolescentUniversitat \nde BarcelonaNovember\nTeresa Ribas-Prats Detection of abnormal neural \nencoding of speech sounds \nat birth using the frequency- \nfollowing responseUniversitat \nde BarcelonaCarles Escera DesemberDoctoral Theses1 FOREWORD\nGovernance and structures\nGlobal numbers 2020\nGlobal numbers 2020-2015\nInstitutional awards\n5 \nCORE \nFACILITIES34 ANNUAL SCIENTIFIC REPORT 2021 \u00b7  INSTITUT  DE RECERCA  \nCORE FACILITIES\nThe Institut de Recerca Sant Joan de \nD\u00e9u makes available to its researchers \na set of fundamental services and \ninfrastructures for the performance \nof their projects. In order to facilitate \nhigh-level research, the IRJSD offers \nits professionals technical, scientific \nand support services as well as the \nmost suitable infrastructures required \nto carry out their work: Scientific core facilities \n\u2022 Biological Sample Processing and \nMol\necular Analysis \n\u2022 Confoc\nal Microscopy and Cellular \nImaging Unit \n\u2022 Clinical T\nrials Unit \n\u2022 Library \n\u2022 Methodology and s\ntatistics \n\u2022 Neuroimaging \n\u2022 Neurol\nogical tissues Biobank for \nresearch \n\u2022 Neuropsy\nchological evaluations \n\u2022 Paediatric Biobank f\nor research \n\u2022 Patient Engagement in Resear\nch \nArea\n\u2022 Sequencing Unit\n\u2022 Animal housing facility \n\u2022 Unit of Desing, Analysis and \nInt\nerpretation of Omic data \n(DAIOmics)\nManagement support services \n\u2022 Administration and corporate \nfinanc\ne \n\u2022 Human Area \n\u2022 Clinical Resear\nch Ethics Committee \n\u2022 Research management and \nPr\nomotion \n\u2022 Management of knowl\nedge and \ncommunication Core  \nfacilities\n1 FOREWORD\nGovernance and structures\nGlobal numbers 2020\nGlobal numbers 2020-2015\nInstitutional awards\n6 \nTRAINING, \nCOMMUNICATION \nAND PARTICIPATION\nSeminars\nTraining programme\nCommunication and public engagement\nNews36 ANNUAL SCIENTIFIC REPORT 2021 \u00b7  INSTITUT  DE RECERCA  \nTRAINING, COMMUNICATION \nAND PARTICIPATION\n22 \nSEMINARS\nRelation of research seminars \nand IRSJD day of debates \n21 JANUARY\nEdici\u00f3 gen\u00e8tica amb CRISPR en \nBiomedicina: on estem actualment?\nDr. Llu\u00eds Montoliu, CSIC Centro \nNacional de Biotecnolog\u00eda (CNB)\n9 FEBRUARY \nMicrobiota en l\u2019entorn maternal-\ninfantil: rellev\u00e0ncia per a la salut \nDra. Mar\u00eda Carmen Collado. CSIC \nInstitut d\u2019Agroqu\u00edmica i Tecnologia \nd\u2019Aliments (IATA)\n16 FEBRUARY \nMitochondria\u2013lysosome membrane \ncontacts are defective in GDAP1-\nrelated Charcot-Marie-Tooth disease\nDra. Lara Cantarero Abad, IRSJD\n23 FEBRUARY \nModel de s\u00edndrome alcoh\u00f2lic fetal en \nratol\u00ed segons dos patrons de consum \nhum\u00e0 i el paper de la EGCG en la seva \nprevenci\u00f3\nDra. Laura Almeida, IRSJD\n27 FEBRUARY \nNano Rare Disease Day 2020 \nOrganise: Nanomed Spain with IBEC \n& IRSJD \n16 MARCH \nSimilarities and differences between \nthe immunopathogenesis of COVID-\n19-related pediatric inflammatory \nmultisystem syndrome and Kawasaki \ndisease\nDra. Ana Esteve-Sol\u00e9, IRSJD\n30 MARCH \nImpacte emocional i de la conducta \nde la pand\u00e8mia COVID19 en poblaci\u00f3 \ninfanto-juvenil\nDra. Esther Via & Dr. Xavier Estrada, \nIRSJD\n13 APRIL \nDetecci\u00f3 de disfuncionalitats \ndel sistema nervi\u00f3s central en \nnounats mitjan\u00e7ant marcadors Seminars\nneurofisiol\u00f2gics: la resposta de \nseguiment de freq\u00fc\u00e8ncia (RSF) \nDra. Teresa Ribas-Prats, IRSJD\n27 APRIL \nCERKL, a retinal dystrophy gene, \nregulates mitochondrial function and \ndynamics in the mammalian retina \nDra. Serena Mirra, IRSJD.\n11 MAY\nRole of Wnt pathway genes in \ncomplex and monogenic phenotypes \nof low and high bone mass \nDra. N\u00faria Mart\u00ednez Gil, IRSJD\n25 MAY\nThe spectrum of COVID-19 in \npregnancy \nDra. Rosalia Pascal, IRSJD, & Dra. \nFrancesca Crovetto (IDIBAPS)\n15 JUNE \nPrevalen\u00e7a i factors explicatius de la \nno iniciaci\u00f3 pedi\u00e0trica i l\u2019impacte en \ncostos de la no iniciaci\u00f3 pedi\u00e0trica en \nantibi\u00f2tics i medicaments de salut \nmental\nCristina Carbonell, IRSJD, & Alba \nS\u00e1nchez, IRSJD\n29 JUNE \nAddressing Clinical Psychology\u2019s \nWEIRD Problem: The cross-\ncultural validity of the Five-Facet \nMindfulness Questionnaire across 16 \ncountries \nDr. Juan Vicente Luciano, IRSJD.\n13 JULY \nGas Plasma technology in \nOsteosarcoma: advances and \nchallenges of a novel selective \ntherapy based on oxidative-stress \nDra. Cristina Canal, IRSJD\n15 SEPTEMBER \nEpigenetic Genotyping (EpiGe): A \nnovel approach for single cytosine \nmethyl-genotyping and its application in Pediatric Oncology\nDra. Soledad G\u00f3mez, IRSJD\n28 SEPTEMBER \nSimulation of Assisted Motion with \nMusculoskeletal Models \nDr. Albert Peiret Gim\u00e9nez, IRSJD\n30 SEPTEMBER \nFunctionalizing the Cancer Genome \nThrough Copy Number Engineering \nDr. Francisco Barriga, Memorial Sloan \nKettering Cancer Center. New York. USA\n19 OCTOBER \nEfecte de la nicotinamida, la forma \namida de la vitamina B3, contra el \ndesenvolupament d\u2019obesitat \nDr. Josep Julve, IRHSCSP\n26 OCTOBER \nLa no iniciaci\u00f3 del tractament \nfarmacol\u00f2gic des de la perspectiva \ndels pacients i els professionals \nM\u00aa Teresa Pe\u00f1arrubia-Maria, IRSJD, & \nDra. Montserrat Gil Girbau, IRSJD\n16 NOVEMBER \nANXA11: un gen, dues malalties \nneuromusculars i l\u2019espectre fenot\u00edpic \nd\u2019una proteinopatia \nDr. Daniel Natera, IRSJD, & Jonathan \nOlival, IRSJD\n30 NOVEMBER\nEstr\u00e8s psicosocial (trauma infantil) i \nfactors protectors en l\u2019aparici\u00f3 d\u2019un \nprimer episodis psic\u00f2tic \nRegina Vila Badia, IRSJD, & Clara \nSerra Arum\u00ed, IRSJD\n14 DECEMBER\nRelationship between the circadian \nrhythms disruption in children with \nneurodevelopmental disorder (ASD) \nand healthy controls with Body Mass \nIndex (BMI) and an altered chronotype \nAres Sentenach, IRSJD37 ANNUAL SCIENTIFIC REPORT 2021 \u00b7  INSTITUT  DE RECERCA  \nTRAINING, COMMUNICATION \nAND PARTICIPATION\n18  \nCOURSES IN 2021 \n250  \nATTENDEES IN 2021\nTo promote the development of the different competence \ndimensions, four types of training modalities are established:  \n\u2022 Knowl\nedge and techniques \n\u2022 Soft Skills \n\u2022 Organization and Go\nvernance \n\u2022 Institutional tr\naining (Values) \nCourses\n\u2022 How to publish a scientific article\n\u2022 Tr\neball en equips a distancia\n\u2022 Oportunitats de finan\u00e7\nament competitiu\n\u2022 Impro\nving your paragraphs and sentences in english\n\u2022 Organitzaci\u00f3 i ges\nti\u00f3 del temps\n\u2022 Est\nad\u00edstica\n\u2022 Writing Retreat (2ed)\n\u2022 Per qu\u00e8 \u00e9s import\nant la divulgaci\u00f3 cient\u00edfica?\n\u2022 Learn to writ\ne concise and impactful reports\n\u2022 Lideratge ( 2 semes\ntre)\n\u2022 Exc\nel nivell mig\n\u2022 Exc\nel nivell avan\u00e7at\n\u2022 R progr\namaci\u00f3 Basica\n\u2022 Bones pr\u00e1ctiques en inv\nestigaci\u00f3\n\u2022 Participaci\u00f3 del pacient en r\necerca\n\u2022 Sessi\u00f3 d\u2019especialitzaci\u00f3: RGPD a Rec\nerca\n\u2022 Sensbilizaci\u00f3n en materia de igualdad\n\u2022 Visibilidad y divulgaci\u00f3n de la actividad inves\ntigadoraTraining \nprogramme38 ANNUAL SCIENTIFIC REPORT 2021 \u00b7  INSTITUT  DE RECERCA  \nTRAINING, COMMUNICATION \nAND PARTICIPATION\nActivities \n18 \nACTIVITIES ORGANIZED \n170 \nRESEARCHERS\n1.000 \nAUDIENCE REACHED\nParticipation in: \n\u2022 International Day of w\nomen and \ngirls in science\n\u2022 Europeans Resear\ncher\u2019s Night\n\u2022 Setamana de la Ci\u00e8ncia\n\u2022 Fes\nta de la Ci\u00e8nciaInternet and Social media \nLINKEDIN \n13.329  FOLLOWERS\nTWITTER\n937  FOLLOWERS\nWEBSITE \n47.275  USERS \n209.231  NUMBER OF VISITS TO PAGESCommunication \nand public \nengagement\n39 ANNUAL SCIENTIFIC REPORT 2021 \u00b7  INSTITUT  DE RECERCA  \nTRAINING, COMMUNICATION \nAND PARTICIPATION\nJanuary\nWe have seen that in mouse models, \nmalnutrition during lactation is \nassociated with alterations in the \nmetabolism of the adult. (Photo 1)\nFebruary\nMetacognitive training has beneficial \neffects on cognitive perception in \npatients with early psychotic episodes.\nThe IRSJD is participating in a \nEuropean project to assess the effects \nof the pandemic on mental health.\nA study analyses the risk genetic factors \nshared between ADHD and disruptive \nbehaviour disorders. (Photo 2)\nMarch\nThe conditions of 70% of people with \nchronic pain have worsened during the \npandemic. (Photo 3)\nSupplementing the maternal diet with \nbetaine during lactation may reduce \nthe risk of childhood obesity.\nApril\nCan a newborn\u2019s brain discriminate \nspeech sounds? (Photo 4)\nA new facial recognition tool could \nmake it easier for people with \nschizophrenia to socialize.\nMay\nThey draw a \u201cmap\u201d of the \nenteroviruses that cause hand-foot-\nand-mouth disease in our country.\nMutations in the GEMIN5 gene as the \norigin of rare genetic disorders in boys \nand girls.\nJune\nThe CERKL gene involved in \nmitochondrial regulation of retinal \ncells. (Photo 5)\nPredicted prognosis of one type \nof childhood cancer by tumour \nengraftment in mica. (Photo 6)\nMore than 6% of Europeans suffer \nfrom depression. (Photo 7)News\n7\n6\n1\n2\n43\n540 ANNUAL SCIENTIFIC REPORT 2021 \u00b7  INSTITUT  DE RECERCA  \nTRAINING, COMMUNICATION \nAND PARTICIPATION\nJuly\nDr. Lourdes Iba\u00f1ez coordinates the \nEuropean SPIOMET4HEALTH  project: a new \ntreatment for polycystic ovary syndrome \nin adolescents and young women.\nSurvival rate of high-risk neuroblastoma \npatients treated with next-generation \nimmunotherapy at SJD Barcelona \nChildren\u2019s Hospital.\nAugust\nStudy the factors associated with \nthe appearance of depression during \nconfinament.\nIRSJD\u2019researchers relate the \nconcentration of certain chemical \nelements in the placenta with fetal \ngrowth. (Photo 8)\nSeptember\nResearchers describe a new pathway \nof the energy metabolism in peripheral \ntissues regulated by cytokine GDF15. \n(Photo 9)\nDetecting long QT syndrome early could \nhelp reduce the impact of sudden infant \ndeath.\nOctober\nA guide to improving pediatric patient \nparticipation in drug research. (Photo 10)\nInstitut de Recerca Sant Joan de D\u00e9u \nis holding its 3rd Scientific Conference. \n(Photo 11)\nNovember\nBrown adipose tissue activity is higher in \ngirls during the first year of life.\nThe European project SARAS, towards \ncognitive robotics in surgery, is coming \nto an end.\nMeasuring antibodies in saliva is a \nuseful and easy strategy to detect SARS-\nCoV-2 infections.\nDecember\nStudy reveals that a high percentage of \nchildren and adolescents with early onset \npsychosis suffer from clinical depression.News\n8\n9\n10\n117 \nSCIENTIFIC \nACTIVITY\n7.1. MEDICINE AND  PEDIATRIC SCIENCE AREA\n7.2. MENTAL\n HEALTH AREA\n7.3. TRANSVERSAL PROGRAM1 FOREWORD\nGovernance and structures\nGlobal numbers 2020\nGlobal numbers 2020-2015\nInstitutional awards\n7.1.1\nNeuroscience7.1\nMEDICINE  \nAND PEDIATRIC \nSCIENCE AREA\nApplied research in neuromuscular diseases\nPediatric neurometabolism: neural communication mechanisms \nand personalized therapies\nNeonatal brain\nNeuropsychology\nCognitive neuroscience\nAttention, Perception and Language Acquisition (APAL)\nResearch in child and adolescent mental health43 INSTITUT  DE RECERCA  \nMEDICINE AND PEDIATRIC  \nSCIENCE AREA \nNEUROSCIENCE\nApplied  \nresearch in \nneuromuscular \ndiseases\nCecilia Jim\u00e9nez Malebrera, PhD\nMEMBERS\nSTAFF RESEARCHER\nJulita Medina, Irene Beatriz Zschaeck \nLuzardo, Andr\u00e9s Nascimento Osorio, \nCarlos Ignacio Ortez Gonzalez\nPOSTDOC ASSOCIATED RESEARCHERS\nAr\u00edstides Lopez Marquez, Selena \nTrifunov, Daniel Natera de Benito\nPHD STUDENTS\nCristina Jou Mu\u00f1oz\nASSISTANT RESEARCHER\nAna Pareja Bosch, Sonia Segovia \nSimon, Jessica Maria Exposito \nEscudero, Laura Carrera Garc\u00eda, Maria \ndel Carmen Badosa Gallego\nTECHNICIAN\nAna Codina Bergad\u00e0\nSELECTED PROJECTS\n\u2022 Emerging biomarkers for spinal \nmuscular atr\nophy. (ES-SPN-1188). \nBiogen International GmbH. \n2021-2023. IP: Cecilia Jim\u00e9nez \nMallebrera. \n\u2022 ArmTr\nacker: A state-of-the-art \nwearable system to assess upper \nlimb motor function in reallife \nconditions for patients with \nDuchenne muscular dystrophy \nand spinal muscular atrophy. \n(561/C/2020). Fundaci\u00f3 La Marat\u00f3 \nde TV3. 2021-2024. IP: Daniel \nNatera de Benito.\n\u2022 Medicina Per\nsonalizada para las \nDistrofias Musculares Cong\u00e9nitas: \nDesarrollo de terapias avanzadas, \nmodelos fisiol\u00f3gicos y herramientas \ndiagn\u00f3sticas precisas. (PI19/00122). \nInstituto de Salud Carlos III (ISCIII). \n2020-2022. IP: Cecilia Jim\u00e9nez \nMallebrera.\nSELECTED CLINICAL TRIALS & \nOBSERVATIONAL STUDIES\n\u2022 Estudio abierto para evaluar \nla seguridad, la t\nolerabilidad \ny la eficacia de viltolars\u00e9n en \nni\u00f1os con distrofia muscular \nde Duchenne (DMD), capaces e incapaces de caminar. A Phase 2 \nOpenl-label Study to Assess the \nSafety, Tolerability, and Efficacy \nof Viltolarsen in Ambulant and \nNon-Ambulant Boys with Duchenne \nMuscular Dystrophy (DMD) \nCompared to Natural History \nControls. (NS-065/NCNP-01-211). \nMedpace Spain, S.L.; Medpace, Inc; \nNS Pharma, Inc. 2021-. IP: Andr\u00e9s \nNascimento Osorio. \n\u2022 Estudio de F\nase 4 de Nusinersen \n(BIIB058) en Pacientes con Atrofia \nMuscular Espinal que Recibieron \nOnasemnogene Abeparvovec. \n(232SM404). Biogen IDEC Research \nLTD; IQVIA RDS Spain SL. 2021-. IP: \nAndr\u00e9s Nascimento Osorio. \n\u2022 Estudio de e\nxtensi\u00f3n de fase \n3, multic\u00e9ntrico y abierto, para \nevaluar la eficacia y la seguridad \nde viltolars\u00e9n en ni\u00f1os con distrofia \nmuscular de Duchenne (DMD) \ncapaces de caminar. (NS-065/\nNCNP-01-302). Medpace Clinical \nResearch, LLC; NS Pharma, Inc. \n2021-. IP: Andr\u00e9s Nascimento \nOsorio. \nSELECTED PUBLICATIONS\n\u2022 L\u00f3pez A, Carrasc o C, Fern\u00e1ndez \nC, Santisteban P. Unraveling \nthe Complex Interplay Between \nTranscription Factors and \nSignaling  Molecules in Thyroid \nDifferentiation and Function, From \nEmbryos to Adults. Front Endocrinol \n(Lausanne). 2021;12:654569-654569. \nIF:5,555. (Q1).\n\u2022 Nater\na D, Aguilera S, Costa L, \nGarc\u00eda M, Miranda MC, R\u00fabies J \net al. COVID-19 in children with \nneuromuscular disorders. J. Neurol. \n2021;268(9):3081-3085. IF:4,849. \n(Q1).\n\u2022 Nater\na D, Foley AR, Dom\u00ednguez C, \nOrtez CI, Jain M, Mebrahtu A et al. \nAssociation of Initial Maximal Motor \nAbility With Long-term Functional \nOutcome in  Patients With COL6-\nRelated Dystrophies. Neurology. \n2021;96(10):1413-1424. IF:9,910. \n(Q1).\n\u2022 Trifuno\nv S, Paredes AJ, Badosa \nMC, Codina A, Montoya C, Ruiz \nE et al. Circulating Cell-Free \nMitochondrial DNA in Cerebrospinal \nFluid as a Biomarker for  \nMitochondrial Diseases. Clin Chem. \n2021;67(8):1113-1121. IF:8,327. (Q1).Pediatric \nneurometabolism: \nneural \ncommunication \nmechanisms  \nand personalized \ntherapies\nM\u00aa Angels Garc\u00eda Cazoral, MD, PhD\nOver the course of 2021, we \nhave been able to advance in the \ncharacterisation of various significant \naspects of neurotransmitter \ndisorders. In the first place we \ndescribed new markers relating to \nprognosis and disease mechanisms \nin dopaminergic neurotransmission \ndefects. We have also described new \nelements of the clinical phenotype \nand neuroimaging of these disorders. \nThis was possible thanks to the \ncollaboration of many different \ncentres through the international \nnetwork I-NTD. Likewise, we \ncarried out our own clinical trial \nwith L-serine on patients with \nmutations due to loss of function in \nNMDA receptors. We also completed \nthe preclinical concept test of the \n\u201cNeuroprotect\u201d formula designed in \nour laboratory, which has the purpose \nof improving various aspects of \nneurodevelopment in neuropaediatric \ndisorders. Additionally, we obtained \nseveral grants and other funding \nto hire research personnel. With \nthe help of these funds, we seek to \ndevelop and/or apply personalised \ntreatments in a group of pathologies \nthat include paediatric parkinsonism \nand neurometabolic disorders in \ngeneral.\nMEMBERS\nSTAFF RESEARCHER\nRoser Colom\u00e9 Roura, Silvia Maria \nMeavilla Olivas, Alejandra Darling, \nJordi Muchart L\u00f3pez, M\u00aadel Mar \nO\u2019Callaghan Gordo, Federico Ramos, \nAnna L\u00f3pez Sala, Maria del Carme \nFons Estupi\u00f1a\nPOSTDOC ASSOCIATED RESEARCHERS\nAlba Tristan Noguero, Alfonso Luis De \nOyarzabal Sanz\nPHD STUDENTS\nJuliana Ribeiro Constante, Noelia 44 INSTITUT  DE RECERCA  \nMEDICINE AND PEDIATRIC  \nSCIENCE AREA \nNEUROSCIENCE\nRivera S\u00e1nchez, Uliana Musokhranova \nMatveeva, Natalia Alexandra Juli\u00e0 \nPalacios\nASSISTANT RESEARCHER\nNeus Guiu Gonzalez, Mariya \nSigatullina Bondarenko\nTECHNICIAN\nAnna Serradell Sal\u00eds, Cristina Grau \nP\u00e1ez\nSELECTED PROJECTS\n\u2022 TREAT-AHC. Identification of \nc\nompounds for the treatment of \nAlternating Hemiplegia of Childhood \nby drug repositioning. Molecular \nand pre-clinical evaluation \nand clinical outcome measure \nvalidation. (283/C/2020). Fundaci\u00f3 \nLa Marat\u00f3 de TV3. 2021-2024. PI: \nCarme Fons Estupi\u00f1a. \n\u2022 Ter\n\u00e0pies personalitzades pels \ntrastorns cognitiu-conductuals de les malalties heredit\u00e0ries del \nmetabolisme en l\u2019edat pedi\u00e0trica. \n(2020 DI 103). Agaur - Ag\u00e8ncia de \nGesti\u00f3 d\u2019Ajuts Universitaris i de \nRecerca. 2021-2024. PI: M\u00aaAngels \nGarc\u00eda Cazorla. \n\u2022 Dev\neloping patient-tailored \ntherapeutic candidates for \nrare genetic forms of pediatric \nparkinsonism. (202012-30). \nFundaci\u00f3 La Marat\u00f3 de TV3. 2021-\n2024. PI: M\u00aaAngels Garc\u00eda Cazorla.\nSELECTED CLINICAL TRIALS & \nOBSERVATIONAL STUDIES\n\u2022 Estudio de la eficacia y seguridad \nde v\natiquinona en el tratamiento \nde la epilepsia farmacorresistente \nen pacientes con enfermedad \nmitocondrial. Efficacy and \nSafety Study of Vatiquinone for \nthe Treatment of Mitochondrial Disease Patients with Refractory \nEpilepsy. (PTC743-MIT-001-EP). \nParexel International S.L; PTC \nTherapeutics, Inc. 2021-. PI: M\u00aadel \nMar O\u2019Callaghan Gordo. \n\u2022 Estudio f\nase 3, multic\u00e9ntrico, \naleatorizado, doble ciego, de \ngrupos paralelos y controlado con \nplacebo, para evaluar la seguridad, \nla tolerabilidad y la eficacia de \n2000 mg/kg de Trappsol\u00ae Cyclo\u00e2\u201e\u00a2 \n(hidroxipropil-\u00ce\u00b2-ciclodextrina) y \ntratamiento est\u00e1ndar comparado \ncon placebo y tratamiento \nest\u00e1ndar en pacientes con la \nenfermedad de Niemann-Pick de \ntipo C1. A Phase III, Double-blind, \nRandomized, Placebo-controlled, \nParallel-group, Multicenter Study \nto Evaluate the Safety, Tolerability, \nPharmacokinetics, and Efficacy of \n2000 mg/kg of Trappsol\u00ae Cyclo\u00e2\u201e\u00a2 \n(Hydroxypropyl-\u00ce\u00b2-cyclodextrin) \nand Standard of Care Compared \nto Placebo and Standard of \nCare in Patients with Niemann-\nPick Disease Type C1. (CTD-\nTCNPC-301). Cyclo Therapeutics, \nInc.; Worldwide Clinical Trials Ltd. \n2021-. PI: M\u00aadel Mar O\u2019Callaghan \nGordo. \n\u2022 Estudio al\neatorizao, de grupos \nparalelo, doble ciego, controlado \ncon placebo, con extensi\u00f3n \nabierta, para evaluar la eficacia \ny la seguridad del vatiquinona \npara el tratamiento de la ataxia \nde Friedreich (MOVE-FA). A \nrandomized, parallel-arm, double-\nblind, placebo-controlled study with \nopen-label extension to assess the \nsafety and efficacy of vatiquinone \nfor the treatment of friedreich \nataxia. (PTC743-NEU-003). CTI \nClinical Trial & consulting services \nSpain S.L; PTC Therapeutics, Inc. \n2021-. PI: Alejandra Darling.\nSELECTED PUBLICATIONS\n\u2022 De Oyarzabal AL, Musokhranova \nU, Barr\nos LF, Garcia A. Energy \nmetabolism in childhood \nneurodevelopmental disorders. \nEBioMedicine. 2021;69:103474. \nIF:8,143. (Q1).\n\u2022 Kuseyri O, Horv\nath G, Cort\u00e9s E, \nYildiz Y, Mastrangelo M, Pons R \net al. Insights into the expanding \nphenotypic spectrum of inherited \ndisorders of biogenic  amines. \nNat Commun. 2021;12(1):5529. \nIF:14,919. (Q1).\n\u2022 Tris\ntan A, Borr\u00e0s E, Molero M, \n45 INSTITUT  DE RECERCA  \nMEDICINE AND PEDIATRIC  \nSCIENCE AREA \nNEUROSCIENCE\nWassenberg T, Peters T, Verbeek \nMM et al. Novel Protein Biomarkers \nof Monoamine Metabolism Defects \nCorrelate with Disease  Severity. \nMov Disord. 2021;36(3):690-703. \nIF:10,338. (Q1).\nNeonatal  \nbrain\nThais Agut Quijano, MD, PhD  \n& Ana Alarcon Allen, MD, PhD\nThe Neonatal Brain Group has \nmaintained its commitment to \ngenerate knowledge on brain \ndisorders of the foetal/neonatal \nperiod with an impact on children\u2019s \nhealth and capacities. The group was \nfounded by Dr Alfredo Garc\u00eda-Alix \nand directed by him until his recent \nretirement in April of 2021. Drs Ana \nAlarc\u00f3n and Tha\u00efs Agut succeeded \nhim as principal investigators and \nthe group has been consolidated \nwith the incorporation of two pre-\ndoctoral researchers, Drs Nuria \nCarreras and Mar Velilla, and the \npaediatric and perinatal pathologist \nDr S\u00edlvia Planas. \nThe group has continued with its line \nof work on pathogenic mechanisms \nand biomarkers in neonatal hypoxic-\nischaemic encephalopathy and \ncerebral arterial infarction. Its other \nactive primary lines are: (1) Brain \nmaturation and assessment of the \nimpact of acquired brain lesions on \nbrain maturation (PI: Tha\u00efs Agut); (2) \nFoetal/neonatal infections with an \nimpact on the developing brain (PI: \nAna Alarc\u00f3n); and (3) Care practices \nfor newborns with neurological \nrisk and their families (PI: Nuria \nHerranz). \nOne of the most positive aspects has \nbeen the continued collaboration with \nother specialists and researchers in \nareas relating to foetal and neonatal \nneurology, and with other groups \nfrom the Sant Joan de D\u00e9u Barcelona \nResearch Institute and from other \ninstitutions. The Group\u2019s projects \nhave adopted several different \napproaches (clinical, including both \nmedical and nursing approaches; \nbasic science; biomedical engineering; epidemiology), favouring \nthe translational character of the \nresearch in all cases. Moreover, \nwithin the sphere of our research, \nwe continued to participate in both \nnational and European working \ngroups with a global teaching and \nresearch outlook. \nThe group\u2019s achievements in 2021 \nincluded a total of 18 publications, \nwith a total impact factor of 74.35. \nLikewise, Ms. Nuria Herranz \ncoordinated three documents with \nevidence-based recommendations on \naspects of neonatal care that influence \nthe developing brain. Lastly, the group \ncontinued to promote pre-doctoral \nresearch, with one doctoral thesis that \nwas presented and three in progress, \nin addition to three final master\u2019s \ndegree projects.\nMEMBERS\nSTAFF RESEARCHER\nS\u00edlvia Planas Rom\u00e1n, Nuria Herranz \nRubia, Maria del mar Velilla Aparicio\nPOSTDOC ASSOCIATED RESEARCHERS\nNuria Carreras Blesa\nASSISTANT RESEARCHER\nJonathan Francisco Olival Tremaria\nTECHNICIAN\nMaria Jose Coll Lobarte, Nerea Li\u00f1an \nRosa\nSELECTED PROJECTS\n\u2022 Estudio CRIB (Cribado de \ncit\nomegalovirus cong\u00e9nito en \nReci\u00e9n nacidos sanos e Ingresados \n\u2013 Barcelona). (PI19/00095). Instituto \nde Salud Carlos III (ISCIII). 2020-\n2024. PI: Ana Alarc\u00f3n Allen.\n\u2022 Elaboraci\u00f3n de un atlas\n \nmorfom\u00e9trico normalizado de la \nmaduraci\u00f3n cerebral del reci\u00e9n \nnacido prematuro y valoraci\u00f3n \ndel impacto de la patolog\u00eda \ncerebral en el proceso madurativo. \n(PI18/00110). Instituto de Salud \nCarlos III (ISCIII). 2019-2023. PI: \nThais Agut Quijano. \n\u2022 Contrat\nos Rio Hortega. \n(CM18/00258). Instituto de Salud \nCarlos III (ISCIII). 2019-2021. \nPI: Alfredo Garcia-Alix P\u00e9rez. \nBeneficiaria del contrato: Nuria \nCarreras Blesa.\n\u2022 Rare Coding Genetic V\nariants \nAssociated with neonatal arterial \nischemic stroke. (201714.10). \nFundaci\u00f3 La Marat\u00f3 de TV3. 2018-\n2021. PI: Alfredo Garcia-Alix P\u00e9rez. SELECTED CLINICAL TRIALS & \nOBSERVATIONAL STUDIES\n\u2022 Randomized, Double-blind, \nPlac\nebo-controlled Single-\nascending Dose Trial to Evaluate \nthe Safety, Tolerability, and \nPharmacokinetics of GWP42003-P \nin Conjunction with Hypothermia in \nNeonates with Moderate or Severe \nHypoxic Ischemic Encephalopathy. \n(GWEP1560). GW Research; \nPaidionResearch, Inc. 2019- PI: Ana \nAlarcon Allen.\nSELECTED PUBLICATIONS\n\u2022 Ades AE, Soriano A, Alarc on A, \nBonafonte F, Thorne C, Peckham CS \net al. Vertical transmission of Zika \nvirus and its outcomes: a Bayesian \nsynthesis of  prospective studies. \nLancet Infect Dis. 2021;21(4):537-\n545. IF:25,071. (Q1).\n\u2022 Fr\nan\u00e7ois C, Rodriguez A, Teixid\u00f3 M, \nAgut T, Bosch L. Attenuated brain \nresponses to speech sounds in \nmoderate preterm infants at term \nage. Dev Sci. 2021;24(1)IF:5,131. \n(Q1).\n\u2022 Garc\u00eda A, Arnaez J, Ar\nca G, Agut \nT, Alarcon A, Mart\u00edn A et al. \nDevelopment, Reliability, and \nTesting of a New Rating Scale for \nNeonatal  Encephalopathy. J Pediatr. \n2021;235:83-91.IF:4,406. (Q1).\n\u2022 Planas S, Cruz O, Miguel S, Albert \nA, Rovir\na C, Bombi JA. Extra-\naxial sacral soft tissue giant cell \nependymoma affecting a child: Case \nreport  and review of the literature. \nNeuropathology. 2021;41(2):139-\n145. IF:1,906. (Q3).\nNeuropsychology\nRoser Pueyo Benito, PhD\nIn 2021, our group continued to \nprogress with the study of the \nneuropsychological functioning \nof persons with risk factors \n(obesity), and with the study of the \nneuropsychological consequences \nof congenital, perinatal and/or \nacquired injuries (cerebral palsy \nand stroke). Likewise, we continued \nwith projects financed in national 46 INSTITUT  DE RECERCA  \nMEDICINE AND PEDIATRIC  \nSCIENCE AREA \nNEUROSCIENCE\ncompetitive calls, including the \ntelethon La Marat\u00f3 de TV3, and \nwe continued to hold the ICREA-\nAcademia award, received by one of \nour researchers. We also continued \nto apply to European calls and \nwe are awaiting the resolution \nof a COST Action in the field of \ncerebral palsy. Our projects and our \nselected publications in Q1 evidence \nour group\u2019s capacity to adopt a \nneuropsychology focus that allows us \nto achieve results ranging from the \ndevelopment of neuropsychological \nassessment guides to the pursuance \nof studies in greater depth on the \nunderlying mechanisms of disorders \n(with analysis of neuroimages, \ngenetics, microbiota, etc.). We have \nalso studied the effectiveness of \ninterventions addressed to improving \ncognitive and emotional functioning, \nsuch as physical exercise, \nmindfulness and cognitive training.\nMEMBERS\nSTAFF RESEARCHER\nIsabel Garc\u00eda Garc\u00eda, Maria Matar\u00f3 \nSerrat, Xavier Cald\u00fa Ferr\u00fas, Maria \nAngeles Jurado Luque\nPOSTDOC ASSOCIATED RESEARCHERS\nCristina S\u00e1nchez Casta\u00f1eda\nPHD STUDENTS\nAnna Prunell Casta\u00f1e, Adri\u00e0 Bermudo \nGallaguet, Montse Blasco Sierra, \nMar\u00eda Garc\u00eda Galant, Sandra Lu\u00eds Ruiz, \nXavier Prats Soteras, Noem\u00ed Lamonja \nVicente, J\u00falia Ballester Plan\u00e9, Olga \nLaporta Hoyos, Jonatan Ottino \nGonz\u00e1lez\nTECHNICIAN\nGemma Mont\u00e9 Rubio\nSELECTED PROJECTS\n\u2022 Gu\u00edas basadas en la evidencia y \nc\nonsensuadas para la evaluaci\u00f3n \nneuropsicol\u00f3gica de las personas \ncon par\u00e1lisis cerebral grave y \npar\u00e1lisis cerebral discin\u00e9tica \n(PID2020-117163RB-I00). Ministerio \nde Economia y Competitividad.\nConvocat\u00f2ria d\u2019ajuts del \nPrograma Estatal d\u2019Investigaci\u00f3, \nDesenvolupament i Innovaci\u00f3 \nOrientada als reptes de la Societat. \nModalitat Reptes. 2021-2024. PI. \nRoser Pueyo Benito.\n\u2022 Ajut per incentiv\nar i consolidar la \nrecerca d\u2019excel\u00b7l\u00e8ncia ja existent \na les universitats p\u00fabliques de \nCatalunya. Programa ICREA Academia 2018. Fundaci\u00f3 Instituci\u00f3 \nCatalana de Recerca i Estudis \nAvan\u00e7ats (ICREA). Convocat\u00f2ria del \nPrograma Icrea Acad\u00e8mia. 2019-\n2023. PI: Maria Mataro Serrat.\n\u2022 Efect\nes de ter\u00e0pies combinades \nd\u2019exercici, mindfulness i \nestimulaci\u00f3 cognitiva en la \ncognici\u00f3 i la neuroplasticitat en \npacients amb ictus isqu\u00e8mic \ncr\u00f2nic. Fundaci\u00f3 La Marat\u00f3 de TV3. \nAjuts econ\u00f2mics a projectes de \nrecerca de la Fundaci\u00f3 Marat\u00f3 de \nTV3. 2018-2022. PI: Maria Mataro \nSerrat.  \n\u2022 Inflamaci\u00f3n, estr\n\u00e9s y microbiota \ncomo mediadores entre la \nobesidad y el funcionamiento \ncerebral durante la adolescencia \n(PSI2017-86536-C2-1-R) Ministerio \nde Economia y Competitividad. \nConvocat\u00f2ria d\u2019ajuts del \nPrograma Estatal d\u2019Investigaci\u00f3, \nDesenvolupament i Innovaci\u00f3 \nOrientada als reptes de la Societat. \nModalitat Projectes I+D+I. 2018-\n2022. PI: Maria Angeles Jurado \nLuque.\nSELECTED PUBLICATIONS\n\u2022 Castells A, Roig F, Dacosta R, \nLamonja N, Sawicka AK, T\nor\u00e1n \nP et al. Exercise and Fitness \nNeuroprotective Effects: Molecular, \nBrain Volume and  Psychological \nCorrelates and Their Mediating \nRole in Healthy Late-Middle-Aged \nWomen  and Men. Front Aging \nNeurosci. 2021;13:615247. IF:5,750. \n(Q1).\n\u2022 Cast\nells A, Roig F, Lamonja N, \nTor\u00e1n P, Pera G, Montero P et al. \nSex Matters in the Association \nbetween Physical Activity and \nFitness with Cognition. Med Sci \nSports Exerc. 2021;53(6):1252-9. \nIF:5,411. (Q1).\n\u2022 Lamonja N, Dacos\nta R, L\u00f3pez J, \nPrades L, Roig F, Castells A et al. \nSex-Specific Protective Effects of \nAPOE e2 on Cognitive Performance. \nJ Gerontol A Biol Sci Med Sci. \n2021;76(1):41-9. IF:6,053. (Q1).\n\u2022 Ottino J, Baggio HC, Jurado MA, \nSegur\na B, Caldu X, Prats X et \nal. Alterations in Brain Network \nOrganization in Adults With Obesity \nas Compared With  Healthy-Weight \nIndividuals and Seniors. Psychosom \nMed. 2021;83(7):700-6. IF:4,312. \n(Q1).Cognitive \nneuroscience\nCarles Escerca Mic\u00f3, PhD\nIn 2021, our group continued \nto foster collaboration with the \nFoetal Environment and Obstetric \nComplications research group, led by \nDr G\u00f3mez-Roig, for the purpose of \npromoting the identification of EEG-\nderived biomarkers obtained at birth, \npredicting neurodevelopment in the \nearly stages of childhood. We have \npublished two significant studies \non this subject: one proposing \na method for obtaining cerebral \nresponse to language sounds \n(frequency-following response \u2013 \nFFR), which allows identification \nof neural coding processes which \nare already mature at birth and of \nothers which are not yet mature \n(Arenillas-Alc\u00f3n et al. , 2021); and \na study establishing the protocols \nrequired to register the neonatal \nFFR (Lemos et al. , 2021). These two \npublications open the way for the \nmass monitoring of the cerebral \nmaturation allowing language \nprocessing in newborns. A third \nsignificant study conducted in this \nperiod identifies the brain structures \nresponsible for FFR, pinpointing \nsubcortical components of the \nauditory pathway (Gorina-Careta et \nal., 2021). Indeed, this study is very \nimportant since it reveals the basis \nfor the use of FFR as a biomarker \nfor language acquisition in persons \nat risk (for example, full-term low-\nweight newborns), thus providing a \nsignificant indicator of subcortical \nactivity in the neonatal population, in \nwhich the cerebral cortex needs to \nundergo a far-reaching experience-\ndependent maturation. At present \nour studies are addressed to \nresearching the consequences of \nhigh-risk pregnancy (low birthweight \nand high birthweight) by means of \nthis indicator. \nOther studies have also been \npromoted in which we will be making \nuse of brain signals associated with \nprediction errors, and glutamatergic \nneuromodulation \u2014such as those \nused in Font-Alaminos et al.  (2021)\u2014 \nin populations with neurodevelopment \nalterations.47 INSTITUT  DE RECERCA  \nMEDICINE AND PEDIATRIC  \nSCIENCE AREA \nNEUROSCIENCE\nMEMBERS\nSTAFF RESEARCHER\nJordi Costa Faidella, Imma Clemente \nLapena, Maria Jos\u00e9 Corral L\u00f3pez, Maria \nIsabel N\u00fa\u00f1ez Pe\u00f1a, Iria San Miguel \nIns\u00faa, Hans Sup\u00e8r, Marc Via Garcia\nPHD STUDENTS\nSonia Arenillas Alc\u00f3n, Marta \nPuertollano Rodr\u00edguez, Teresa Ribas \nPrats, Alejandro Lerer\nSELECTED PROJECTS\n\u2022 Ajut per incentiv ar i consolidar la \nrecerca d\u2019excel\u00b7l\u00e8ncia ja existent \na les universitats p\u00fabliques de \nCatalunya. Programa ICREA \nAcademia 2020. Fundaci\u00f3 Instituci\u00f3 \nCatalana de Recerca i Estudis \nAvan\u00e7ats (ICREA). Convocat\u00f2ria \ndel Programa Icrea. 2021-2025. PI: \nCarles Escera.\n\u2022 Tr\nastornos del espectro alcoh\u00f3lico \nfetal (TEAF): Identificaci\u00f3n precoz \ny biomarcadores de riesgo para \nalteraciones neurocognitivas \nmediante el potencial de \nseguimiento de frecuencia (PSF). \nFundaci\u00f3n Alicia Koplowitz. \nConvocatoria de Ayudas a \nProyectos de Investigaci\u00f3n en el \n\u00e1rea de Psiquiatr\u00eda de la Infancia y \nAdolescencia y Neurociencias en el \nNi\u00f1o. 2020-2022. PI: Carles Escera.\n\u2022 Caract\nerizaci\u00f3n de la respuesta \nde seguimiento de frecuencia \n(RSF) en reci\u00e9n nacidos como \nposible biomarcador de desarrollo \nneurocognitivo (PGC2018-094765-\nB-I00). Ministerio de Ciencia, \nInnovaci\u00f3n y Universidades. \nConvocat\u00f2ria d\u2019ajuts del Programa \nEstatal de Foment de la Investigaci\u00f3 \nCient\u00edfica i T\u00e8cnica d\u2019Excel\u00b7l\u00e8ncia. \nSubprograma Estatal de generaci\u00f3 \ndel coneixement. Modalitat \nProjectes d\u2019R+D de Generaci\u00f3 del \nConeixement. 2019-2022. PI: Carles \nEscera.\n\u2022 ARTSOUNDSCAPES - The sound \nof special plac\nes: exploring rock \nart soundscapes and the sacred \n(787842). European Research \nCouncil (ERC). Advanced Grant. \n20218-2024. PI: Carles Escera.\nSELECTED PUBLICATIONS\n\u2022 Arenillas-Alc\u00f3n S, Costa J, Ribas \nT, G\u00f3mez MD, Esc\nera C. Neural \nencoding of voice pitch and formant \nstructure at birth as revealed by  \nfrequency-following responses. Sci Rep. 2021;11(1):6660. IF:4,379. (Q1).\n\u2022 Font-Alaminos M, Ribas T, Gorina \nN, Esc\nera C. Emergence of \nprediction error along the human \nauditory hierarchy. Hear Res. \n2021;399:107954. IF:3,208. (Q1).\n\u2022 Gorina-Caret\na N, Kurkela J, \nH\u00e4m\u00e4l\u00e4inen J, Astikainen P, \nEscera C. Neural generators \nof the frequency-following \nresponse elicited to stimuli \nof low and  high frequency: \nA magnetoencephalographic \n(MEG) study. Neuroimage. \n2021;231:117866. IF:6,556. (Q1).\n\u2022 Lemos FA, da Sil\nva Nunes AD, de \nSouza CK, Escera C, Taveira KVM, \nBalen SA. Frequency-Following \nResponse in Newborns and Infants: \nA Systematic Review of Acquisition \nParameters. J Speech Lang Hear \nRes. 2021;64(6):2085-2102. IF:2,297. \n(Q1).\nAttention, \nPerception \nand Language \nAcquisition (APAL)\nLaura Bosch Galceran, PhD\nOur research activity has been affected \nby the pandemic situation and by the \nchange of location of the APAL group\u2019s \nlaboratory to the facilities at Num\u00e0ncia \nStreet. We have advanced in three \ndirections. Firstly, in the research line \non the child population with bilateral \nprofound deafness, we completed \nthe sample of pre-implant patients \nand started up their 24-months \npost-implant reassessment with \nmeasurements of lexical learning and \noral language level achieved (research \nin collaboration with the ORL unit [Dr \nClaveria and Dr Haag], Neuroradiology \n[M. Rebollo] and Psychology [D. Polo]). \nAt the same time, we assessed two \ngroups of children with normal hearing, \nat 10 months and at 18-24 months, \nwho will form the control groups of this \nstudy, which is expected to end in 2022. \nPreliminary data suggest differences \nbetween groups at 10 months in social \ncognition tasks, and a great variability \nin post-implant performance. These results will be analysed, taking into \nconsideration the neuroimaging data \nobtained in the pre-implant period and \nother cognitive and communicative \ndevelopment variables that have been \ncollected. We have also progressed in \na second research line focused on the \nstudy of the audiovisual processing of \nspeech from the age of 4 months in \nfull-term and moderately premature \nchildren (the sample is pending \ncompletion, with the collaboration of Dr \nAgut). The purpose of this research line \nis to analyse the impact of a bilingual/\nmultilingual family setting on the basic \nprocesses of recognition of the mother \ntongue, the association between the \nspeaker and the speech ordinarily \nused, and the association between the \nvoice of the speaker and speech. Lastly, \nwe succeeded in completing the follow-\nup study of a sample of full-term low-\nweight (SGA) children with cognitive \nand speech data, and with data on \nschool performance, at the age of 7-8 \nyears (a study in collaboration with \nDr Ib\u00e1\u00f1ez\u2019s group). The preliminary \nresults, which were presented at the \n3rd Research Conference of the IRSJD, \nshow differences between groups in \nthe areas of attention and executive \nfunction, and minor differences in \nspeech, which were more prominent \nin the phonological and articulatory \ndomain, with a possible link to reading \ndifficulties. We also worked on the \nconnection between endocrine-\nmetabolic variables and cognitive-\nlinguistic performance, and on the \nsearch for catch-up patterns that may \npredict cognitive results to be achieved \nin the long term.\nMEMBERS\nSTAFF RESEARCHER\nFerran Pons Gimeno, Marta Ramon \nCasas\nPOSTDOC ASSOCIATED RESEARCHERS\nJoan Birul\u00e9s Muntan\u00e9, Cl\u00e9ment \nFran\u00e7ois\nASSISTANT RESEARCHER\nJessica S\u00e1nchez-Gal\u00e1n Frauca\nSELECTED PROJECTS\n\u2022 Pr\u00f2rroga del conveni de col\u00b7laboraci\u00f3 \nper una r\necerca sobre cognici\u00f3 i \npercepci\u00f3 de lleng\u00fces en nens. \nFundaci\u00f3 Privada Bet\u00e0nia-Patmos. \n2019-2023. PI: Ferran Pons Gimeno.\n\u2022 Variabilidad en el pr\nocesamiento \naudiovisual del habla en la infancia: 48 INSTITUT  DE RECERCA  \nMEDICINE AND PEDIATRIC  \nSCIENCE AREA \nNEUROSCIENCE\nrol de la experiencia ling\u00fc\u00edstica, \nmaduraci\u00f3n neurol\u00f3gica y capacidad \nsensorial (PGC2018-097487-B-I00). \nMinisterio de Ciencia, Innovaci\u00f3n y \nUniversidades. Convocat\u00f2ria d\u2019ajuts \ndel Programa Estatal de Foment de \nla Investigaci\u00f3 Cient\u00edfica i T\u00e8cnica \nd\u2019Excel\u00b7l\u00e8ncia. Subprograma Estatal \nde generaci\u00f3 del coneixement. \nModalitat Projectes d\u2019R+D de \nGeneraci\u00f3 del Coneixement. 2019-\n2022. PI: Ferran Pons Gimeno i \nLaura Bosch Galceran.\n\u2022 Resonancia magn\u00e9tica funcional \ne imagen de t\nensor de difusi\u00f3n \nen la valoraci\u00f3n prequir\u00fargica del \npaciente pedi\u00e1trico con hipoacusia \nprelingual neurosensorial \nprofunda bilateral de detecci\u00f3n \nen el cribado neonatal como \npotenciales biomarcadores de \ndesarrollo de lenguaje oral tras la \ncolocaci\u00f3n de un implante coclear \n(PCP00215). Sociedad Espa\u00f1ola de \nNeuroradiolog\u00eda. SERN 2017. 2017-\n2022. PI: M\u00f3nica Rebollo.\nSELECTED PUBLICATIONS\n\u2022 Fran\u00e7ois C, Garc\u00eda-Alix A, Bosch L, \nRodriguez-F\nornells A. Signatures of \nbrain plasticity supporting language \nrecovery after perinatal arterial  \nischemic stroke. Brain Lang. \n2021;212:104880. IF:2,381. (Q1).\n\u2022 Fr\nan\u00e7ois C, Rodriguez-Fornells \nA, Teixid\u00f3 M, Agut T, Bosch L. \nAttenuated brain responses to \nspeech sounds in moderate preterm \ninfants at term age. Dev Sci. \n2021;24(1):12990. IF:5,131. (Q1).\n\u2022 Martinez A, Sanz M, Pons F, de\n \nDiego R. Rethinking attention in \ntime: Expectancy violations reconcile \ncontradictory developmental \nevidence. J Exp Child Psychol. \n2021;206:105070. IF:2,610. (Q2).\nResearch in child \nand adolescent \nmental health\nMontserrat Dolz Abadia, MD, PhD\nThe primary purpose of our \nresearch group is the clinical investigation of various psychiatric \ndisorders, with special emphasis on \nneurodevelopment disorders and \nearly-onset disorder. At present our \nefforts are focused on the study of \nchildhood-onset psychosis (PI: Dr \nDolz), of attention deficit hyperactivity \ndisorder (ADHD) (PI: Dr Alda) and \nof autism spectrum disorder (ASD) \n(PI: Dr Mairena, Dr Aranbarri), as \nwell as on promoting the prevention \nand detection of child witnesses to \ndomestic violence (PI: Dr \u00c1lvarez, Dr \nLacasa).\nIn recent years, our group has \nbecome consolidated through the \nimplementation of various projects \nfinanced by public (FIS projects, \nMINECO) and private institutions, both \nnational and European (European \nCommission), as well as through \ncollaboration with various stable \nresearch groups of the CIBERSAM \nnetwork for biomedical research on \nmental health, and with the G04 group \nof the Clinical and Provincial Hospital \nof Barcelona and the G01group of the \nGregorio Mara\u00f1\u00f3n Hospital in Madrid.\nOf special note is the recent award \n(2021) of the FIS grant \u201cMulti-centre \nlongitudinal study of markers for \nprediction of transition to psychosis \nof children and adolescents with risk \nof psychosis: The role of intrauterine \nstress\u201d (PI: Dr Dolz; PI21/00090).\nMention should also be made of \nthe development of the TEA-CARE \nprogramme in collaboration with the \nMas Casadevall Autism Foundation \nand financed by La Caixa Foundation, \naddressed to implementing a clinical \nprogramme of autism care based \non research and to the education of \nchildren aged 0-4 years.\nMEMBERS\nSTAFF RESEARCHER\nAlazne Gorrotxategi Aizpitarte, Aritz \nAranbarri Paredes, Inmaculada Insa \nPineda, Xavier Estrada Prat, Francisco \nVillar Cabeza, Laia Moll\u00e0 Cus\u00ed, Esther \nVia Virgili, Neus Elias Carbonell, Jos\u00e9 \n\u00c1ngel Alda D\u00edez, Mar Alvarez Segura, \nEster Camprodon Rosanas, Maria Diez \nJuan, Fernando Lacasa Saludes, Ma \n\u00c1ngeles Mairena Garc\u00eda de la Torre, \nJosep Llu\u00eds Matal\u00ed Costa, Daniel \nMu\u00f1oz Samons,, Marta Pardo Gallego, \nIsabel Rueda Barcena, Bernardo \nS\u00e1nchez Fern\u00e1ndez, Eduardo Serrano \nTroncoso, Anna Sintes Estevez\nPOSTDOC ASSOCIATED RESEARCHERS\nAnna Butjosa MolinesPHD STUDENTS\nLaia Villalta Maci\u00e1, Ania Perez Racana, \nClaudia Caprile Elola - Olaso, Laura \nPuigcerver Navarro, Jordina Tor Fabra\nASSISTANT RESEARCHER\nCarolina Morales Guerrero, Berta \nSanfeliu Salv\u00e0, Anna Mart\u00ednez Garc\u00eda, \nFederica Lombardini, Sara Parrilla \nCarrasco, Ingrid Tortad\u00e8s Arum\u00ed, \nMarina Fabrega Ribera, Carlota \nSaumell Andreu, Andrea Gonz\u00e1lez \nContijoch\nSELECTED PROJECTS\n\u2022 Impacte de l\u2019estressor ambiental \nCO\nVID19 sobre les emocions i \nla conducta en poblaci\u00f3 infanto-\njuvenil: Macro-Estudi longitudinal \nEmCoVID19 i EmCoVID19-unitats \ncl\u00edniques. (BML 2021_HSJD). \nO.H.S.J.D.-Curia Provincial. 2021-\n2022. IP: Esther Via Virgili. \n\u2022 Beca Ret\norno Fundaci\u00f3n Alicia \nKoplowitz_Alba Vilaplana. (Beca \nRetorno_Alba Vilaplana). Fundaci\u00f3n \nAlicia Koplowitz. 2020-2021. IP: \nMontserrat Dolz Abadia. \n\u2022 Beca Ret\norno Fundaci\u00f3n Alicia \nKpplowitz_Maria Andreu. (Beca \nRetorno_Maria Andreu). Fundaci\u00f3n \nAlicia Koplowitz. 2020-2021. IP: \nMontserrat Dolz Abadia. \n\u2022 Efect\nos del tratamiento \nfarmacol\u00f3gico en pacientes con \nTrastorno por D\u00e9ficit de Atenci\u00f3n \ny Hiperactividad (TDAH). (Ayudas \nInvestigaci\u00f3n 2019). Banc de \nSabadell, S.A. 2020-2021. IP: Miriam \nSanabra Gonzalez. \n\u2022 Disrupci\u00f3n de los ritmos cir\ncadianos \nen poblaci\u00f3n infantil con Trastornos \ndel Neurodesarrollo (TDAH y TEA) y \nsu impacto sobre la salud y calidad \nde vida. (PI19/00113). Instituto de \nSalud Carlos III (ISCIII). 2020-2022. \nIP: Jos\u00e9 \u00c1ngel Alda D\u00edez. \nSELECTED CLINICAL TRIALS & \nOBSERVATIONAL STUDIES\n\u2022 Ensayo controlado con placebo \nen sujet\nos con alto riesgo para la \npsicosis comparado con \u00e1cidos \ngrasos omega-3 en Europa. \nPURPOSE / ABR54654. University \nMedical Center Utrecht. 2016-. PI: \nMontserrat Dolz Abadia.\n\u2022 A Double-blind, Randomized, \nP\nsychoactive Placebo-controlled, \nStudy to Evaluate the Efficacy and \nSafety of 3 Fixed Doses (28 mg, \n56 mg and 84 mg) of Intranasal 49 INSTITUT  DE RECERCA  \nMEDICINE AND PEDIATRIC  \nSCIENCE AREA \nNEUROSCIENCE\nEsketamine in Addition to \nComprehensive Standard of Care \nfor the Rapid Reduction of the \nSymptoms of Major Depressive \nDisorder, Including Suicidal \nIdeation, in Pediatric Subjects \nAssessed to be at Imminent Risk for \nSuicide. ESKETINSUI2002. Janssen \n- Cilag, S.A. 2018-. PI: Montserrat \nDolz Abadia. \nSELECTED PUBLICATIONS\n\u2022 ENIGMA Clinical High Risk \nf\nor Psychosis Working Group;  \nJalbrzikowski M, Hayes RA, \nWood SJ, Nordholm D, Zhou JH, \nFusar-Poli P et al. Association of \nStructural Magnetic Resonance \nImaging Measures With Psychosis \nOnset  in Individuals at Clinical \nHigh Risk for Developing Psychosis: \nAn ENIGMA Working  Group \nMega-analysis. JAMA Psychiatry. \n2021;78(7):753-766. IF:21,596. (Q1). \n\u2022 Insa Pineda I, Via E, Estr\nada-Prat \nX, G\u00f3mez-Gonz\u00e1lez CL, Alda JA. \nAttention Deficit Hyperactivity \nDisorder (ADHD) & COVID-19: Do Caregivers and Children Report \nthe Same?. Int J Mental Health \nPsychiatry. 2021;7(1). \n\u2022 Serra-Blasc\no M, Radua J, Soriano-\nMas C, G\u00f3mez-Benlloch A, Porta-\nCaster\u00e0s D, Carulla-Roig M et al. \nStructural brain correlates in major \ndepression, anxiety disorders and  \npost-traumatic stress disorder: A \nvoxel-based morphometry meta-\nanalysis. Neurosci Biobehav Rev. \n2021;129:269-281. IF:8,989. (Q1). \n\u2022 Zer\u00f3n-Rugerio MF, Carpio-Arias TV, \nFerreira-Garc\u00eda E, D\u00edez-Noguera \nA, Cambras T, Alda JA et al. ADHD \nsubtypes are associated differently \nwith circadian rhythms of motor \nactivity,  sleep disturbances, and \nbody mass index in children and \nadolescents: a case-control  study. \nEur Child Adolesc Psychiatry. \n2021;30(12):1917-1927. IF:4,785. \n(Q1).\n1 FOREWORD\nGovernance and structures\nGlobal numbers 2020\nGlobal numbers 2020-2015\nInstitutional awards\n7.1\nMEDICINE  \nAND PEDIATRIC \nSCIENCE AREA\n7.1.2\nAdaptive response, \nmetabolism and \nimmunobiology\nMetabolic endocrinology\nMetabolic diseases of paediatric origin\nMolecular biology and gene regulation of adipose tissue and its \npathologies\nNeonatology research group\nPharmacological targets in inflammation and metabolic diseases\nStudy of diseases due to immune dysfunction in pediatrics (GEMDIP)\nInfectious diseases and microbiome\nGut microbiota\nEnvironment and complications in pregnancy\nCardiovascular diseases in development\nImmune and respiratory dysfunction in the critical child\nAllergic diseases in childhood and adolescence51 INSTITUT  DE RECERCA  \nMEDICINE AND PEDIATRIC  \nSCIENCE AREA \nADAPTIVE RESPONSE, METABOLISM  \nAND IMMUNOBIOLOGY\nMetabolic \nendocrinology\nLourdes Ib\u00e1\u00f1ez Toda, MD, PhD\nDuring this year, we completed the \npreparations to begin the recruitment \nof patients for the SPIOMET4HEALTH \n(Horizon 2020, European Commission) \nmulti-centre, multi-national, \nrandomised double-blind European \nclinical trial. The final protocol was \ncompleted, the permits of the ethical \ncommittees and of the agencies of the \nparticipating countries were obtained, \nthe electronic data collection logbook \nwas developed, the communication \nand patient recruitment strategy \nwas prepared, and the production \nand distribution of the drugs under \nstudy was completed. Likewise, we \nadvanced in the study of adipose \ntissue biomarkers in newborns and \nbabies, and in the study of their \nrelation to body composition, which \nled to the publication of two articles \nin Q1 journals. We also continued to \ninvestigate the pathophysiological \nmechanisms determining the \npolycystic ovary syndrome, and the \neffects of different treatments on \nthe intestinal microbiome, as well as \nthe changes in the concentrations of \ngrowth and differentiation factor 15 \n(GDF15), which controls body weight \nby means of a central receptor. These \nstudies led to the publication of two \nmore articles in Q1. We completed the \nlongitudinal follow-up of patients and \nbegan the analysis of the circulating \nexosomes and of their proteome in \nchildren with low weight and normal \nweight for gestational age, within \nthe framework of the ISCIII project \nPI18/00109. We communicated all \nthe results of these studies in guest \nconferences, notably including those \nof the 15th Congress of the European \nAssociation of Paediatric and \nAdolescent Gynaecology (EURAPAG, \nJune 2021); the 22nd Congress of \nthe Mexican Society for Paediatric \nEndocrinology (August 2021); and the \n48th Annual Meeting of the British \nSociety for Paediatric Endocrinology & \nDiabetes (November 2021).\nMEMBERS\nSTAFF RESEARCHER\nSilvia Xargay Torrent, Paula Casano \nSancho, Marta D\u00edaz SilvaPHD STUDENTS\nCristina Garc\u00eda Beltran\nASSISTANT RESEARCHER\nChristian Mata Miquel, Cristina Plou \nP\u00e9rez\nTECHNICIAN\nRita Maria Martins de Sousa Maia \nMalpique\nCOLLABORATOR RESEARCHER\nGemma Carreras Badosa, Esther \nLizarraga Mollinedo, Judith Bassols \nCasadevall, Francis de Zegher, Abel \nL\u00f3pez Bermejo\nSELECTED PROJECTS\n\u2022 SPIOMET4HEALTH_PCOS in \nadol\nescent girls and young women: \nToward a treatment guided by \npathopsysiology. (899671). European \nCommission. 2021-2026. PI: \nLourdes Iba\u00f1ez Toda.\n\u2022 Perfil l\nongitudinal de exosomas \ncirculantes y de su proteoma en \nni\u00f1os nacidos con bajo peso y peso \nadecuado para la edad gestacional: \nUtilidad como biomarcador de \ns\u00edndrome metab\u00f3lico. (PI18/00109). \nInstituto de Salud Carlos III (ISCIII). \n2019-2023. PI: Lourdes Iba\u00f1ez \nToda.\n\u2022 SGR 2017_Repercus\nsi\u00f3 de les \nalteracions prenatals perinatals \nen el desenvolupament postnatal. \nMalalties d\u2019origen fetal. (2017 SGR \n01236). Agaur - Ag\u00e8ncia de Gesti\u00f3 \nd\u2019Ajuts Universitaris i de Recerca. \n2017-2021. PI: Lourdes Iba\u00f1ez Toda.\nSELECTED CLINICAL TRIALS & \nOBSERVATIONAL STUDIES\n\u2022 Estudio observacional, prospectivo \ny multic\n\u00e9ntrico a largo plazo en \nuna cohorte de ni\u00f1os con talla \nbaja nacidos peque\u00f1os para su \nedad gestacional (PEG) que han \nsido tratados con Saizen\u00ae. (EMR \n200098_008 / MER-GRH-2009-01). \nMerck KGaA. 2018-. PI: Lourdes \nIba\u00f1ez Toda. \n\u2022 Tr\neatment with recombinant growth \nhormone (rGH) in short patients \nborn small-for-gestional-age (SGA) \nfollowed at Hospital Sant Joan de \nD\u00e9u: Analysis of early predictors \nof good response useful in clinical \npractice. (WI191603). Fundaci\u00f3 \nPrivada per a la Recerca i la \nDoc\u00e8ncia Sant Joan de D\u00e9u - FSJD. \n2014-. PI: Lourdes Iba\u00f1ez Toda. \n\u2022 Identification of cir\nculating \nmicroRNAs in short children born small for gestational age: \nRelationship with pre- and postnatal \ngrowth and metabolic parameters. \n(LOR-HOR-2013-01). L\u00f3pez. 2014-. \nPI: Lourdes Iba\u00f1ez Toda. \n\u2022 GHLiquid-3676 (NNH-SOM-2012-01) \nEstudio int\nernacional de \ndesenlaces de NordiNet\u00ae (IOS \nde NordiNet\u00ae)\u201d. (GHLiquid-3676 \n(NNH-SOM-2012-01)). Novo Nordisk \nPharma, S.A. 2012-. PI: Lourdes \nIba\u00f1ez Toda.\nSELECTED PUBLICATIONS\n\u2022 de Zegher F, D\u00edaz M, Villarro ya J, \nCairo M, L\u00f3pez A, Villarroya F et \nal. The relative deficit of GDF15 \nin adolescent girls with PCOS can \nbe changed into an abundance \nthat reduces liver fat. Sci Rep. \n2021;11(1):7018-7018. IF: 4,379. \n(Q1).\n\u2022 D\u00edaz M, Blasco A, Villarr\noya J, \nL\u00f3pez A, de Zegher F, Villarroya \nF et al. Circulating diazepam-\nbinding inhibitor in infancy: \nRelation to markers of adiposity \nand metabolic health. Pediatr Obes. \n2021;16(11):12802. IF: 4,000. (Q1).\n\u2022 Garc\u00eda C, Malpique R, Carbonett\no \nB, Gonz\u00e1lez P, Henares D, \nBrotons P et al. Gut microbiota in \nadolescent girls with polycystic \novary syndrome: Effects of \nrandomized treatments. Pediatr \nObes. 2021;16(4):12734-12734. IF: \n4,000. (Q1).\n\u2022 Inarejos E, Nav\narro OM, Navallas \nM, Enrique G, Colombo C, Su\u00f1ol \nM et al. Omphalomesenteric \nDuct Anomalies in Children: \nA Multimodality Overview. \nRadiographics. 2021;41(7):2090-\n2110. IF: 5,333. (Q1).\nMetabolic diseases \nof paediatric origin\nJosep Jim\u00e9nez Chillar\u00f3n, PhD  \n& Carles Lerin Mart\u00ednez, PhD\nOur research focuses on gaining \na better understanding of the \nmolecular mechanisms at play when \nnutrition and growth during very early \nstages of life affect the subsequent 52 INSTITUT  DE RECERCA  \nMEDICINE AND PEDIATRIC  \nSCIENCE AREA \nADAPTIVE RESPONSE, METABOLISM  \nAND IMMUNOBIOLOGY\ndevelopment of childhood obesity \nor metabolic diseases in adulthood. \nThis paradigm is known as the \nDevelopmental Origins Of Health and \nDisease (DOHaD). We have brought \ntogether a multidisciplinary group for \nthis research effort including doctors, \nnutritionists, biologists, biochemists, \nand laboratory technicians. Together \nwe carry out highly translational \nresearch involving: \n1. The dev\nelopment and \ncharacterisation of experimental \nmodels (mouse) that \neffectively recapitulate human \npathophysiology. \n2. The design of clinical studies aimed \nat developing new prevention and \ntreatment strategies. \nOver the past few years, we have \napplied omic techniques to help \nfurther understand these processes \nand identify early biomarkers. We are \ncurrently evaluating the physiological \nrole of these biomarkers through in \nvitro and in vivo animal cell models \nas well as clinical studies, including \ntwo ongoing clinical studies. The aim \nis to attain a better understanding \nof the possible implication in the \npathophysiology associated with \nmetabolic diseases and to design new \nnutritional-therapeutic interventions \nfor the treatment of childhood obesity \nand associated metabolic disorders.\nMEMBERS\nSTAFF RESEARCHER\nMontserrat Amat Bou, Serafin Murillo \nGarcia, Marina Llobet Garces, Ruben \nD\u00edaz Naderi, Marta Ramon Krauel\nPOSTDOC ASSOCIATED RESEARCHERS\nMarcela Catalina Parra Vargas\nPHD STUDENTS\nMarta Mourin Fern\u00e1ndez, Paula \nXimena Molina Giraldo, Charlotte \nMartine Juton\nCOLLABORATOR RESEARCHER\nIvonne Palacios Marin\nSELECTED PROJECTS\n\u2022 Non-genomic Inheritanc e of \nenvironmentally-induced traits: \nDeciphering epigenetically-driven \ngenetic variation in mammals. \nID 62167. JOHN TEMPLETON \nFOUNDATION. 2021-2024. IP: Jos\u00e9 \nCarlos Jim\u00e9nez Chillar\u00f3n.\n\u2022 Modulaci\u00f3n de la dieta dur\nante las \nprimeras etapas de la vida como \nestrategia de prevenci\u00f3n de la obesidad infantil. (PDC2021-121816-\n100). Ministerio de Econom\u00eda Y \nCompetitividad (MINECO). 2021-\n2023. IP: Carles Lerin Martinez. \n\u2022 Impact of maternal SARS-CoV-2 \ninf\nection and vaccination on breast \nmilk antibodies, milk bioactive \ncompounds and maternal-child \nhealth (MilkCORONA). (202106-32). \nFundaci\u00f3 La Marat\u00f3 de TV3. 2021-\n2023. IP: Carles Lerin Martinez. \n\u2022 El microbioma int\nestinal como \ndiana terap\u00e9utica en el s\u00edndrome de \nPrader-Willi: efectos metab\u00f3licos \ny en el comportamiento de los \npacientes. (PI20/00301). Instituto de \nSalud Carlos III (ISCIII). 2021-2023. \nIP: Marta Ramon Krauel.\nSELECTED CLINICAL TRIALS & \nOBSERVATIONAL STUDIES\n\u2022 El microbioma intestinal como \ndiana t\nerap\u00e9utica en el s\u00edndrome de \nPrader-Willi: efectos metab\u00f3licos \ny en el comportamiento de los \npacientes. (PI20/00301). Instituto de \nSalud Carlos III (ISCIII). IP: Marta \nRamon Krauel.\n\u2022 Suplement\naci\u00f3n con beta\u00edna de la \ndieta materna durante la lactancia \ncomo estrategia de prevenci\u00f3n \nde obesidad infantil. (SAF2017-\n88005-R). Ministerio de Econom\u00eda Y \nCompetitividad (MINECO). IP: Carles \nLerin Martinez.\nSELECTED PUBLICATIONS\n\u2022 Ribas F, Parr a M, Ramon M, D\u00edaz R, \nLerin C, Cambras T et al. Time-\nRestricted Feeding during Puberty \nAmeliorates Adiposity and Prevents \nHepatic Steatosis in a Mouse Model \nof Childhood Obesity. Nutrients. \n2021;13(10):3579. IF:5,717. (Q1).\n\u2022 Ribas F, Rib\u00f3 S, Parr\na M, Fern\u00e1ndez \nA, Cebri\u00e0 J, Guardiola M et al. \nNeonatal overfeeding during \nlactation rapidly and permanently \nmisaligns the hepatic  circadian \nrhythm and programmes adult \nNAFLD. Mol Metab. 2021;45:101162. \nIF:7,422. (Q1).\n\u2022 Rib\u00f3 S, S\u00e1nchez D, Mart\u00ednez L, \nGarc\u00eda I, Ramon M, T\nondo M et \nal. Increasing breast milk betaine \nmodulates Akkermansia abundance \nin mammalian neonates and \nimproves long-term metabolic \nhealth. SCI TRANSL MED. \n2021;13(587):322. IF:17,956. (Q1).Molecular \nbiology and gene \nregulation of \nadipose tissue and \nits pathologies\nFrancesc Villarroya Gombau, PhD\nIn 2021, our team continued its basic \nand translational research on the \ncontrol mechanisms of adiposity and \ncardiometabolism, and their changes \nunder pathological conditions such as \nobesity, diabetes, and other metabolic \nand cardiovascular diseases. We \nidentified new adipokines and \ncardiokines which are predominantly \nproduced by brown adipose tissue \nand heart and new intracellular \ncontrol factors of adipose and cardiac \nplasticity in response to hormonal \nstimuli. In the translational field, we \nanalysed the activity of the brown \nadipose tissue and the variations \nin the levels of new metabolic \nbiomarkers in connection with \npathophysiological determinants in \nthe paediatric population, as well \nas we analyzed new cardiokines as \nmolecular biomarkers of cardiac \ndiseases.\nMEMBERS\nSTAFF RESEARCHER\nAleix Gavald\u00e0 Navarro, Joan Villarroya \nTerrade, Marta Giralt Oms, Roser \nIglesias Coll, Teresa Mampel Astals, \nAnna Planavila Porta\nPOSTDOC ASSOCIATED RESEARCHERS\nMarion Peyrou, Tania Quesada L\u00f3pez, \nMontserrat Cair\u00f3 Calzada, Rub\u00e9n \nCereijo T\u00e9llez\nPHD STUDENTS\nLaura Campderr\u00f3s Traver, Gemma \nFerrer Curriu, Samantha Mor\u00f3n Ros, \nCelia Helena Rup\u00e9rez Gonzalo\nTECHNICIAN\nMercedes Morales Rueda, Gemma \nMoreno Besora, Albert Per\u00f2 Garcia\nSELECTED PROJECTS\n\u2022 ACBP, \u00bfuna nueva cardiomioquina \npar\na la detecci\u00f3n y tratamiento \nde la enfermedad card\u00edaca?. \nSociedad Espa\u00f1ola de Cardiolog\u00eda. \nBecas de ayuda para proyectos de \nInvestigaci\u00f3n B\u00e1sica o Traslacional 53 INSTITUT  DE RECERCA  \nMEDICINE AND PEDIATRIC  \nSCIENCE AREA \nADAPTIVE RESPONSE, METABOLISM  \nAND IMMUNOBIOLOGY\nen Salud Cardiovascular de la \nSociedad Espa\u00f1ola de Cardiolog\u00eda \ny Fundaci\u00f3n Espa\u00f1ola del Coraz\u00f3n. \n2021-2022. PI: Ana Planavila Porta.\n\u2022 Descifrando el papel endocrino \ndel t\nejido adiposo marr\u00f3n: \nnuevos actores, nuevas funciones \n(PID2020-114112RB-I00). \nMinisterio de Ciencia e Innovaci\u00f3n \n(MICINN). Convocat\u00f2ria d\u2019ajuts del \nPrograma Estatal d\u2019Investigaci\u00f3, \nDesenvolupament i Innovaci\u00f3 \nOrientada als reptes de la Societat. \nModalitat Reptes. 2021-2024. PI: \nFrancesc Villarroya Gombau.\n\u2022 Estudios pr\necl\u00ednicos para \ndeterminar las alteraciones \nen el balance energ\u00e9tico y/o la \nfunci\u00f3n adipocitaria subyacentes \nal incremento de peso corporal en \npersonas que viven con VIH tratadas \ncon INsTI y/o TAF (PI20/00106). \nMinisterio de Ciencia, Innovaci\u00f3n \ny Universidades. Ajuts de l\u2019Acci\u00f3 \nEstrat\u00e8gica en Salut: Subprograma \nde projectes d\u2019investigaci\u00f3 en salut \n(PI). 2020-2023. PI: Marta Giralt \nOms.\nNeonatology \nresearch group\nMartin Iriondo Sanz, MD, PhD\nOur group has two main research \nlines: nutrition and prematurity, on \nthe one hand, and the critical patient, \non the other. In our nutrition and \nprematurity line, we have helped to \ndemonstrate, within the framework \nof a European multi-centre study, the \nutility of the continuous monitoring of \nthe blood glucose level in real time in \npremature patients under intensive \ncare. We continued investigating \nthe factors present in human milk \nthat may have an impact on the \ndevelopment of very premature \nnewborns (born sooner than the 32nd \nweek of pregnancy), with special \nattention to microbiota and to the \nnutritional and hormonal content. \nWe also studied the long-term \nconsequences of our interventions \nand we are following our cohort of \nvery premature newborns in the \nprepubertal period, focusing on the evolution of their growth, metabolism \nand neurodevelopment.\nWith respect to the critical patient, \nwe continue to research brain injury, \nespecially in the patients affected by \ncongenital heart defects. The projects \nwe have conducted with non-invasive \nneuromonitoring studies have allowed \nus to collaborate on a European \nproject for the development of a new \nintegrated neuromonitoring device \n(TinyBrains). The use of a new optical \ntechnology will help us to determine \nnon-invasively oxygen consumption at \nall times, haemodynamics-dependent \nchanges in cerebral blood flow, and \nchanges in brain electrical activity \nduring the most vulnerable periods \nor at moments of greatest risk, such \nas during surgery or in the immediate \npostoperative period.  Along this same \nline, our studies with biomarkers \nof brain injury and oxidative stress \nmarkers are opening up for us new \nclinical assessment strategies for the \nperiod of foetal life or at the patient\u2019s \nbedside, providing us with instruments \nthat will help us to detect patients at \nrisk in order to be able to implement \nneuroprotective strategies. All this \nis being done with a translational \napproach, expanding our knowledge \nthrough experimental animal models.\nMEMBERS\nSTAFF RESEARCHER\nCristina Carrasco Carrasco, Isabel \nIglesias Platas, Ana Morillo Palomo\nPOSTDOC ASSOCIATED RESEARCHERS\nMarta Camprubi Camprubi, Africa \nPertierra Cortada\nPHD STUDENTS\nCarla Balcells Esponera, Jordi \nClotet Caba, Ruth Del Rio Florentino, \nBeatriz Del Rey Hurtado De Mendoza, \nMontserrat Izquierdo Renau, Alba \nRivas Piorno\nASSISTANT RESEARCHER\nInes Fernanda Medina Rivera\nCOLLABORATOR RESEARCHER\nMar\u00eda Dolores Salvia Roiges, Mattia \nBosio, Marta Thi\u00f3 Lluch, Cristina \nBorr\u00e0s Novell, Ana Herranz Barbero\nSELECTED PROJECTS\n\u2022 Validaci\u00f3n prospectiva mediante \nun es\ntudio multic\u00e9ntrico estatal \n(REDSAMID) de modelos predictivos \nde mortalidad neonatal en \nprematuros. (PI20/00295). Instituto \nde Salud Carlos III (ISCIII). 2021-2023. IP: Martin Iriondo Sanz. \n\u2022 Consecuencias en la infancia del \nf\nallo perinatal de crecimiento en \nReci\u00e9n Nacidos Muy Prematuros: \nestudio cl\u00ednico y metabol\u00f3mico. \n(PI20/00294). Instituto de Salud \nCarlos III (ISCIII). 2021-2023. IP: \nIsabel Iglesias Platas. \n\u2022 TinyBrains_Bio-phot\nonic imaging \nof the infant brain, the missing \nlink between the cellular brain \ndamage and the neurovascular unit \nduring acute illness. (101017113). \nEuropean Commission. 2021-2024. \nIP: Marta Camprub\u00ed Camprub\u00ed/Joan \nS\u00e1nchez de Toledo.\nSELECTED CLINICAL TRIALS & \nOBSERVATIONAL STUDIES\n\u2022 Efecto del Alopurinol en \npacient\nes con encefalopat\u00eda \nhip\u00f3xico-isqu\u00e9mica tratados con \nhipotermia. ALBINO ensayo cl\u00ednico \nmultic\u00e9ntrico, aleatorizado, ciego, \ncontrolado con placebo. (H2020-\nPHC-18-2015-667224). Instituto \nde investigaci\u00f3n Sanitaria Hospital \nLa Fe. 2017-. IP: Marta Camprubi \nCamprubi.\n\u2022 Evaluation of Real Time Continuous \nGluc\nose Monitoring in the very \npreterm infant. (REACT RCT). \nUniversity of Cambridge. 2017-. IP: \nIsabel Iglesias Platas.\nSELECTED PUBLICATIONS\n\u2022 Aldecoa V, Velilla M, Teresa M, \nBal\ncells C, Herranz A, Sin M, Iriondo \nM, Salvia D. Lung Ultrasound in \nBronchopulmonary Dysplasia: \nPatterns and Predictors in Very  \nPreterm Infants. Neonatology. \n2021;118(5):537-545. IF:4,035. (Q1).\n\u2022 Basurto D, F\nuenzalida J, Martinez \nRJ, Russo FM, Pertierra A, Martinez \nJM et al. Intrapulmonary artery \nDoppler to predict mortality and \nmorbidity in fetuses with  mild or \nmoderate left-sided congenital \ndiaphragmatic hernia. Ultrasound \nObstet Gynecol. 2021;58(4):590-596. \nIF:7,299. (Q1).\n\u2022 Beardsall K, Thomson L, Guy C, \nIgl\nesias I, van MM, Bond S et al. \nReal-time continuous glucose \nmonitoring in preterm infants \n(REACT): an  international, open-\nlabel, randomised controlled trial. \nLancet Child Adolesc Health. \n2021;5(4):265-273. IF:11,288. (Q1).\n\u2022 Dur\u00e1n F\nern\u00e1ndez C, Rodr\u00edguez J, 54 INSTITUT  DE RECERCA  \nMEDICINE AND PEDIATRIC  \nSCIENCE AREA \nADAPTIVE RESPONSE, METABOLISM  \nAND IMMUNOBIOLOGY\nL\u00f3pez M, Hadley S, Cavia M, Mu\u00f1iz \nP et al. Effects of Hypothermia and \nAllopurinol on Oxidative Status in \na Rat Model of Hypoxic  Ischemic \nEncephalopathy. Antioxidants \n(Basel). 2021;10(10):1523. IF:6,312. \n(Q1).\n\u2022 Iglesias I, Bear\ndsall K. Strict \nglycemic control in very low \nbirthweight infants using \ncontinuous glucose  monitoring \nreduces dysglycemic. J Pediatr. \n2021;238:338-342. IF:4,406. (Q1).\nPharmacological \ntargets in \ninflammation  \nand metabolic \ndiseases\nManuel V\u00e1zquez Carrera, PhD\nThe purpose of our line of research is \nto study new pharmacological targets \nfor the treatment of insulin resistance \nand type 2 diabetes, as well as such \nassociated disorders as non-alcoholic \nfatty liver disease and diabetic \ncardiomyopathy. More specifically, one \nof our group\u2019s research lines is the \nstudy of the molecular mechanisms by \nwhich the activators of the peroxisome \nproliferator-activated receptor (PPAR) \n\u03b2/\u03b4 improve insulin resistance. In \n2021, our research group discovered \nthat a large part of the antidiabetic \nand anti-inflammatory effects of the \nPPAR\u03b2/\u03b4 activators are mediated by \nthe increase of the stress-induced \ncytokine GDF15 (growth differentiation \nfactor 15), which is involved in many \nbiological processes including the \nregulation of energy balance. In effect, \nthese PPAR\u03b2/\u03b4 activators increase \nGDF15 by the AMPK-p53 pathway. \nWhat\u2019s more, this increase of GDF15 \nproduced by PPAR\u03b2/\u03b4 activators \nis of fundamental importance for \nits metabolic effects, since these \neffects are significantly reduced in \nGDF15-deficient mice. Additionally, \nPPAR\u03b2/\u03b4 ligands require GDF15 for \nthe activation of AMPK, although this \nactivation does not appear to require \nthe presence of GFRAL, which is the central receptor responsible for the \naction of GDF15. This fact suggests \nthe presence of other peripheral \nreceptors of GDF15 which could be \nresponsible for this action.\nLikewise, in collaboration with the \nPharmaceutical Chemistry Unit of \nour department, we took part in a \nstudy in which nine compounds were \nsynthesized which inhibit the soluble \nepoxide hydrolase that reduces \nthe inflammation and stress of the \nendoplasmic reticulum in an animal \nmodel of acute pancreatitis, a disorder \nfor which there is not yet any specific \npharmacological treatment.\nMEMBERS\nSTAFF RESEARCHER\nF. Xavier Palomer Tarridas\nPOSTDOC ASSOCIATED RESEARCHERS\nEmma Barroso Fern\u00e1ndez, Marta \nMontori Grau, Luc\u00eda Pe\u00f1a Moreno, \nJavier Pizarro Delgado\nSELECTED PROJECTS\n\u2022 Unveiling the role of the growth \ndiff\nerentiation factor 15 (GDF15) \nin non-alcoholic fatty liver disease \n(NAFLD). (CIBERDEM 2021/PIM04). \nProjectes intramurals CIBERDEM. \nCIBERDEM. 2021-2022. PI: Emma \nBarroso, Rcardo Rodriguez and \nMar\u00eda Garcia Altares.\n\u2022 Activaci\u00f3n de PP\nARb/d y HRI: \nexplorando nuevos mecanismos \ncompensatorios para el tratamiento \nde la inflamaci\u00f3n, la resistencia \na la insulina y la esteatohepatitis \nno alcoh\u00f3lica (RTI2018-093999-\nB-I00). Convocat\u00f2ria d\u2019ajuts del \nPrograma Estatal d\u2019Investigaci\u00f3, \nDesenvolupament i Innovaci\u00f3 \nOrientada als reptes de la Societat. \nModalitat Reptes. Ministerio de \nCiencia, Innovaci\u00f3n y Universidades. \n2019-2022. PI: Manuel Vazquez \nCarrera.\n\u2022 Diabetes y enf\nermedades \nmetab\u00f3licas (CB07/08/0003). \nConvocat\u00f2ria d\u2019ajuts destinats \na finan\u00e7ar estructures estables \nd\u2019investigaci\u00f3 cooperativa, a l\u2019\u00e0rea \nde biomedicina i ci\u00e8ncies de la \nsalut, en el marc del Programa \nIngenio 2010, Programa Consolider, \naccions CIBER. Ministerio de \nSanidad y Consumo. 2007-2022. PI: \nManuel Vazquez Carrera.SELECTED PUBLICATIONS\n\u2022 Aguilar D, Barroso E, Gum\u00e1 \nL, Pizarr\no J, Pena L, Ruart \nM et al. GDF15 mediates the \nmetabolic effects of PPAR\u00df/d by \nactivating AMPK. Cell Reports. \n2021;36(6):109501-109501. IF:9,423. \n(Q1).\n\u2022 Codony S, Calv\n\u00f3 C, Valverde E, \nOsuna S, Morisseau C, Loza \nMI et al. From the Design \nto the In Vivo Evaluation of \nBenzohomoadamantane-Derived \nSoluble Epoxide Hydrolase \nInhibitors for the Treatment of \nAcute Pancreatitis. J Med Chem. \n2021;64(9):5429-5446. IF:7,446. (Q1).\n\u2022 Pal\nomer FX, Aguilar D, Garc\u00eda R, \nNistal JF, Vazquez M. Sirtuins: \nTo Be or Not To Be in Diabetic \nCardiomyopathy. Trends Mol Med. \n2021;27(6):554-571. IF:11,951. (Q1).\n\u2022 Zarei M, Aguilar D, P\nalomer FX, \nVazquez M. Revealing the role of \nperoxisome proliferator-activated \nreceptor \u00df/d in nonalcoholic fatty \nliver disease. METABOLISM. \n2021;114:154342. IF:8,694. (Q1).\nStudy of diseases \ndue to immune \ndysfunction \nin pediatrics \n(GEMDIP)\nLaia Alsina Manrique de Lara, MD, \nPhD & Jordi Ant\u00f3n L\u00f3pez, MD, PhD\nThe group is actively participating in \nvarious European multicentre trials to \nidentify new effective treatments for \nrheumatological, autoinflammatory \nand primary immunodeficiency \ndiseases. We have secured various \ncompetitive projects to study the \npathophysiological bases of these \ndiseases and have published several \nhigh-impact articles. Our focus \nthis year has been on inflammatory \ndiseases (multisystem inflammatory \nsyndrome and COVID-19 and \nsystemic lupus erythematosus) and \nimmunodeficiencies secondary to \nB-cell depletion therapies (CART-19 \nand Rituximab) in children. 55 INSTITUT  DE RECERCA  \nMEDICINE AND PEDIATRIC  \nSCIENCE AREA \nADAPTIVE RESPONSE, METABOLISM  \nAND IMMUNOBIOLOGY\nMEMBERS\nSTAFF RESEARCHER\nVioleta Bittermann, Juan Manuel \nMosquera Angarita, Ana M\u00aa Plaza \nMart\u00edn, Andrea Zacarias Crovato, \nRosa Bou i Torrent, \u00c0ngela Dey\u00e0 \nMart\u00ednez, Estibaliz Iglesias Jimenez, \nM\u00f3nica Piquer Gibert, Judith S\u00e1nchez \nManubens\nPOSTDOC ASSOCIATED RESEARCHERS \nAnna Esteve Sol\u00e9\nPHD STUDENTS\nYiyi Luo, Joan Calzada Hern\u00e1ndez\nASSISTANT RESEARCHER\nLucia Rodriguez Diez, Clara Isabel \nGim\u00e9nez Roca\nCOLLABORATOR RESEARCHER\nJordi Yag\u00fce Ribes, Manel Juan Otero, \nJuan Ignacio Arostegui Gorospe\nSELECTED PROJECTS\n\u2022 Characterization of the \nnasopharyngeal micr\nobiota in \nKawasaki disease. (PI20/00517). \nInstituto de Salud Carlos III (ISCIII). \n2021-2023. PI: Jordi Ant\u00f3n L\u00f3pez. \n\u2022 PIVIT_Construc\nci\u00f3 d\u2019una sala blanca \nper al seu \u00fas en ter\u00e0pies avan\u00e7ades \nen pacients pedi\u00e0trics, dirigit \nprincipalment a la producci\u00f3 de \nvectors virals per a ter\u00e0pia g\u00e8nica. \n(IU16-016824). Agaur - Ag\u00e8ncia \nde Gesti\u00f3 d\u2019Ajuts Universitaris i de \nRecerca; Departament de Salut - \nGeneralitat de Catalunya. 2020-2022. \nPI: Laia Alsina Manrique de Lara.\n\u2022 Contrat\no predoctoral de formaci\u00f3n en \ninvestigaci\u00f3n en salud_Beneficiario: \nYiyi Luo. (FI19/00208). Instituto de \nSalud Carlos III (ISCIII). 2020-2023. PI: \nLaia Alsina Manrique de Lara.\n\u2022 ImmunAID_Immunome project \nc\nonsortium for AutoInflammatory \nDisorders. (779295). European \nCommission. 2018-2023. PI: Jordi \nAnt\u00f3n L\u00f3pez.\n\u2022 Los nuev\nos criterios de PRINTO \npara la clasificaci\u00f3n de la artritis \nidiop\u00e1tica juvenil. Un proyecto \nbasado en la evidencia cient\u00edfica para \nla revisi\u00f3n de los criterios de la Liga \nInternacional contra el Reumatismo \n(ILAR). (ILAR). Accountancy \nDepartament Instituto Giannina \nGaslini. 2019 PI: Jordi Ant\u00f3n L\u00f3pez.\nSELECTED CLINICAL TRIALS & \nOBSERVATIONAL STUDIES\n\u2022 Estudio abierto, multic\u00e9ntrico, de \ndos c\nohortes y un solo grupo para evaluar la eficacia, la seguridad y la \ntolerabilidad, la farmacocin\u00e9tica y la \nfarmacodin\u00e1mica de emapalumab \nen ni\u00f1os y adultos con s\u00edndrome de \nactivaci\u00f3n de macr\u00f3fagos (SAM) en \nla enfermedad de Still (incluida la \nartritis idiop\u00e1tica juvenil sist\u00e9mica \ny la enfermedad de Still del adulto) \no con SAM en el lupus eritematoso \nsist\u00e9mico. A two-cohort, open-\nlabel, single arm, multicenter \nstudy to evaluate efficacy, safety \nand tolerability, pharmacokinetics \n(PK) and pharmacodynamics (PD), \nof emapalumab in children and \nadults with macrophage activation \nsyndrome (MAS) in Still\u2019s disease \n(including systemic juvenile \nidiopathic arthritis and adult onset \nStill\u2019s disease) or with MAS in \nsystemic lupus erythematous. (NI-\n0501-14). Pharmaceutical Research \nAssociates Espa\u00f1a SAU; Swedish \nOrphan Biovitrum AG. 2021-. PI: \nJordi Ant\u00f3n L\u00f3pez.\n\u2022 Estudio abiert\no y de dosis \nm\u00faltiples ascendentes para \nevaluar la seguridad, tolerabilidad, \nfarmacocin\u00e9tica de romosozumab \nen ni\u00f1os y adolescentes con \nosteog\u00e9nesis imperfecta. A \nRandomized, Double-blind, \nPlacebo-controlled, Ascending \nMultiple-dose Study to Evaluate \nSafety, Pharmacokinetics, \nand Pharmacodynamics of \nRomosozumab in Children and \nAdolescents With Osteogenesis \nImperfecta. (20160227). AMGEN S.A. \n2021-. PI:Rosa Bou i Torrent.  \nSELECTED PUBLICATIONS\n\u2022 Brogan PA, Arch B, Hickey H, \nAnt\non J, Iglesias E, Baildam E \net al. Mycophenolate Mofetil \nVersus Cyclophosphamide for \nRemission Induction in Childhood  \nPolyarteritis Nodosa: An Open-\nLabel, Randomized, Bayesian \nNoninferiority Trial. Arthritis \nRheumatol. 2021;73(9):1673-1682. \nIF:10,995. (Q1).\n\u2022 Dey\n\u00e0 A, Alonso A, Garcia AP, Faura \nA, Torrebadell M, Vlagea A et al. \nKinetics of humoral deficiency in \nCART19-treated children and young \nadults with  acute lymphoblastic \nleukaemia. Bone Marrow \nTransplant. 2021;56(2):376-386. \nIF:5,483. (Q1).\n\u2022 Dey\n\u00e0 A, Garcia AP, Vlagea A, \nJord\u00e1n I, Fumad\u00f3 V, Fortuny C et al. \nConfirmed SARS-COV-2 Infection In A Cohort Of Children And Young \nAdults With Moderate Or Severe \nPrimary Immunodeficiencies. J Clin \nImmunol. 2021;41(SUPPL 1):107-\n109. IF:8,317. (Q1).\n\u2022 Est\neve A, Anton J, Pino RM, S\u00e1nchez \nJ, Fumad\u00f3 V, Fortuny C et al. \nSimilarities and differences between \nthe immunopathogenesis of COVID-\n19-related  pediatric multisystem \ninflammatory syndrome and \nKawasaki disease. J Clin Invest. \n2021;131(6):1-28. IF:14,808. (Q1).\nInfectious  \ndiseases and \nmicrobiome\nCarmen Mu\u00f1oz Almagro, MD, PhD\nWe were acknowledged as an \nemerging group in 2009, as a \nconsolidated group in 2014, and as \na consolidated group with AGAUR \nfinancing (SGR00742) in 2017. \nLikewise, we have belonged to the \nConsortium for Networked Biological \nResearch on Epidemiology and \nPublic Health (CIBERESP) since \n2016. Our group is focused on the \nstudy of the clinical, molecular \nand epidemiological aspects of \nthe principal paediatric infectious \ndiseases, and on the diagnostic \ninnovation of infectious diseases and \nthe study of the human microbiome. \nThe cumulative impact factor of our \ngroup has been 1176.34 over the last \n5 years and it is following an upward \ntrend. Ours is a multidisciplinary \nteam formed by 16 doctors, 12 \npredoctoral researchers and 2 \nresearch technicians specialised in \npaediatrics, microbiology, biostatistics, \nepidemiology, and management. \nWe have 7 consolidated research \nlines (infection in vulnerable \npatients, tuberculosis, vaccine-\npreventable diseases, respiratory \ninfection, diagnostic innovation, \nmolecular epidemiological vigilance, \nand microbiome). These seven \nlines are directed by doctors who \ncombine their research activity with \nuniversity teaching. Two of them are \nfull professors (Dr Fortuny and Dr 56 INSTITUT  DE RECERCA  \nMEDICINE AND PEDIATRIC  \nSCIENCE AREA \nADAPTIVE RESPONSE, METABOLISM  \nAND IMMUNOBIOLOGY\nMu\u00f1oz-Almagro), three are associate \nprofessors (Dr Jord\u00e1n, Dr Noguera-\nJuli\u00e1n and Dr Garc\u00eda-Garc\u00eda), one is an \nadjunct lecturer (Dr Launes) and one \nis a contracted doctor (Dr Brotons). \nIn 2021, we consolidated our human \nmicrobiome line, as is shown by our \nfive publications on this subject. Also \nof note are our studies on the impact \nof the COVID-19 pandemic on the \npaediatric population, which were \ncarried out thanks to the collaboration \nof numerous donors who supported \nour research. We published 16 articles \nin which we analysed epidemiological, \nclinical, immunological, \nmicrobiological, and diagnostic \ninnovation factors influencing the \nSARS-CoV2 infection.\nMEMBERS\nSTAFF RESEARCHER\nCl\u00e0udia Fortuny Guasch, Maria Goretti \nL\u00f3pez Ramos, Antoni Noguera Juli\u00e1n, \nPedro Brotons de los Reyes, Victoria \nFumad\u00f3, Juan Jos\u00e9 Garc\u00eda Garc\u00eda, \nCristian Launes Monta\u00f1a, Silvia Sim\u00f3 \nNebot\nPOSTDOC ASSOCIATED RESEARCHERS\nMuntsa Rocafort Junca, Cristina \nEsteva Afonso, Maria Fern\u00e1ndez de \nSevilla Estrach\nPHD STUDENTS\nMar\u00eda Rios Barn\u00e9s, Ferran Bossacoma \nBusquets, Desiree Henares Bonilla, \nM\u00edriam Trivi\u00f1o Rodr\u00edguez, Eneritz \nVelasco, Joan Vinent Genestar\nASSISTANT RESEARCHER\nRaul Mu\u00f1oz Garc\u00eda, Lucia Sanchis \nBadenes, Alba Redin Alonso, Susana \nHern\u00e1ndez Bou\nTECHNICIAN\nCarles Cisneros Camps, Amaresh \nP\u00e9rez Arg\u00fcello, Jesica Saucedo Verdes\nCOLLABORATOR RESEARCHER\nQuique Bassat, Emilia S\u00e1nchez Ruiz\nSELECTED PROJECTS\n\u2022 Tecnolog\u00edas NGS para la Vigilancia \nEpidemiol\n\u00f3gica Molecular de S. \npneumoniae y para determinar su \ninvasividad. Quo vadis y Quo invades \npneumococcus?. (PI19/00104). \nInstituto de Salud Carlos III (ISCIII). \n2020-2022. IP: Carmen Mu\u00f1oz \nAlmagro. \n\u2022 Estudio CRIB (Cribado de \ncit\nomegalovirus cong\u00e9nito en \nreci\u00e9n nacidos sanos e ingresados \n- Barcelona). (PI19/00095). Instituto \nde Salud Carlos III (ISCIII). 2020-2022. IP: Antoni Noguera Juli\u00e1n.\n\u2022 Contract ECD.11486- De\nveloping \nan infrastructure and performing \nvaccine effectiveness studies for \nCOVID-19 vaccine in the EU/EEA\u00e2\u20ac. \nLOT3 (HCW). European Centre for \nDisease Prevention and Control \n(ECDC). 2021-2022. IP: Carmen \nMu\u00f1oz Almagro. \n\u2022 Plataf\norma Kids Corona. Clientes \nDiversos. 2020-2022. IP: Juan Jos\u00e9 \nGarc\u00eda Garc\u00eda.\nSELECTED CLINICAL TRIALS & \nOBSERVATIONAL STUDIES\n\u2022 Estudio de fase II, sin \nenmasc\naramiento, no comparativo \ny multic\u00e9ntrico para evaluar la \nseguridad, la tolerabilidad, la \neficacia y la farmacocin\u00e9tica del \nsulfato de isavuconazonio en el \ntratamiento de la aspergilosis \ninvasiva (AI) o la mucormicosis \ninvasiva (MI) en pacientes \npedi\u00e1tricos. (9766-CL-0107). \nAstellas Pharma Global \nDevelopment, Inc,; Syneos Health \nUK Limited. 2021-. IP: Cl\u00e0udia \nFortuny Guasch. \n\u2022 Estudio de f\nase 3, multic\u00e9ntrico, \nalatorizado, con enmascaramiento \nparcial y controldo con palivizumab \npara evaluar la seguridad, la \neficacia y la farmacocin\u00e9tica de \nMK-1654 en lactantes y ni\u00f1os con \nunriesgo elevado de enfermedad \ngrave por el VRS. Phase 3, \nMulticenter, Randomized, Partially \nBlinded, Palivizumab-Controlled \nStudy to Evaluate the Safety, \nEfficacy, and Pharmacokinetics of \nMK-1654 in Infants and Children \nat Increased Risk for Severe RSV \nDisease. (MK-1654-007). Merck, \nSharp & Dohme de Espa\u00f1a. S.A. \n2021-. IP: Cl\u00e0udia Fortuny Guasch.\n\u2022 Estudio f\nase III, aleatorizado, doble \nciego, controlado con placebo y \nmultic\u00e9ntrico para demostrar la \neficacia de una dosis \u00fanica de la \nvacuna materna no adyuvada frente \nal Virus Respiratorio Sincitial (VRS), \nadministrada por v\u00eda IM a gestantes \nde 18 a 49 a\u00f1os de edad, para la \nprevenci\u00f3n de la Enfermedad v\u00edas \nrespiratorias Bajas (EVRB) asociada \nal VRS en sus hijos hasta los 6 \nmeses de edad. (212171 (RSV MAT-\n009)). Glaxosmithkline, S.A. 2021-. \nIP: Victoria Fumad\u00f3.\n\u2022 Estudio de inmunogenia y \nseguridad de una v\nacuna conjugada \nantimeningoc\u00f3cica tetravalente con respecto a Nimenrix\u00ae, y cuando \nse administra sola o de manera \nconcomitante con las vacunas \n9vHPV-IPV en adolescentes sanos. \n(MEQ00071). Sanofi-Aventis S.A. \n2021-. IP: Antoni Noguera Juli\u00e1n.\nSELECTED PUBLICATIONS\n\u2022 Brotons P, Launes C, Buetas E, \nF\numad\u00f3 V, Henares D, Fern\u00e1ndez \nde Sevilla M et al. Susceptibility \nto Severe Acute Respiratory \nSyndrome Coronavirus 2 Infection \nAmong  Children and Adults: A \nSeroprevalence Study of Family \nHouseholds in the Barcelona \nMetropolitan Region, Spain. Clin \nInfect Dis. 2021;72(12):1-8. IF:9,079. \n(Q1).\n\u2022 Est\neve A, Anton J, Pino RM, S\u00e1nchez \nJ, Fumad\u00f3 V, Fortuny C et al. \nSimilarities and differences between \nthe immunopathogenesis of COVID-\n19-related  pediatric multisystem \ninflammatory syndrome and \nKawasaki disease. J Clin Invest. \n2021;131(6):1-28. IF:14,808. (Q1).\n\u2022 Henares D, Br\notons P, Fern\u00e1ndez de \nSevilla M, Fern\u00e1ndez A, Hern\u00e1ndez \nS, P\u00e9rez A et al. Differential \nnasopharyngeal microbiota \ncomposition in children according \nto  respiratory health status. Microb \nGenom. 2021;7(10):661. IF:5,237. \n(Q1).\n\u2022 Redin A, Ciruela P, Fern\u00e1ndez \nde Se\nvilla M, Gomez F, Gonzalez \nS, Benitez MA et al. Serotypes \nand Clonal Composition of \nStreptococcus pneumoniae Isolates \nCausing IPD in  Children and Adults \nin Catalonia before 2013 to 2015 \nand after 2017 to 2019  Systematic \nIntroduction of PCV13. Microbiol \nSpectr. 2021;9(3) :e0115021. \nIF:7,171. (Q1).\nGut microbiota\nLaura Baldom\u00e0 Llavin\u00e9s, PhD\nGut bacteria release extracellular \nvesicles as an intercellular \ncommunication mechanism that \nprime the host innate immune system. \nPrevious studies of our group showed 57 INSTITUT  DE RECERCA  \nMEDICINE AND PEDIATRIC  \nSCIENCE AREA \nADAPTIVE RESPONSE, METABOLISM  \nAND IMMUNOBIOLOGY\nthat extracellular vesicles from gut \nresident E. coli activate dendritic cells \n(DCs) and subsequent T cell responses \nin a strain-specific manner. In addition \nto direct cell-to-cell contacts, DCs \ncommunicate with neighboring T cells \nthrough secreted mediators. This year \nwe have provided new insights into the \nmechanisms used by microbiota to \norchestrate host immune regulation. \nIn particular, we have analysed the \nimpact of microbiota vesicles on \nDC-secreted effectors including \ncytokines and exosomes. DC-derived \nexosomes were characterized in \nterms of costimulatory molecules and \nmiRNAs cargo. Exosomes released by \nDCs activated by microbiota vesicles \nwere enriched in surface proteins \ninvolved in antigen presentation \nand T cell activation but differ in the \ncontent of immune-related miRNA \ndepending on the producer bacterial \nstrain. These differences were \nconsistent with the derived immune \nresponses. To our knowledge, this is \nthe first study showing the influence \nof microbiota extracellular vesicles on \nthe immunomodulatory cargo of DC-\nderived exosomes.\nIn the context of our contribution \nto the study of biological activities \nof nanoparticles for drug delivery, \nwe have collaborated with groups \nof the Nanobiotechnology Research \nInstitute-UB. In particular, we \nhave shown that thymol-loaded \nnanoparticles are an efficient \nalternative for the treatment of \nskin acne infection based on their \nantioxidant and antimicrobial activity \nagainst Cutibacterium acnes . We have \nalso contributed to characterize the \nuptake and anti-inflammatory activity \nof lactoferrin-loaded liposomes as a \ndrug delivery system for the treatment \nof dry eye disease.\nMEMBERS\nSTAFF RESEARCHER\nRosa Gim\u00e9nez Claudia, Josefa Badia \nPalacin\nSELECTED PROJECTS\n\u2022 Evaluaci\u00f3n de nuevas actividades \nde v\nes\u00edculas secretadas por \nprobioticos y microbiota intestinal \ny su potencial aplicaci\u00f3n como \npostbioticos en salud humana. \n(PID2019-107327RB-I00). \nMinisterio de Ciencia, Innovaci\u00f3n y Universidades. Convocat\u00f2ria d\u2019ajuts \ndel Programa Estatal d\u2019Investigaci\u00f3, \nDesenvolupament i Innovaci\u00f3 \nOrientada als reptes de la Societat. \nModalitat Reptes. 2020-2023. PI: \nLaura Baldoma Llavines.  \n \n\u2022 C-C Bond Formation Using T\nop \nPerforming Enzymes (CC-TOP). \n(956631). Uni\u00f3 Europea. Horizon \n2020 (2014-2020). P1. Marie \nSk&#321;Odowska-Curie Innovative \nTraining Networks (H2020-MSCA-\nITN-2020). 2021-2025. PI: Josefa \nBadia Palacin.\nSELECTED PUBLICATIONS\n\u2022 D\u00edaz N, Badia J, Baldoma \nL. Microbiot\na-derived \nextracellular vesicles in \ninterkingdom communication \nin the gut. J Extracell Vesicles. \n2021;10(13):12161. IF:25,841. (Q1).\n\u2022 Diaz N, Corder\no C, Olivo Y, Badia \nJ, Baldoma L. Cell-to-Cell \nCommunication by Host-Released \nExtracellular Vesicles in the Gut:  \nImplications in Health and Disease. \nInt. J. Mol. Sci. 2021;22(4):2213. \nIF:5,923. (Q1).\n\u2022 Foll\ne C, Marqu\u00e9s AM, Jorge G, \nEspina M, S\u00e1nchez E, Badia J et al. \nThymol-loaded PLGA nanoparticles: \nan efficient approach for acne \ntreatment. J Nanobiotechnology. \n2021;19(1):359. IF:10,435. (Q1).\u2022 L\u00f3pez A, Jorge G, Cano A, Espina \nM, Badia J, Baldoma L et al. \nDe\nvelopment of Lactoferrin-Loaded \nLiposomes for the Management \nof Dry Eye Disease and Ocular \nInflammation. Pharmaceutics. \n2021;13(10):1698. IF:6,321. (Q1).\nEnvironment and \ncomplications in \npregnancy\nMaria Dolores G\u00f3mez Roig, MD, PhD\nWe continued to study the influence \nof abusive substances and of the \nmaterno-foetal environment on \nfoetal and newborn health. We \ncompleted the recruitment of the \nBarcelona Life Study Cohort (BISC), \nwhich comprises 1,100 mother-\nchild pairs in the Greater Barcelona \narea, who are well phenotyped for \nenvironmental exposure. With this \ncohort, we will be able to continue \nconducting research along our line. \nOur areas of interest are the study of \nthe influence of lifestyle and exposure \nto environmental contaminants on \n58 INSTITUT  DE RECERCA  \nMEDICINE AND PEDIATRIC  \nSCIENCE AREA \nADAPTIVE RESPONSE, METABOLISM  \nAND IMMUNOBIOLOGY\nfoetal neurodevelopment, and on \nheart morphology and functionalism. \nWe have also extended our studies to \ninclude new methodologies for the \nstudy of postnatal neurodevelopment \nsuch as frequency-following response \n(FFR). Another aspect of the work \nthat we have carried out is the study \nof how the environment affects the \nplacental function and foetal growth, \nand it may also be noted that we \nhave increased our experimental \nknowledge about alcohol consumption \nduring pregnancy.\nMEMBERS\nSTAFF RESEARCHER\nEduardo Gonz\u00e1lez Bosquet, N\u00faria \nLorente Colom\u00e9, Rosalia Pascal \nCapdevila, Silvia Irena Ferrero \nMart\u00ednez, Joan Sabri\u00e0 Bach\nPOSTDOC ASSOCIATED RESEARCHERS\nEdurne Mazarico Gallego, Miriam \nP\u00e9rez Cruz\nPHD STUDENTS\nMarta Muniesa Aurrocoechea, Diana \nLucia Lip Sosa\nASSISTANT RESEARCHER\nNat\u00e0lia Gorina Careta, Patricia \nFerrer Aguilar, Laura Mall\u00e9n Perez, \nMarc Josep Cahuana Bartra, Estela \nRodriguez Quinteiro, Laura Almeida \nToledano\nTECHNICIAN\n\u00c0gueda Garc\u00eda Meseguer\nSELECTED PROJECTS\n\u2022 Impacto de un programa de \nint\nervenci\u00f3n prenatal estructurado, \nde disminuci\u00f3n de consumo \nde alcohol, en los resultados \nperinatales y de neurodesarrollo. \n(PI20/00490). Instituto de Salud \nCarlos III (ISCIII). 2021-2023. PI: \nMaria Dolores G\u00f3mez Roig.\n\u2022 Respuest\na de seguimiento de \nfrecuencia (RSD) como biomarcador \nde desarrollo neurocognitivo en \nreci\u00e9n nacidos con exposici\u00f3n \nprenatal al alcohol. Hospital Sant \nJoan de D\u00e9u - Esplugues HSJD. \n2020-2023. PI: Maria Dolores G\u00f3mez \nRoig. \n\u2022 ATHLETE_Adv\nancing Tools for \nHuman Early Lifecourse Exposome \nresearch and Translation. (874583). \nEuropean Commission. 2020-2024. \nPI: Maria Dolores G\u00f3mez Roig. \n\u2022 Tr\naffic-related air pollution \nand birth weight: the roles of \nnoise, placental function, green space, diet, physical activity, and \nsocioeconomic status (FRONTIER). \n(CR-83590201). Health Effects \nInstitute (HEI). 2018-2022. PI: Maria \nDolores G\u00f3mez Roig.\nSELECTED CLINICAL TRIALS & \nOBSERVATIONAL STUDIES\n\u2022 Hydroxychloroquine efficacy in \npr\neventing SARS-CoV-2 infection \nand CoVid-19 disease severity \nduring pregnancy. (CoVid-Preg). \nFundaci\u00f3 Privada ISGLOBAL. 2020-. \nPI: Edurne Mazarico Gallego. \n\u2022 Tr\natamiento del crecimiento \nintrauterino restringido precoz con \nheparina de bajo peso molecular: \nEnsayo Cl\u00ednico Randomizado \n(TRACIP). (FSJD-TRACIP-2017). \nFundaci\u00f3 Privada per a la Recerca \ni la Doc\u00e8ncia Sant Joan de D\u00e9u - \nFSJD. 2017-. PI: Edurne Mazarico \nGallego. \n\u2022 Tr\natamiento del cir precoz con \nheparina de bajo peso molecular \n(TRACIP): ensayo cl\u00ednico \nrandomizado. (PI16/00151). \nInstituto de Salud Carlos III (ISCIII). \n2017-2021. PI: Edurne Mazarico \nGallego.\nSELECTED PUBLICATIONS\n\u2022 Almeida L, Andreu V, Ar as R, \nGarc\u00eda \u00d3, Mart\u00ednez L, G\u00f3mez \nMD. Epigallocatechin Gallate \nAmeliorates the Effects of Prenatal \nAlcohol Exposure in a  Fetal \nAlcohol Spectrum Disorder-Like \nMouse Model. Int. J. Mol. Sci. \n2021;22(2):715. IF:5,923. (Q1).\n\u2022 Arenillas S, Cos\nta J, Ribas T, \nG\u00f3mez MD, Escera C. Neural \nencoding of voice pitch and formant \nstructure at birth as revealed by  \nfrequency-following responses. \nSci Rep. 2021;11(1):6660-6660. \nIF:4,379. (Q1).\n\u2022 Cro\nvetto F, F\u00e0tima B, Llurba E, \nPascal R, Larroya M, Trilla C et al. \nImpact of Severe Acute Respiratory \nSyndrome Coronavirus 2 Infection \non Pregnancy  Outcomes: A \nPopulation-based Study. Clin \nInfect Dis. 2021;73(10):1768-1775. \nIF:9,079. (Q1).\n\u2022 Meler E, Mazaric\no E, Eixarch E, \nGonzalez A, Peguero A, Martinez \nJ et al. Ten-year experience of \nprotocol-based management of \nsmall-for-gestational-age  fetuses: \nperinatal outcome in late-pregnancy cases diagnosed after 32 weeks. \nUltrasound Obstet Gynecol. \n2021;57(1):62-69. IF:7,299. (Q1).\nCardiovascular \ndiseases in \ndevelopment\nJoan S\u00e1nchez de Toledo, MD, PhD & \nGeorgia Sarquella Brugada, MD, PhD\nMEMBERS\nSTAFF RESEARCHER\nEsther Aurensanz Clemente, Jose \nCarlos Cruzalegui G\u00f3mez, Esther \nCarro Fernandez, Sergio C\u00e9sar Diaz, \nIsaac Moll Adrian\nPHD STUDENTS\nOscar Recasens Lopez, Maria Lucia \nRossi, Estefan\u00eda Mart\u00ednez Barrios\nASSISTANT RESEARCHER\nAlba Rivas Piorno, D\u00e9bora Ca\u00f1izo \nV\u00e1zquez, Joana Victoria Fiol Ramis\nTECHNICIAN\nBosco Alejandro Moscoso Garrido\nSELECTED PROJECTS\n\u2022 CoALeS: Impro ving long term \noutcome in infants with coarctation \nthrough machine learning for data \nintegration from fetus to childhood. \n(202016-31). Fundaci\u00f3 La Marat\u00f3 de \nTV3. 2021-2024. IP: Joan S\u00e1nchez \nde Toledo. \n\u2022 Antioxidant\nes y neuroprotecci\u00f3n \nen un modelo animal pedi\u00e1trico de \ncirculaci\u00f3n extracorporea y parada \ncirculatoria: Nuevos horizontes \nterap\u00e9uticos. (PI20/00298). Instituto \nde Salud Carlos III (ISCIII). 2021-\n2023. IP: Joan S\u00e1nchez de Toledo. \n\u2022 AICCELERATE_AI Ac\ncelerator \u00e2\u20ac\u201c \nA Smart Hospital Care Pathway \nEngine. (101016902). European \nCommission. 2021-2024. IP: Joan \nS\u00e1nchez de Toledo. \n\u2022 TinyBrains_Bio-phot\nonic imaging \nof the infant brain, the missing \nlink between the cellular brain \ndamage and the neurovascular unit \nduring acute illness. (101017113). \nEuropean Commission. 2021-2024. \nIP : Joan S\u00e1nchez de Toledo.\n\u2022 ECG neonatal sis\ntem\u00e1tico para la 59 INSTITUT  DE RECERCA  \nMEDICINE AND PEDIATRIC  \nSCIENCE AREA \nADAPTIVE RESPONSE, METABOLISM  \nAND IMMUNOBIOLOGY\ndetecci\u00f3n precoz de enfermedades \ncardiacas relacionadas con \nla muerte s\u00fabita del lactante. \nSociedad Espa\u00f1ola de Cardiologia. \n2019-2021. IP: Georgia Sarquella \nBrugada.\nSELECTED CLINICAL TRIALS & \nOBSERVATIONAL STUDIES\n\u2022 Estudio aleatorizado, multic\u00e9ntrico, \ndobl\ne ciego, controlado con \nplacebo, de grupos paralelos, \nbasado en acontecimientos y con \ndise\u00f1o secuencial por grupos con \nun periodo de ampliaci\u00f3n abierto \npara evaluar la eficacia y seguridad \nde selexipag como tratamiento \ncomplementario al tratamiento \nde referencia en ni\u00f1os de \u00e2\u2030\u00a52 \na <18 a\u00f1os con hipertensi\u00f3n \narterial pulmonar. A Randomized, \nMulticenter, Double-Blind, Placebo-\nControlled, Parallel-Group, Event-\nDriven, Group-Sequential Study \nwith Open-Label Extension Period \nto Assess the Efficacy and Safety \nof Selexipag as Add-On Treatment \nto Standard of Care in Children \nAged \u00e2\u2030\u00a52 to <18 years with \nPulmonary Arterial Hypertension. \n(AC-065A310). Janssen - Cilag, S.A. \n2020-. IP: Joan S\u00e1nchez de Toledo. \n\u2022 Estudio multic\n\u00e9ntrico para evaluar \nla seguridad y tolerabilidad a \nlargo plazo de un tratamiento \nen abierto con sacubitrilo/\nvalsart\u00e1n en pacientes pedi\u00e1tricos \ncon insuficiencia cardiaca \ndebida a disfunci\u00f3n sist\u00f3lica de \nventr\u00edculo izquierdo sist\u00e9mico, \nque han completado el estudio \nCLCZ696B2319. (CLCZ696B2319E1 \n- Ext.). Novartis Farmac\u00e9utica, S.A. \n2020-. IP: Joan S\u00e1nchez de Toledo. \n\u2022  Estudio multic\n\u00e9ntrico, abierto, para \nevaluar la seguridad, tolerabilidad, \nfarmacocin\u00e9tica y farmacodin\u00e1mica \nde LCZ696, seguido de un estudio \nde 52 semanas, aleatorizado, \ndoble ciego, paralelo controlado \ncon f\u00e1rmaco activo para evaluar \nla eficacia y seguridad de \nLCZ696 comparado con enalapril \nen pacientes pedi\u00e1tricos con \nedades desde 1 mes hasta < 18 \na\u00f1os, con insuficiencia cardiaca \ndebida a disfunci\u00f3n sist\u00f3lica del \nventr\u00edculo izquierdo sist\u00e9mico. \n(CLCZ696B2319). Novartis \nFarmac\u00e9utica, S.A. 2019-. IP: Joan \nS\u00e1nchez de Toledo.SELECTED PUBLICATIONS\n\u2022 Esteve A, Anton J, Pino RM, \nS\u00e1nchez J, F\numad\u00f3 V, Fortuny C \net al. Similarities and differences \nbetween the immunopathogenesis \nof COVID-19-related pediatric \nmultisystem inflammatory \nsyndrome and Kawasaki disease. \nJ Clin Invest. 2021;131(6):1-28. \nIF:14,808. (Q1).\n\u2022 Sarquella G, F\nernandez A, Cesar \nS, Arbelo E, Jord\u00e0 P, Garc\u00eda A et al. \nPediatric Malignant Arrhythmias \nCaused by Rare Homozygous \nGenetic Variants in TRDN: A \nComprehensive Interpretation. Front \nPediatr. 2021;8:601708-601708. \nIF:3,418. (Q1).\n\u2022 Sarquella G, Lor\nena A, Zambrano \nMD, Fern\u00e1ndez A, Sailer S, Cesar \nS et al. Early Identification of \nProlonged QT Interval for Prevention \nof Sudden Infant Death. Front \nPediatr. 2021;9:704580-704580. \nIF:3,418. (Q1).\n\u2022 Val\nverde I, Singh Y, Sanchez J, \nTheocharis P, Chikermane A, \nDi S et al. Acute Cardiovascular \nManifestations in 286 Children \nWith Multisystem Inflammatory \nSyndrome Associated With \nCOVID-19 Infection in Europe. \nCirculation. 2021;143(1):21-32. \nIF:29,690. (Q1).\nImmune and \nrespiratory \ndysfunction in the \ncritical child\nFrancisco Jos\u00e9 Cambra Lasaosa, MD, \nPhD\nNotable aspects of 2021 included \nour research on the pathophysiology \nof severe illness caused by COVID \nin paediatric patients as well as in \nadults, considering the number of \npatients over age 18 years hospitalised \nin our intensive care unit during the \nCOVID epidemic. We investigated \nvarious aspects in depth and produced \nseveral publications. Our research, \nwhich was led by Dr Iolanda Jordan, \nwas conducted with a multidisciplinary approach, involving various services of \nour hospital. \nOur scientific output was maintained \nwith several publications along our \ntwo priority research lines: the field \nof inflammatory response and that of \nrespiratory insufficiency.\nAlso during this period, Sara Bobillo \nP\u00e9rez presented her doctoral thesis \n\u201cUtility of biomarkers in systemic \ninflammatory response and in the \nimplementation of antibiotic-therapy \nhandling algorithms in paediatric \ncritical patients\u201d. The thesis was \ndirected by Iolanda Jordan and \nFrancisco Jos\u00e9 Cambra. University of \nBarcelona (UB). Grade: Excellent Cum \nLaude.\nMEMBERS\nSTAFF RESEARCHER\nIolanda Jord\u00e1n Garc\u00eda, Mart\u00ed Pns \n\u00d3dena, Anna Sol\u00e9 Ribalta, Carmina \nGuitart Pardellans, M\u00f3nica Balaguer \nGargallo, Elisabeth Esteban Torne, \nM\u00f3nica Girona Alarc\u00f3n \nASSISTANT RESEARCHER\nJorgelina Lopez Zabala, Vanessa \nAndrino Estrecha, Nuria Mill\u00e1n Garc\u00eda \ndel Real, Elena Fres\u00e1n Ruiz, Sergio \nBenito Fern\u00e1ndez, Lluisa Hernandez \nPlatero, Carme Alejandre Galobardes, \nPatricia Corniero Alonso, Aida Felipe \nVillalobos, Susana Segura Matute, \nDavid Vila P\u00e9rez, Sergi Huerta Calpe, \nRicardo Suarez Ramirez\nCOLLABORATOR RESEARCHER\nMontserrat Esquerda Areste\nSELECTED PROJECTS\n\u2022 Implicaci\u00f3n de la microbiota \nbact\neriana de la nasofaringe en el \ndesarrollo de neumon\u00eda asociada a \nventilaci\u00f3n mec\u00e1nica en la unidad \nde cuidados intensivos pedi\u00e1tricos. \nEstudio MiNoReP. (PI19/00106). \nInstituto de Salud Carlos III (ISCIII). \n2020-2022. IP:Iolanda Jord\u00e1n \nGarc\u00eda. \n\u2022 Val\noraci\u00f3n del efecto neuroprotector \nde la dexmedetomidina en el \nmodelo animal pedi\u00e1trico de \ncirculaci\u00f3n extracorporea y parada \ncirculatoria. Sociedad y Fundaci\u00f3n \nEspa\u00f1ola de Cuidados Intensivos \nPedi\u00e1tricos (SECIP). 2018-2022. IP: \nSergio Benito Fern\u00e1ndez. \n\u2022 Estudio de seguridad de un \ndispositiv\no de presi\u00f3n positiva \nno mec\u00e1nico en pacientes \ncon insuficiencia respiratoria 60 INSTITUT  DE RECERCA  \nMEDICINE AND PEDIATRIC  \nSCIENCE AREA \nADAPTIVE RESPONSE, METABOLISM  \nAND IMMUNOBIOLOGY\nhipox\u00e9mica secundaria a neumon\u00eda \npor SARS COV 2. (CPAP). Fundaci\u00f3 \nPrivada per a la Recerca i la \nDoc\u00e8ncia Sant Joan de D\u00e9u - FSJD. \n2020IP: Mart\u00ed Pons \u00d2dena.\nSELECTED CLINICAL TRIALS & \nOBSERVATIONAL STUDIES\n\u2022 Estudio aleatorizado con control \nactiv\no para comparar la eficacia y \nla seguridad de isoflurano inhalado \nadministrado por el AnaConDa-S \n(dispositivo de conservaci\u00f3n de \nanest\u00e9sico) con el midazolam \nintravenoso para la sedaci\u00f3n \nen pacientes pedi\u00e1tricos con \nventilaci\u00f3n mec\u00e1nica de entre 3 \ny 17 a\u00f1os (menos de 18 a\u00f1os). A \nRandomised Active-controlled Study \nto Compare Efficacy and Safety \nof Inhaled Isoflurane Delivered \nby the AnaConDa-S (Anaesthetic \nConserving Device) to Intravenous \nMidazolam for Sedation in \nMechanically Ventilated Paediatric \nPatients 3 to 17 (Less than 18) \nYears Old. (SED002). LINK Medical \nResearch; Sedana Medical AB. \n2021IP:Monica Girona Alarcon.\n\u2022 Estudio abiert\no, de un solo brazo \npara evaluar la farmaconcin\u00e9tica, \nseguridad y tolerabilidad, y para \nexplorar los resultados cl\u00ednicos \ndel tratamiento con dosis \u00fanica \no m\u00faltiple de zanamivir IV en \nneonatos e infantes menores de \n6 meses con infecci\u00f3n por gripe \nconfirmada complicada. An open \nlabel, single arm study to evaluate \nthe pharmacokinetics, safety and \ntolerability of intravenous (IV) \nzanamivir in hospitalised neonates \nand infants under 6 months of \nage with confirmed or suspected \ninfluenza infection. (200925). \nGlaxosmithkline, S.A. 2020IP: \nM\u00f3nica Balaguer Gargallo. \n\u2022 A Phase 1, open-label, non-\ncompar\native, multicenter clinical \ntrial to evaluate the safety, \ntolerability, and pharmacokinetics \nof ceftolozane/tazobactam (MK-\n7625A) in pediatric participants \nwith nosocomial pneumonia. (MK-\n7625A-036). Merck, Sharp & Dohme \nde Espa\u00f1a. S.A. 2019IP: Iolanda \nJord\u00e1n Garc\u00eda.\nSELECTED PUBLICATIONS\n\u2022 Alejandre C, Guitart C, Balaguer \nM, T\norr\u00fas I, Bobillo S, Cambra F J et al. Use of procalcitonin and \nC-reactive protein in the diagnosis \nof bacterial infection  in infants \nwith severe bronchiolitis. Eur \nJ Pediatr. 2021;180(3):833-842. \nIF:3,183. (Q1).\n\u2022 Bobillo S, Balaguer M, Jor\nd\u00e1n I, \nBatista A, Ramon M, Otero O et al. \nDelivery room ultrasound study \nto assess heart rate in newborns: \nDELIROUS study. Eur J Pediatr. \n2021;180(3):783-790. IF:3,183. \n(Q1).\n\u2022 Doba\u00f1o C, Alonso S, F\nern\u00e1ndez \nde Sevilla M, Vidal M, Jim\u00e9nez A, \nPons G et al. Antibody conversion \nrates to SARS-CoV-2 in saliva from \nchildren attending summer  schools \nin Barcelona, Spain. BMC Med. \n2021;19(1):309. IF:8,775. (Q1).\n\u2022 Esquerda M, P\nalau F, Lorenzo-\nIzquierdo D, Cambra F J, \nBofarull M, Cusi V et al. Ethical \nquestions concerning newborn \ngenetic screening. Clin Genet. \n2021;99(1):93-98. IF:4,438. (Q2).\nAllergic diseases \nin childhood and \nadolescence\nMontserrat Alvaro Lozano, MD, PhD\nMEMBERS\nSTAFF RESEARCHER\nRosa Jim\u00e9nez Feijoo, Jaime Lozano \nBlasco, Adrianna Machinena Spera\nPHD STUDENTS\nOlga Dominguez S\u00e1nchez\nSELECTED PROJECTS\n\u2022 Estudio de la alergenicidad de \ndif\nerentes prote\u00efnes en la alergia \nalimentaria a pescado en poblaci\u00f3n \npedi\u00e0trica. Sociedad Espa\u00f1ola de \nInmunolog\u00eda Cl\u00ednica, Alergia y Asma \nPedi\u00e1trica. 2021-2022. IP: Olga \nDominguez S\u00e1nchez.\n\u2022 Genetics of Food All\nergy Barcelona \nMontserrat Alvaro. Max Delbr\u00fcck \nCentrum f\u00fcr Molekulare medizin \nBerlin-Buch. 2021-2022. IP: \nMontserrat Alvaro Lozano.SELECTED CLINICAL TRIALS & \nOBSERVATIONAL STUDIES\n\u2022 Estudio de 52 semanas, \nal\neatorizado, doble ciego, controlado \ncon placebo, de grupos paralelos, \nmultic\u00e9ntrico sobre la eficacia y \nseguridad de la terapia adyuvante \nde GSK3511294 en participantes \nadultos y adolescentes con asma \ngrave no controlada con un fenotipo \neosinof\u00edlico. A 52-week, randomised, \ndouble-blind, placebo-controlled, \nparallel-group, multi-centre \nstudy of the efficacy and safety of \nGSK3511294 adjunctive therapy in \nadult and adolescent participants \nwith severe uncontrolled asthma \nwith an eosinophilic phenotype. \n(213744). Glaxosmithkline, S.A; IQVIA \nRDS Spain SL. 2021-. IP: Jaime \nLozano Blasco. \n\u2022 Estudio de 52 semanas de dur\naci\u00f3n, \naleatorizado, doble ciego, con \ndoble simulaci\u00f3n, de grupos \nparalelos, multic\u00e9ntrico, de no \ninferioridad, para evaluar la tasa \nde exacerbaci\u00f3n, las mediciones \nadicionales de control del asma y la \nseguridad en participantes adultos \ny adolescentes con asma grave \ncon fenotipo eosinof\u00edlico tratados \ncon GSK3511294 en comparaci\u00f3n \ncon mepolizumab o benralizumab. \nA 52-week, randomised, double-\nblind, double-dummy, parallel \ngroup, multi-centre, non-inferiority \nstudy assessing exacerbation rate, \nadditional measures of asthma \ncontrol and safety in adult and \nadolescent severe asthmatic \nparticipnts with an eosinophilic \nphenotype treated with GSK3511294 \ncompared with mepolizumab \nor benralizumab. (206785). \nGlaxosmithkline, S.A; IQVIA RDS \nSpain SL. 2021-. IP: Jaime Lozano \nBlasco. \n SELECTED PUBLICATIONS\n\u2022 Escarrer M, Julia JC, Quevedo S, \nPriet\no Del A, M\u00f3nica Paola Sandoval \nR, Quesada F et al. Cambios en \nla epidemiolog\u00eda y en la pr\u00e1ctica \ncl\u00ednica de la alergia mediada por IgE  \nen pediatr\u00eda. An. Pediatr. 2021;95(1): \n56.e1-56.e8. IF:1,500. (Q4). \n\u2022 Pfaar O, Agache I, Bonini M, Br\nough \nHA, Chivato T, Del Giacco SR et al. \nCOVID-19 pandemic and allergen \nimmunotherapy-an EAACI survey. \nAllergy. 2021;76(11):3504-3516. \nIF:13,146. (Q1).1 FOREWORD\nGovernance and structures\nGlobal numbers 2020\nGlobal numbers 2020-2015\nInstitutional awards\n7.1\nMEDICINE  \nAND PEDIATRIC \nSCIENCE AREA\n7.1.3\nPaediatric cancer\nTranslational genomics\nSarcomas and histiocytosis\nTherapy development in pediatric oncology\nPaediatric leukaemia and haematopoiesis\nMolecular pharmacology and experimental therapies\nPaediatric cancer epigenetics62 INSTITUT  DE RECERCA  \nMEDICINE AND PEDIATRIC  \nSCIENCE AREA \nPAEDIATRIC CANCER\nTranslational \ngenomics\nCecilia Emilia Lavarino, PhD\nMEMBERS\nSTAFF RESEARCHER\nH\u00e9ctor Salvador Hern\u00e1ndez\nPOSTDOC ASSOCIATED RESEARCHERS\nMarta Garc\u00eda L\u00f3pez, Soledad Gomez \nGonzalez\nPHD STUDENTS\nAl\u00edcia Garrido Garcia\nASSISTANT RESEARCHER\nAlba Parra Checa\nTECHNICIAN\nSonia Paco Mercader, Isadora Lemos \nDas Neves\nSELECTED PROJECTS\n\u2022 Desarrollo de clasificadores \nepigen\u00e9tic\nos para el C\u00e1ncer \nPedi\u00e1trico (ECPC). (PI20/00519). \nInstituto de Salud Carlos III (ISCIII). \n2021-2023. IP: Cinzia Emilia \nLavarino. \n\u2022 Platform of Epigenetic Clas\nsifiers \nfor Childhood CAncer (PECA). \n(201921-30). Fundaci\u00f3 La Marat\u00f3 \nde TV3. 2020-2023. IP: Cinzia Emilia \nLavarino. \n\u2022 M\u00e9todo par\na la clasificaci\u00f3n \nen subgrupos moleculares de \npacientes con Meduloblastoma. \n(PI17/00353). Instituto de Salud \nCarlos III (ISCIII). 2018-2022. IP: \nCinzia Emilia Lavarino.\nSELECTED CLINICAL TRIALS & \nOBSERVATIONAL STUDIES\n\u2022 Ensayo de Fase I/II, Abierto y \nde un sol\no brazo para Evaluar \nla Farmacocin\u00e9tica, Seguridad/\nTolerabilidad y Eficacia de la \nFormulaci\u00f3n Granulada de \nSelumetinib en ni\u00f1os de 1 a \n< 7 A\u00f1os con Neurofibromas \nPlexiformes (NP) Sintom\u00e1ticos \ne Inoperables relacionados con \nNeurofibromatosis Tipo 1 (NF1) \n(SPRINKLE). (D1346C00004). \nAstrazeneca Farmaceutica Spain, \nS.A. 2021-. IP: H\u00e9ctor Salvador \nHern\u00e1ndez. \n\u2022 Ensayo f\nase I, de un solo brazo, \nsecuencial, para evaluar el efecto \nde los alimentos sobre la seguridad \ny farmacocin\u00e9tica de selumetinib despu\u00e9s de dosis m\u00faltiples en ni\u00f1os \nadolescentes con neurofibromas \nplexiformes (NP) asociados a \nneurofibromatosis tipo 1 (NF1). A \nPhase I, Single-Arm, Sequential \nStudy to Evaluate the Effect of \nFood on the Gastrointestinal \nToxicity and Pharmacokinetics \nof Selumetinib after Multiple \nDoses in Adolescent Children with \nNeurofibromatosis Type 1 (NF1) \nRelated Plexiform Neurofibromas \n(PN). (D1346C00015). Astrazeneca \nFarmaceutica Spain, S.A. 2021-. IP: \nH\u00e9ctor Salvador Hern\u00e1ndez. \nSELECTED PUBLICATIONS\n\u2022 Khan S, Solano P, Suwal T, Lu M, Al \nS, Ho B et al. Clinical phenotypes \nand pr\nognostic features of \nembryonal tumours with multi-\nlayered  rosettes: a Rare Brain \nTumor Registry study. Lancet Child \nAdolesc Health. 2021;5(11):800-813. \nIF:11,288. (Q1).\n\u2022 Petit M, Guasp M, Armangue T, \nLav\narino C, Morales A, Saiz A et \nal. Absence of GluD2 Antibodies \nin Patients With Opsoclonus-\nMyoclonus Syndrome. Neurology. \n2021;96(7): e1082-e1087. IF:9,910. \n(Q1).\n\u2022 Olivan M, Gar\ncia M, Su\u00e1rez L, Guiu \nM, Gros L, M\u00e9ndez O et al. Loss of \nmicroRNA-135b Enhances Bone \nMetastasis in Prostate Cancer and \nPredicts  Aggressiveness in Human \nProstate Samples. Cancers (Basel). \n2021;13(24):6202IF:6,639. (Q1).\n\u2022 Siev\ners P, Henneken SC, Blume \nC, Sill M, Schrimpf D, Stichel D et \nal. Recurrent fusions in PLAGL1 \ndefine a distinct subset of pediatric-\ntype  supratentorial neuroepithelial \ntumors. Acta Neuropathol. \n2021;142(5):827-839. IF:17,088. (Q1).\nSarcomas and \nhistiocytosis\nJaume Mora Graupera, MD, PhD\nIn 2021, while we were still immersed \nin the pandemic, which has fortunately \nnot adversely affected children and \njuveniles, our Cancer Group carried on with its mission of expanding our \nknowledge of this disease, which is \nresponsible for the greatest mortality \nin the child population of the advanced \ncountries.  \nIn the scientific sphere, mention \nshould be made of the publications of \nthe neuroblastoma immunotherapy \nteam directed by Dr Jaume Mora, \nwhich has become consolidated \nas an international reference \ngroup in the treatment of high-risk \nneuroblastoma. The information \ncollected in the \u201cPivotal phase 2 \ntrial of antibody naxitamab (hu3F8) \nand granulocyte-macrophage \ncolony stimulating factor (GM-\nCSF) in high-risk neuroblastoma \npatients with primary refractory \ndisease or incomplete response to \nsalvage treatment in bone and/or \nbone marrow (Y-MABS 201) Y-mAbs \nTherapeutics A/S. 2018\u201d , 50% of \nwhich was provided by patients of our \ncentre, allowed the FDA to approve \nnaxitamab for the treatment of \nrelapsed/refractory neuroblastoma in \nbone marrow/bone on 20 November \n2020.  \nMEMBERS\nSTAFF RESEARCHER\nMaite Gorostegui Obanos, Alicia \nCasta\u00f1eda Heredia, Lucas Krauel \nGim\u00e9nez-Salinas, Moira Garraus \nOneca, Veronica Celis Passini\nPOSTDOC ASSOCIATED RESEARCHERS\nAnastasia Herrero, Elisabet Figuerola \nBou, Silvia Mateo Lozano, Sara \nS\u00e1nchez Molina\nPHD STUDENTS\nPablo T\u00e1boas Out\u00f3n, Maria Sanchez \nJimenez\nASSISTANT RESEARCHER\nCarla Rios Astorch, Jara Martin \nSerrano, Irene Cuervas Oliveras, \nAlejandro Manzanares Quintela, Estela \nPrada Varela, Sara P\u00e9rez Jaume\nTECHNICIAN\nSoraya Morales Moreno, \u00d3scar Mu\u00f1oz \nAznar, Noelia Salvador Marcos\nCOLLABORATOR RESEARCHER\nMaria Inmaculada Hernandez Mu\u00f1oz\nSELECTED PROJECTS\n\u2022 Evaluation of the effects of Oryzon \nGenomics pr\noprietary compounds \non pediatric patient tumors. Oryzon \nGenomics S.A. 2021-2023. IP: \nJaume Mora Graupera. \n\u2022 Ipatasertib in Rhabdomy\nosarcoma. 63 INSTITUT  DE RECERCA  \nMEDICINE AND PEDIATRIC  \nSCIENCE AREA \nPAEDIATRIC CANCER\nRoche Diagnostics International \nLtd. 2019-2021. IP: Jaume Mora \nGraupera.\n\u2022 Influencia del cont\nexto epigen\u00e9tico \nen la edad como factor pron\u00f3stico \nen Ewing Sarcoma. (PI20/00179). \nInstituto de Salud Carlos III \n(ISCIII). 2021-2023. IP:Jaume Mora \nGraupera.\nSELECTED CLINICAL TRIALS & \nOBSERVATIONAL STUDIES\n\u2022 Ensayo Cl\u00f3inico plataforma en fase \nII de inmuno-onc\nolog\u00eda de precisi\u00f3n \ncon indicaci\u00f3n tumor agn\u00f3stica para \nmutaciones som\u00e1ticas espec\u00edficas \n(TAPISTRY). Tumor-agnostic \nprecision immuno-oncology and \nsomatic targeting rational for you \n(Tapistry) phase II platform trial. \n(BO41932). Roche Farma, S.A. \n2021IP: Jaume Mora Graupera. \n\u2022 An ov\nerarching study for children \nand adults with Frontline and \nRelapsed RhabdoMyoSarcoma. \n(FaR-RMS). Fundaci\u00f3n Sociedad \nEspa\u00f1ola de Hematolog\u00eda y \nOncolog\u00eda Pedi\u00e1tricas. 2021IP: \nMoira Garraus Oneca.\n\u2022 Estudio de f\nase 1, multic\u00e9ntrico, \nabierto, con intesificaci\u00f3n de dosis y \nexpansi\u00f3n de cohorte con Niraparib \ny Dostarlimab en pacientes \npedi\u00e1tricos con tumores s\u00f3lidos \nrecurrentes o refractarios. A phase \n1, multicentre, open-label, dose-\nescalation and cohort expansion \nstudy of niraparib and dostarlimab \nin paediatric patients with recurrent \nor refractory solid tumours. \n(213406). GlaxoSmithKline Research \nand Development Ltd. 2021IP: \nJaume Mora Graupera.\nSELECTED PUBLICATIONS\n\u2022 Mora J, Casta\u00f1eda A, Colombo \nMC, Gor\nostegui M, Fernando \nM, Ma\u00f1e S et al. Clinical and \nPathological Evidence of \nAnti-GD2 Immunotherapy \nInduced Differentiation in \nRelapsed/Refractory High-Risk \nNeuroblastoma. Cancers (Basel). \n2021;13(6): 164.IF:6,639. (Q1).\n\u2022 Mora J, Cas\nta\u00f1eda A, Gorostegui \nM, Santa V, Garraus M, Mu\u00f1oz JP \net al. Naxitamab combined with \ngranulocyte-macrophage colony-\nstimulating factor as  consolidation \nfor high-risk neuroblastoma \npatients in complete remission. Pediatr Blood Cancer. 2021;68(10): \ne29121. IF:3,167. (Q1).\n\u2022 Castill\no H, Pascual G, P\u00e9rez S, \nResa C, Vil\u00e0 M, Monterrubio C et al. \nPrognostic value of patient-derived \nxenograft engraftment in pediatric \nsarcomas. J Pathol Clin Res. \n2021;7(4):338-349. IF:5,638. (Q1).\n\u2022 Garc\u00eda D\nJ, Hajji N, S\u00e1nchez S, \nFiguerola E, de Pablos RM, Espinosa \nAM et al. Selective inhibition of \nHDAC6 regulates expression of \nthe oncogenic driver EWSR1-FLI1 \nthrough the EWSR1 promoter \nin Ewing sarcoma. Oncogene. \n2021;40(39):5843-5853. IF:9,867. \n(Q1).\nTherapy \ndevelopment in \npediatric oncology\nAngel Montero Carcaboso, PhD\nMEMBERS\nPOSTDOC ASSOCIATED RESEARCHERS\nMaria del Rosario Aschero\nPHD STUDENTS\nCl\u00e0udia Resa Par\u00e9s, Maria Cuadrado \nVilanova, Helena Castillo Ecija\nASSISTANT RESEARCHER\nFrancisco Javier Vicario la Torre, \nV\u00edctor Burgue\u00f1o Sandoval, Leire \nBalaguer Lluna, Merc\u00e8 Baulenas \nFarr\u00e9s\nTECHNICIAN\nAna Jim\u00e9nez Cabaco, M\u00f2nica Vil\u00e0 \nUbach\nCOLLABORATOR RESEARCHERS\nGuillermo Chantada, Ofelia Cruz \nMart\u00ednez, Andr\u00e9s Morales La Madrid\nSELECTED PROJECTS\n\u2022 Desenvolupament precl\u00ednic del \nf\n\u00e0rmac G2B-001 i aplicaci\u00f3 en \nel tractament de tumors s\u00f2lids \npedi\u00e0trics. (2021 DI 008). Agaur \n- Ag\u00e8ncia de Gesti\u00f3 d\u2019Ajuts \nUniversitaris i de Recerca. 2021-\n2024. IP: Angel Montero Carcaboso. \n\u2022 Inhibition of the PI3K/Akt pathway \nin pediatric high grade and diffuse \nintrinsic pontine gliomas (pHGG/\nDIPG). (201927-30). F\nundaci\u00f3 La Marat\u00f3 de TV3. 2020-2023. IP: Angel \nMontero Carcaboso.\n\u2022 Contrat\no predoctoral de formaci\u00f3n \nen investigaci\u00f3n en salud_\nBeneficiario: Helena Castillo. \n(FI19/00138). Instituto de Salud \nCarlos III (ISCIII). 2020-2023. \nIP:Angel Montero Carcaboso.\nSELECTED CLINICAL TRIALS & \nOBSERVATIONAL STUDIES\n\u2022 SIOP Ependimoma II - Progr ama \ncl\u00ednico internacional para el \ndiagn\u00f3stico y tratamiento de ni\u00f1os, \nadolescentes y adultos j\u00f3venes \ncon ependimoma. (ET-13-002). \nSociedad Espa\u00f1ola de Hematolog\u00eda \ny Oncolog\u00eda Pedi\u00e1tricas. 2017-. IP: \nOfelia Cruz Mart\u00ednez. \n\u2022 Phase Ib Clinical T\nrial on the Safety \nof Immunotherapy With Autologous \nDendritic Cells Primed With Lysate \nAllogeneic Tumor Lines in Patients \nWith Diffuse Intrinsic Pontine \nGlioma (DIPG). (FSJD-DIPG-DC). \nFundaci\u00f3 Privada per a la Recerca \ni la Doc\u00e8ncia Sant Joan de D\u00e9u - \nFSJD. 2016-- IP: Andr\u00e9s Morales La \nMadrid. \n\u2022 Estudio pr\nospectivo internacional \nen ni\u00f1os mayores de 3 a 5 a\u00f1os con \nmeduloblastoma de riesgo est\u00e1ndar \ncl\u00ednico de perfil biol\u00f3gico de bajo \nriesgo. (SIOP - PNET 5 MB - LR). \nSociedad Espa\u00f1ola de Hematolog\u00eda \ny Oncolog\u00eda Pedi\u00e1tricas. 2016-. IP: \nOfelia Cruz Mart\u00ednez. \nSELECTED PUBLICATIONS\n\u2022 Aschero R, Francis JH, Ganiewich \nD, Gomez S, Sampor C, Zugbi \nS et al. Recurr\nent Somatic \nChromosomal Abnormalities \nin Relapsed Extraocular \nRetinoblastoma. Cancers (Basel). \n2021;13(4):673IF:6,639. (Q1).\n\u2022 Castill\no H, Pascual G, P\u00e9rez S, \nResa C, Vil\u00e0 M, Monterrubio C et al. \nPrognostic value of patient-derived \nxenograft engraftment in pediatric \nsarcomas. J Pathol Clin Res. \n2021;7(4):338-349. IF:5,638. (Q1).\n\u2022 Mukkada S, Bhakta N, Chant\nada \nG, Chen Y, Vedaraju Y, Faughnan \nL et al. Global characteristics and \noutcomes of SARS-CoV-2 infection \nin children and  adolescents with \ncancer (GRCCC): a cohort study. \nLancet Oncol. 2021;22(10):1416-\n1426. IF:41,316. (Q1).\n\u2022 Siev\ners P, Henneken SC, Blume 64 INSTITUT  DE RECERCA  \nMEDICINE AND PEDIATRIC  \nSCIENCE AREA \nPAEDIATRIC CANCER\nC, Sill M, Schrimpf D, Stichel D et \nal. Recurrent fusions in PLAGL1 \ndefine a distinct subset of pediatric-\ntype  supratentorial neuroepithelial \ntumors. Acta Neuropathol. \n2021;142(5):827-839. IF:17,088. (Q1).\nPaediatric \nleukaemia and \nhaematopoiesis\nMireia Cam\u00f3s Guijosa, MD, PhD\nThe Leukaemias and Other Paediatric \nHaemopathies group was very active \nin 2021, despite external difficulties. \nWe continued to work on the projects \nwhich had been previously begun and \nwe obtained important grants for the \nstart-up of new projects.\nFor example, some new projects were \nimplemented in 2021 in relation to \nacute leukaemia. On the one hand, Dr \nCatal\u00e0 is leading the GEMMA study \nfor the complete characterisation of \nthe myelodysplastic syndromes and \nhereditary acute myeloid leukaemias \nin childhood, a project funded by the \nFoundation La Marat\u00f3 de TV3. \nOn the other hand, the \nUnoentrecienmil (One in a Hundred \nThousand) Foundation financed a \nproject to facilitate the implementation \nof the ALLTogether treatment strategy \nfor paediatric acute lymphoblastic \nleukaemia in Spain, which will become \nthe next nationwide healthcare \nprotocol.\nOur activity in clinical trials was very \nintense in all fields in 2021, and our \ngroup leads and participates in trials \nwith directed treatments and with \nvarious forms of immunotherapy \nin leukaemia and other types of \nhaemopathies. Notably, Dr Rives \ncontinues to lead nationally and \ninternationally the CART therapy for \nacute leukaemia, conducting various \nclinical trials and promoting new \nresearch projects.\nMEMBERS\nSTAFF RESEARCHER\nIzaskun Elorza Alvarez, Isabel Badell \nSerra, Julia Marsal Ricoma, Ruben Berrueco Moreno, Albert Catal\u00e0 \nTemprano, Susana Rives Sol\u00e0, Anna \nRuiz Llobet, Montserrat Torrebadell \nBurriel\nPOSTDOC ASSOCIATED RESEARCHERS\nNerea Vega Garc\u00eda\nPHD STUDENTS\nClara Vicente Garces, Susanna Gassiot \nRiu, Elena Esperanza Cebollada, \nSandra Pont Marti, Maria Trabazo del \nCastillo, Anna Alonso Saladrigues, \nMontserrat Mesegue Meda\nASSISTANT RESEARCHER\nMaximiliano Ezequiel Distefano Mu\u00f1oz\nTECHNICIAN\nC\u00e8lia Portillo Bog, Warda Suleman, \nLidia Ruiz Bocanegra, Maria Camino \nEstella Aguado, Merc\u00e9 Richarte \nFrnaqu\u00e9s\nSELECTED PROJECTS\n\u2022 New approaches for the \nidentific\nation and functional \ncharacterization of prognostic \ngenetic biomarkers in inherited \nchildhood myelodysplastic/acute \nleukemia syndromes Acronym: \nGEMMA. Fundaci\u00f3 La Marat\u00f3 de \nTV3. 2021-2024. IP: Albert Catal\u00e0 \nTemprano. \n\u2022 Hacia la personalizaci\u00f3n de la \npr\nofilaxis de la trombosis venosa \nprofunda en pacientes pedi\u00e1tricos \nafectos de leucemia linfobl\u00e1stica \naguda: uso de test de generaci\u00f3n de \ntrombina. (PI17/00356). Instituto de \nSalud Carlos III (ISCIII). 2018-2022. \nIP: Rub\u00e9n Berrueco Moreno.\n\u2022 Implement\naci\u00f3n de la estrategia \nde tratamiento Alltogether para \nleucemia linfobl\u00e1stica aguda \npedi\u00e1trica en Espa\u00f1a. Fundaci\u00f3n \nUno entre Cien Mil. 2021-2022. IP: \nSusana Rives Sol\u00e0.\nSELECTED CLINICAL TRIALS & \nOBSERVATIONAL STUDIES\n\u2022 Estudio de fase 1/2, abierto y \nde un sol\no brazo que eval\u00faa la \nseguridad y eficacia del ponatinib \npara el tratamiento de leucemias \no tumores s\u00f3lidos recurrentes \no refractarios en pacientes \npedi\u00e1tricos. An Open-Label, \nSingle-Arm, Phase 1/2 Study \nEvaluating the Safety and Efficacy \nof Ponatinib for the Treatment of \nRecurrent or Refractory Leukemias \nor Solid Tumors in Pediatric \nParticipants. (INCB 84344-102). \nIncyte Biosciences International S\u00e0rl; Pharmaceutical Product \nDevelopment Spain, S.L. 2021. IP: \nAlbert Catal\u00e0 Temprano.\n\u2022 Estudio de f\nase 1/2 multic\u00e9ntrico \npara evaluar la seguridad y eficacia \nde KTEX19 en sujetos pedi\u00e1tricos \ny adolescentes con leucemia \nlinfobl\u00e1stica aguda de precursores \nde linfocitos B recidivante/\nrefractaria o linfoma no Hodgkin de \nlinfocitos B recidivante/refractario \n(ZUMA-4). A Phase 1/2 Multi-Center \nStudy Evaluating the Safety and \nEfficacy of KTE-X19 in Pediatric \nand Adolescents Subjects with \nRelapsed/Refractory B-precursor \nAcute Lymphoblastic Leukemia \nor Relapsed/Refractory B-Cell \nNon-Hodgkin Lymphoma (ZUMA-\n4). (KTE-C19-104 (Zuma - 4)). \nKite Pharma Inc; Labcorp Drug \nDevelopment Inc. 2021. IP: Susana \nRives Sol\u00e0.\n\u2022 Estudio en f\nase III, aleatorizado, \nabierto, con control activo, \nmultic\u00e9ntrico, para evaluar \nla eficacia y la seguridad de \nCrovalimab frente a Eculizumab \nen pacientes con hemoglobinuria \nparox\u00edstica previamente con \ninhibidores del complemento. \nA Phase III, Randomized, \nOpen-Label, Active-Controlled, \nMulticenter Study Evaluating \nThe Efficacy And Safety Of \nCrovalimab Versus Eculizumab \nIn Adult And Adolescent Patients \nWith Paroxysmal Nocturnal \nHemoglobinuria not previously \ntreated with complement inhibitors. \n(BO42162). IQVIA RDS Spain SL; \nRoche Diagnostics International \nLtd. 2021. IP: Albert Catal\u00e0 \nTemprano.\n\u2022 Un estudio de f\nase III, abierto, \nde un solo grupo, multic\u00e9ntrico \nde Ravulizumab junto al mejor \ntratamiento sintom\u00e1tico en \nparticipantes pedi\u00e1tricos (de 1 mes \na <18 a\u00f1os) con microangiopat\u00eda \ntromb\u00f3tica (MAT) despu\u00e9s de \nun trasplante de c\u00e9lulas madre \nhematopoy\u00e9ticas (TCMH). A \nPhase 3, Open-label, Single Arm, \nMulticenter Study of Ravulizumab \nin Addition to Best Supportive Care \nin Pediatric articipants (from 1 \nmonth to < 18 years of age) with \nThrombotic Microangiopathy (TMA) \nafter Hematopoietic Stem Cell \nransplantation (HSCT). (ALXN1210-\nTMA-314). Alexion Pharmaceuticals \nInc.; IQVIA RDS Spain SL. 2021. IP: \nJulia Marsal Ricom\u00e0.65 INSTITUT  DE RECERCA  \nMEDICINE AND PEDIATRIC  \nSCIENCE AREA \nPAEDIATRIC CANCER\nSELECTED PUBLICATIONS\n\u2022 Levine JE, Grupp SA, Pulsipher \nMA, Dietz A\nC, Rives S, Myers \nGD et al. Pooled safety analysis \nof tisagenlecleucel in children \nand young adults with B cell  \nacute lymphoblastic leukemia. \nJ Immunother Cancer. \n2021;9(8):e002287. IF: 13,751. (Q1).\n\u2022 Navarr\no S, Sevilla J, Rio P, \nSanchez R, Zubicaray J, Galvez \nE et al. Hematopoietic Stem Cell \nCollection for the Gene Therapy of \nFanconi Anemia Patients. Mol Ther. \n2021;29(4):342-342. IF: 11,454. (Q1).\n\u2022 Ort\u00edz V, Rives S, Cas\ntell\u00e0 M, Alonso \nA, Ben\u00edtez D, Caballero M et al. \nCART19-BE-01: A Multicenter \nTrial of ARI-0001 Cell Therapy in \nPatients with CD19(+)  Relapsed/\nRefractory Malignancies. Mol Ther. \n2021;29(2):636-644. IF: 11,454. (Q1).\n\u2022 Rives S. C\nAR T cells in CNS-relapsed leukaemia: one step \nforward. Lancet Haematol. \n2021;8(10):e675-e676.IF: 18,959. \n(Q1).\n\u2022 Sahoo SS, P\nastor VB, Goodings \nC, Voss RK, Kozyra EJ, Szvetnik \nA et al. Clinical evolution, genetic \nlandscape and trajectories of \nclonal hematopoiesis in  SAMD9/\nSAMD9L syndromes. Nat Med. \n2021;27(10):1806-1817. IF: 53,440. \n(Q1).\n\u2022 Vega N, P\n\u00e9rez S, Esperanza E, \nVicente C, Torrebadell M, Jim\u00e9nez A \net al. Measurable Residual Disease \nAssessed by Flow-Cytometry Is \na Stable Prognostic Factor for \nPediatric T-Cell Acute Lymphoblastic \nLeukemia in Consecutive SEHOP \nProtocols  Whereas the Impact \nof Oncogenetics Depends \non Treatment. Front Pediatr. \n2021;8:614521. IF: 3,418. (Q1).Molecular \npharmacology \nand experimental \ntherapies\nMar\u00e7al Pastor-Anglada, PhD\nThe bioavailability of certain anti-\ntumoural drugs whose mechanism \nof action is based on interference \nwith nucleotide metabolism depends \non transport proteins located in the \ncell membrane. The expression of \nthese transporters is modified in \nboth solid and liquid tumours and it \nis not uncommon to find that some \nspecific subtypes responsible for \nthe uptake of these drugs, such \nas the protein hCNT1, present \nnegligible levels in tumours. This \n66 INSTITUT  DE RECERCA  \nMEDICINE AND PEDIATRIC  \nSCIENCE AREA \nPAEDIATRIC CANCER\ncircumstance, as well as being able to \ncontribute to the tumoural metabolic \nreprogramming, can also be the cause \nof chemoresistance. Last year, our \ngroup\u2019s foremost contribution was \nthe demonstration of the fact that the \nloss of expression of hCNT1 in a wide \nrange of tumours has an epigenetic \norigin associated with the deregulation \nof the expression pattern of miRNAs in \nthe tumours. The oncomiRs miR-106a \nand miR-17 negatively and directly \nregulate the nucleoside-derived drug \ntransporter hCNT1. By silencing these \nmiRNAs, we succeed in recovering the \nexpression and part of the function \nof this drug transporter, and this \ncontributes to the improvement \nof the cellular response to these \nanti-tumoural agents. We believe \nthis is a new epigenetic mechanism \nthat may condition the response to \nchemotherapy. \nMEMBERS\nSTAFF RESEARCHER\nSandra Perez-Torras\nPOSTDOC ASSOCIATED RESEARCHERS\nLiska Caviedes C\u00e1rdenas, Jose \nAntonio Ag\u00fcero Fern\u00e1ndez, Laura \nGarc\u00eda Vega, Aida Mata Ventosa, Nerea \nUrtasun Plans\nPHD STUDENTS\nAndrea Valentina Prieto Carruyo, Eloy \nPena Rodr\u00edguez\nSELECTED PROJECTS\n\u2022 Desoxiribonucle\u00f2sids com a ter\u00e0pia \nper als tr\nastorns de la replicaci\u00f3 de \nl\u2019ADN mitocondrial: investigaci\u00f3 dels \nmecanismes terap\u00e8utics i ampliaci\u00f3 \ndel tractament a les mutacions en \nPOLG i altres gens (97/C/2020). \nFundaci\u00f3 La Marat\u00f3 de TV3. Ajuts \necon\u00f2mics a projectes de recerca \nde la Fundaci\u00f3 Marat\u00f3 de TV3. 2021-\n2024. PI: Mar\u00e7al Pastor Anglada.\n\u2022 Descubrimiento y desarr\nollo de \nnuevos tratamientos Inmuno-\nOncol\u00f3gicos (RTC2019-006865-\n1). Ministerio de Economia y \nCompetitividad. Convocat\u00f2ria \nReptes-Col\u00b7laboraci\u00f3 del \nPrograma Estatal de Recerca, \nDesenvolupament i Innovaci\u00f3 \nOrientada als Reptes de la Societat. \n2020-2022. PI: Mar\u00e7al Pastor \nAnglada.\n\u2022 Doctor\nats industrials 2019. \nEmpresa: Laboratorios Reig Jofr\u00e9, \nS.A (2019DI005). Ag\u00e8ncia de Gesti\u00f3 d\u2019Ajuts Universitaris i de Recerca \n(AGAUR). Ajuts a universitats i a \nempreses per al desenvolupament \nd\u2019un projecte de doctorat industrial, \nen qualsevol \u00e0mbit de coneixement \ni qualsevol sector empresarial. \nDoctorats industrials 2019. 2019-\n2022. PI: Sandra P\u00e9rez Torras\n\u2022 Prot\ne\u00ednas transportadoras de \nnucle\u00f3sidos (NT), metabolismo \nde nucle\u00f3tidos y c\u00e1ncer (RTI2018-\n094655-B-I00). Ministerio de \nCiencia, Innovaci\u00f3n y Universidades. \nConvocat\u00f2ria d\u2019ajuts del \nPrograma Estatal d\u2019Investigaci\u00f3, \nDesenvolupament i Innovaci\u00f3 \nOrientada als reptes de la Societat. \nModalitat Reptes. 2019-2022. PI: \nMar\u00e7al Pastor Anglada\nSELECTED PUBLICATIONS\n\u2022 Boces C, Mata A, Mart\u00edn M, Boix \nL, Gir\nonella M, Pastor M et al. \nOncomiRs miR-106a and miR-17 \nnegatively regulate the nucleoside-\nderived drug transporter hCNT1. \nCell Mol Life Sci. 2021;78(23):7505-\n7518. IF:9,261. (Q1).\n\u2022 Pena E, Lajarin M, Mat\na A, Perez \nS, Fern\u00e1ndez F. Dexamethasone-\nLoaded Lipomers: Development, \nCharacterization, and Skin  \nBiodistribution Studies. \nPharmaceutics. 2021;13(4):533.\nIF:6,321. (Q1).\n\u2022 Pena E, Mat\na A, Laura V, P\u00e9rez S, \nFern\u00e1ndez F. The Physicochemical, \nBiopharmaceutical, and In Vitro \nEfficacy Properties of  Freeze-Dried \nDexamethasone-Loaded Lipomers. \nPharmaceutics. 2021;13(8):1322. \nIF:6,321. (Q1).\nPaediatric  \ncancer  \nepigenetics\nAlexandra Avgustinva, PhD\nOur research group was founded \nin late 2020 with the overall goal \nto identify specific epigenomic \nvulnerabilities of developmental \ntumours, and to exploit them in the \npursuit of personalised therapies to improve patient welfare and \nprognosis. We believe that one size \ndoes not fit all, and we need to treat \neach individual, not the disease. \nCurrently we are focussing on \nmalignant rhabdoid tumours (MRTs), \nhighly malignant and heterogeneous \npaediatric cancers characterized \nby biallelic inactivation of the SWI/\nSNF chromatin remodelling complex \nsubunit SMARCB1. During 2021 \nwe established a plethora of tools \nnecessary for our studies, including \nmouse models, cell lines and \noptimised genome editing protocols. \nWe have been granted the \u201cPrograma \nEstatal de I+D+i Orientada a los \nRetos de la Sociedad\u201d grant entitled \n\u201cThe rogue epigenome of malignant \nrhabdoid tumours \u2013 define to treat\u201d \n(MINECO) to support and develop \nthis project. Additionally, we have \nincorporated new members into the \ngroup and expanded our national and \ninternational collaborator network: \ntogether we will bring about change \nsooner. \nMEMBERS\nPOSTDOC ASSOCIATED RESEARCHERS\nCarlos Javier Rodriguez Hernandez\nPHD STUDENTS\n\u00c0lex Cebri\u00e0 Xart\nSELECTED PROJECTS\n\u2022 El epigenoma malv ado de los \ntumores rabdoides - definir para \ntratar. (PID2020-118241RA-I00). \nMinisterio de Econom\u00eda Y \nCompetitividad (MINECO). 2021-\n2024. IP: Alexandra Avgustinova. \n\u2022 Ayudas par\na contratos Ram\u00f3n y \nCajal (RYC) 2019. Beneficiario: \nAlexandra Avgustinova. (RYC2019-\n027738-I). Ministerio de Econom\u00eda Y \nCompetitividad (MINECO). 2020-\n2025. IP: Alexandra Avgustinova.1 FOREWORD\nGovernance and structures\nGlobal numbers 2020\nGlobal numbers 2020-2015\nInstitutional awards\n7.1\nMEDICINE  \nAND PEDIATRIC \nSCIENCE AREA\n7.1.4\nPrecision medicine  \nin rare diseases \nMetabolic and mitochondrial medicine\nNeurogenetics and molecular medicine\nHuman molecular genetics I\nHuman molecular genetics II\nGenomics for the diagnosis of rare diseases\nDiagnostic and therapeutic imaging68 INSTITUT  DE RECERCA  \nMEDICINE AND PEDIATRIC  \nSCIENCE AREA\nPRECISSION MEDICINE  \nIN RARE DISEASES\nMetabolic and \nmitochondrial \nmedicine\nRafael Artuch Iriberri, MD, PhD\nOur research group participated in 32 \nscientific publications in 2021 and here \nwe will mention those led by members \nof our team and those which are of \nspecial scientific significance.\nIn the field of mitochondrial \ndisorders, we should point out \nour participation in the first \nepidemiological study of this type of \ndiseases at national level (Bellusci et \nal., Genes 2021), and the development \nof a new biomarker for the study of \nmitochondrial disorders (Paredes-\nFuentes et al., Clin Chem 2021). We \nalso renewed our research project \non these pathologies, PI20/00340, \nfor the Carlos III Health Institute \n(ISCIII). In the sphere of technological \ndevelopment, we culminated the \ngeneration of a new biosensor for \nthe measurement of ammonium, \nwhich is currently under testing \nat our hospital, through a health \ntechnologies development project. \nAdditionally, we consolidated our \nmetabolomic platform for research \non cellular and animal models, which \nhas given rise to four collaborative \nhigh-impact publications with basic \nresearchers.\nWith respect to congenital disorders \nof glycosylation, we continued \nto expand our knowledge of the \nphenotypic complex of PMM2-CDG \n(PMID: 34140212; PMID: 34442375) \nand, in particular, we developed an \ninternational project on stroke-like \nepisodes (PMID: 34708008), which \nled to a project funded by ISCIII \n2022-2024 (AES 2021). The project \ncalled \u201cSigmA. MicroRNA signature \nin cerebellar development: exploring \nearly biomarkers of cerebellar \ndisease\u201d has allowed us to find a \ncirculating microRNA signature \nwhich is characteristic of cerebellar \natrophy associated with PMM2-CDG \nand which may be a diagnostic and \nprognostic biomarker in an accessible \nsample such as plasma. Lastly, we \ndeveloped an international consensus \non follow-up of the PGM1-CDG \ndefect (PMID: 32681750). Likewise, \nour collaboration with groups from \nPompeu Fabra University (UPF) (Dr Fern\u00e1ndez Fern\u00e1ndez and Dr Gallego) \nallowed the development of a yeast \nand human cell model of RFT1-CDG \ndeficiency.\nMEMBERS\nSTAFF RESEARCHER\nRoser Urreizti Frexedas, Jaume \nCampistol Plana, Mercedes Serrano \nGimar\u00e9, Camila Garc\u00eda Volpe, Rosa \nGassi\u00f3 Subirachs, Aida Ormazabal \nHerrero, Cristina Sierra March\nPOSTDOC ASSOCIATED RESEARCHERS\nMercedes Casado Rio, Raquel \nMontero S\u00e1nchez, Juan Dar\u00edo \nOrtigoza\nPHD STUDENTS\nM\u00f3nica Centeno Pla, Abraham Jos\u00e9 \nParedes Fuentes\nASSISTANT RESEARCHER\nGregorio Alexander Nolasco Tovar, Iria \nTrasobares Magdalena\nTECHNICIAN\nAngela Yasmina Arias Dimas, Adriana \nBalen Valeiro, Yahel Calzadilla \nBorras, Aroa Fern\u00e1ndez de Miguel, \nJuan Moreno Garc\u00eda, Tania Pardal \nChofle\nSELECTED PROJECTS\n\u2022 Secuenciaci\u00f3n de ex oma para \nel diagn\u00f3stico de pacientes con \nenfermedades mitocondriales: \ninvestigaci\u00f3n de aspectos \nfisiopatol\u00f3gicos y terap\u00e9uticos de \nlas deficiencias de conezima Q10. \n(PI20/00340). Instituto de Salud \nCarlos III (ISCIII). 2021-2023. PI: \nRafael Artuch Iriberri.\n\u2022 PHENYLKETONURIA: fr\nom \nChildhood to Adults througt \nBrain Functional Connectomics, \nCardiovascular Changes, \nMetabolomic and MIcrobiota \nCharacteristics. Fundaci\u00f3 La \nMarat\u00f3 de TV3. PI: Aida Ormazabal \nHerrero.\n\u2022 Progr\nama MIMeS_Detecci\u00f3n, \nprevenci\u00f3n y tratamiento precoz \nde Salud Mental en pacientes con \nMalalties Minorit\u00e0ries Cognitiu-\nConductuals de base Gen\u00e8tica. \n(Programa MIMeS). OSSJD.\nSELECTED CLINICAL TRIALS & \nOBSERVATIONAL STUDIES\n\u2022 Estudio abierto, multic\u00e9ntrico para \ne\nvaluar la seguridad, tolerabilidad, \nfarmacocin\u00e9tica y farmacodinamia de RO7248824 en participantes \ncon S\u00edndrome de Angelman. \nAn open-label, multicenter \nstudy to investigate the safety, \ntolerability, pharmacokinetics and \npharmakodynamics of RO7248824 \nin participants with angelman \nsyndrome. (BP41674). Roche \nDiagnostics International Ltd; Roche \nFarma, S.A. 2020- PI: Mercedes \nSerrano Gimar\u00e9. \n\u2022 Estudio de f\nase IV, abierto y de una \nsola cohorte, de los resultados \nneurocognitivos (NC) a largo \nplazo en ni\u00f1os de 4 a 5 a\u00f1os \ncon fenilcetonuria tratados con \ndihidrocloruro de sapropterina \n(Kuvan\u00ae) durante 7 a\u00f1os. (EMR \n700773-002). Merck KGaA; Parexel \nInternational S.L. 2014- PI: Jaume \nCampistol Plana.  \n\u2022 RRHH03 - Ciberer\n. PI: Rafael Artuch \nIriberri.\n\u2022 Pruebas cl\u00ednicas y b\u00e1sic\nas sobre \nla carencia de fosfomanomutasa \n(PMM2-CDG). (GLY-000). And \nGlycomine, Inc; Voisin Consulting. \n2020- PI: Mercedes Serrano \nGimar\u00e9.\nSELECTED PUBLICATIONS\n\u2022 Kour S, Rajan DS, Fortuna \nTR, Ander\nson EN, Ward C, \nLee Y et al. Loss of function \nmutations in GEMIN5 cause a \nneurodevelopmental disorder. Nat \nCommun. 2021;12(1):2558-2558. \nIF:14,919. (Q1).\n\u2022 Pe\u00f1a M, Rold\u00e1n G, P\nerez J, Ortu\u00f1o \nFM, Carmona R, Aquino V et al. \nCSVS, a crowdsourcing database \nof the Spanish population genetic \nvariability. NUCLEIC ACIDS RES. \n2021;49(D1): D1130-37.IF:16,971. \n(Q1).\n\u2022 Pic\u00f3 S, P\narras A, Santos M, \nPose J, Castro M, Fraga E et al. \nCPEB alteration and aberrant \ntranscriptome-polyadenylation \nlead to a treatable  SLC19A3 \ndeficiency in Huntington\u2019s disease. \nSCI TRANSL MED. 2021;13(613)\nIF:17,956. (Q1).\n\u2022 Tris\ntan A, Borr\u00e0s E, Molero M, \nWassenberg T, Peters T, Verbeek \nMM et al. Novel Protein Biomarkers \nof Monoamine Metabolism Defects \nCorrelate with Disease  Severity. \nMov Disord. 2021;36(3):690-703. \nIF:10,338. (Q1).69 INSTITUT  DE RECERCA  \nMEDICINE AND PEDIATRIC  \nSCIENCE AREA\nPRECISSION MEDICINE  \nIN RARE DISEASES\nNeurogenetics  \nand molecular \nmedicine\nJanet Hoenicka, PhD  \n& Francesc Palau Mart\u00ednez, MD, PhD\nThe Neurogenetics and Molecular \nMedicine (NeuroGene) Group \ndoes research on the genetic, \npathophysiological and therapeutic \naspects of disorders affecting the \ncentral and peripheral nervous \nsystems, with special emphasis on \nrare diseases, genetic disorders \nand development disorders. The \nmilestones reached in 2021 in the \nareas of basic and translational \nbiomedicine and clinical research \nincluded the following:\n\u2022  Charact\nerisation of the interaction, \nin membrane contact sites, between \nmitochondria and lysosomes, and \ntheir role in the axonopathy of \nCharcot-Marie-Tooth disease.\n\u2022 The relation betw\neen the dopamine \ngene ANKK1, related to addictions, \nand the susceptibility to Parkinson\u2019s \ndisease.\n\u2022 Disco\nvery of new genes related \nto complex forms of autism \nspectrum (PLXNA and LRRC40) \nand neurodevelopmental syndrome \ndisorders (ZBTB7A, MIM #619769).\n\u2022 Inclusion of the Tr\nanslational \nDiagnosis of Functional Validation \nof Gene Variants Programme in \nthe Paediatric Institute of Rare \nDiseases (IPER) and the Genetic \nMedicine Service of Sant Joan de \nD\u00e9u Barcelona Children\u2019s Hospital \n(HSJD), and publication of the \npreliminary results.\nThe group\u2019s national and international \ncollaboration is intense: (i) member \nof the Rare Diseases Networked \nBiomedical Research Centre \n(CIBERER); (ii) collaboration with \nthe Genomic Sciences and Precision \nMedicine Center (GSPMC), Medical \nCollege of Wisconsin; (iii) member of \nthe International Parkinson\u2019s Disease \nGenomics Consortium (IPDGC) and the \nonly Spanish member of GP2 (Global \nParkinson\u2019s Genetics Program); (iv) \nmember of the Academy of Sciences \nof Latin America (ACAL); and (v) \neditor-in-chief, Orphanet Journal of \nRare Diseases .\nIn the sphere of training activity, four \nfinal master\u2019s degree projects and three final bachelor\u2019s degree projects \nwere carried out by students of the \nUniversity of Barcelona (UB), the \nAutonomous University of Barcelona \n(UAB) and Pompeu Fabra University \n(UPF).\nMEMBERS\nSTAFF RESEARCHER\nJoan Maynou Fern\u00e1ndez, M\u00f3nica \nRoldan Molina, Guerau Fernandez \nIsern\nPOSTDOC ASSOCIATED RESEARCHERS\nMar Borreg\u00e1n Prats, Esther \nCuatrecasas Capdevila, Cristina Hernando Davalillo, Laura Marti \nSanchez, Maria Rodriguez Sanz, Jordi \nPijuan Marquilles, Lara Cantarero \nAbad, Loreto Martorell Sampol\nPHD STUDENTS\nBerta Est\u00e9vez Arias\nASSISTANT RESEARCHER\nGemma Tort V\u00e1zquez, Edurne Urquizu \nLlop, Yaiza D\u00edaz Osorio, Adri\u00e1n Alcal\u00e1 \nSan Mart\u00edn, Jodie Kane, Alba Pascual \nRodr\u00edguez, Merc\u00e8 Bolasell Girgas, \nAntonio F Martinez Monseny\nTECHNICIAN\nDaniel Castillo Mestres, Jordi Genov\u00e8s \nEscarr\u00e9\n70 INSTITUT  DE RECERCA  \nMEDICINE AND PEDIATRIC  \nSCIENCE AREA\nPRECISSION MEDICINE  \nIN RARE DISEASES\nSELECTED PROJECTS\n\u2022 Mitochondrial membrane dynamics \nand its int\nerorganelle contact \nsites in the cellular and nerve \npathophysiology of neurogenetic \ndisease \u2013 NeuroContacts. (PID2020-\n114655RB-100). Agencia Estatal de \nInvestigaci\u00f3n \u2013 MICINN, 2021-2024. \nPI: Francesc Palau Mart\u00ednez.\n\u2022 Genes y fenotipos de s\u00edndr\nomes \nparkinsonianos: estudio cl\u00ednico y \nexperimental. (PI19/00126). Instituto \nde Salud Carlos III (ISCIII). 2020-\n2022. PI: Janet Hoenicka.\n\u2022 Infraes\ntructura de Medicina de \nPrecisi\u00f3n asociada a la Ciencia y \nTecnolog\u00eda (IMPaCT). Ciencia de \ndatos. Instituto de Salud Carlos III \n(ISCIII). 2021-2023. PI: Joan Maynou \nFern\u00e1ndez. \n\u2022 El cer\nebro cl\u00ednico del s\u00edndrome \nCoffin-Siris: estudio integral de \nun trastorno del neurodesarrollo. \nHospital Sant Joan de D\u00e9u - \nEsplugues HSJD. 2020-2023. PI: \nFrancesc Palau Mart\u00ednez. \n\u2022 Pro\nyecto de investigaci\u00f3n \ntraslacional sobre los aspectos \nfisiopatol\u00f3gicos y cl\u00ednicos de la \nenfermedad de Menkes. (Amigos de \nNono). Fundaci\u00f3n amigos de nono \ncontra la enfermedad de Menkes. \n2017-2022. PI: Francesc Palau \nMart\u00ednez y Janet Hoenicka.\n\u2022 Pro\nyecto piloto sobre la \nimplementaci\u00f3n de un cribado \nneonatal gen\u00e9tico en Espa\u00f1a. \nFundaci\u00f3n Ram\u00f3n Areces. 2019-\n2022. PI: Francesc Palau Mart\u00ednez. \n\u2022 Application of Adv\nanced multimodal \nmicroscopy and imaging to \nfoster therapy development in \nneuromuscular diseases. (Turrons \nVicens). Torrons Vicens SL. 2020-\n2023. PI: M\u00f3nica Roldan Molina.\nSELECTED PUBLICATIONS\n\u2022 Cantarero L, Ju\u00e1rez-Escoto E, \nCiv\nera-Treg\u00f3n A, Rodr\u00edguez-Sanz \nM, Roldan M, Ben\u00edtez R et al. \nMitochondria-lysosome membrane \ncontacts are defective in GDAP1-\nrelated Charcot-Marie-Tooth \ndisease. Hum Mol Genet. 2021; 29: \n3589-3605. IF: 6,150. (Q1).\n\u2022 Nater\na-De Benito D, Sola A, Sousa \nPR, Boronat S, Exp\u00f3sito J, Carrera-\nGarc\u00eda L et al. Copper Toxicity \nAssociated With an ATP7A-Related \nComplex Phenotype. Pediatr Neurol. \n2021; 119: 40-44. IF: 3,372. (Q1).\n\u2022 P\u00e9r\nez-Santamarina E, Garc\u00eda-Ruiz P, Mart\u00ednez-Rubio D, Ezquerra \nM, Pla-Navarro I, Puente J et al. \nRegulatory rare variants of the \ndopaminergic gene ANKK1 as \npotential risk factors for Parkinson\u2019s \ndisease. Sci Rep. 2021; 11 (1): 9879-\n9879. IF: 4,379. (Q1).\n\u2022 Pijuan J, Rodr\u00edguez-Sanz M, Nater\na-\nDe Benito D, Ortez CI, Altimir \nA, Osuna M et al. Translational \nDiagnostics: an in-house pipeline to \nvalidate genetic variants in children \nwith undiagnosed and rare diseases. \nJ Mol Diagn. 2021; 23 (1):71-90. IF: \n5,568. (Q1).\nHuman molecular \ngenetics I\nDaniel Ra\u00fal Grinberg Vaisman, PhD\nIn 2021 we described new genes and \nmutations responsible for intellectual \ndisability in patients originally \ndiagnosed as Opitz C or Bohring-Opitz \n(PORCN, ZIC2 ). We delved deeper \ninto the immunohistochemical, \ntranscriptomic and metabolomic \nanalysis of fibroblasts of patients with \nSchaaf-Yang syndrome (caused by \nmutations that truncate the MAGEL2 \nprotein) or with TRAF7 syndrome, and \nwe derived iPSCs from the former for \nthe future derivation of brain neurons \nand organoids.\nLikewise, we functionally analysed \nthe effect of variants in the SOST  \ngene in relation to osteoporosis, and \nmutations in the CYP1A1  gene in \npatients with atypical femoral fracture. \nWe also took part in multi-centre \nstudies on monogenic disorders \nof high and low bone mass, and \non functional validation in genetic \ndiseases of the skeleton.\nIn a study of genetic factors involved \nin stroke recovery, we have identified \na gene involved in the migration of \nneutrophils through the blood-brain \nbarrier, in which the presence of \nmissense variants would be protective. \nWe have studied the genetic and \nepigenetic risk factors that lie behind \nvarious psychiatric and neurological \ndisorders of complex nature. On the \none hand, the genetic analysis of a \nmurine model of cocaine dependence, which allowed us to propose a new \npharmacological target for relapse \n(the protein PLCB1), and on the \nother hand we have investigated \nthe epigenetics of drug addiction, \nidentifying genetic risk variants that \nalter the methylation of the genes \nCTNNBL1 , SCP2  and ECHDC2 . We also \nhelped to define the genetic landscape \nof autism, ADHD, obsessive-\ncompulsive disorder, disruptive \nbehaviour disorders, migraine, \nParkinson\u2019s disease, epilepsies, and \naggressiveness. \nIn the field of lysosomal diseases, we \nhave demonstrated that the inhibition \nof soluble epoxide hydrolase improves \ncognitive capacities in a murine model \nof Niemann-Pick disease, type C.\nLastly, we made progress in the \nproject of generating and studying \nneuronal models based on iPSs \ncells derived from patients with \nWilliams-Beuren syndrome or 7q11.23 \nmicroduplication syndrome. \nMEMBERS\nSTAFF RESEARCHER\nSusana Balcells Comas, Bru Cormand \nRif\u00e0, Roser Corominas\nPOSTDOC ASSOCIATED RESEARCHERS\nRaquel Rabionet Janssen, Noelia \nFern\u00e1ndez Castillo, N\u00faria Mart\u00ednez Gil\nASSISTANT RESEARCHER\nEstefania Alcaide Consuegra\nTECHNICIAN\nM\u00f3nica Cozar Morillo\nSELECTED PROJECTS\n\u2022 GENIUS: GENetic Influences on \nfunctional oUt\ncome after Stroke. \n(Reg. 70/307 Proj. 201726). Fundaci\u00f3 \nLa Marat\u00f3 de TV3. 2018-2021. PI: \nRaquel Rabionet Janssen.\n\u2022 Effects of Nutrition and Lif\nestyle \non Impulsive, Compulsive, \nand Externalizing behaviors \n(Eat2beNICE) (728018). Uni\u00f3 \nEuropea. HORIZON 2020 (2014-\n2020). P3. SC2: SUSTAINABLE \nFOOD SECURITY \u2013 RESILIENT AND \nRESOURCE-EFFICIENT VALUE \nCHAINS (H2020-SFS-2016-2017). \n2017-2022. PI: Bru Cormand Rifa.\n\u2022 Estudios gen\u00e9tic\nos y funcionales \nhacia aproximaciones terap\u00e9uticas \npara varias enfermedades \u00f3seas \ny s\u00edndromes de discapacidad \nintelectual (PID2019-\n107188RB-C21). Ministerio de \nCiencia, Innovaci\u00f3n y Universidades. 71 INSTITUT  DE RECERCA  \nMEDICINE AND PEDIATRIC  \nSCIENCE AREA\nPRECISSION MEDICINE  \nIN RARE DISEASES\nConvocat\u00f2ria d\u2019ajuts del \nPrograma Estatal d\u2019Investigaci\u00f3, \nDesenvolupament i Innovaci\u00f3 \nOrientada als reptes de la Societat. \nModalitat Reptes. 2020-2023. PI. \nSusanna Balcells Comas\n\u2022 Modeling 7q11.23 aneusomy \nsyndromes with iPSC-deriv\ned \nneurons (iNeuro7q) (RTI2018-\n101960-A-I00). Ministerio de Ciencia \nInnovaci\u00f3n y Universidades. RETOS. \n2019-2021. PI: Roser Corominas.\nSELECTED PUBLICATIONS\n\u2022 Cabana J, Mart\u00edn E, Gallego A, \nMaldonado R, F\nernandez N, \nCormand B. Reduced cue-induced \nreinstatement of cocaine-seeking \nbehavior in Plcb1 +/- mice. Transl \nPsychiatry. 2021;11(1):521. IF:6,222. \n(Q1).\n\u2022 Castilla L, G\u00fcr\nsoy S, Giray \u00d6, Prat \nA, Bullich G, Matalonga L et al. De \nNovo PORCN and ZIC2 Mutations \nin a Highly Consanguineous Family. \nInt. J. Mol. Sci. 2021;22(4):1549.\nIF:5,923. (Q1).\n\u2022 Demontis D, Walt\ners RK, Rajagopal \nVM, Waldman ID, Grove J, Als TD \net al. Risk variants and polygenic \narchitecture of disruptive behavior \ndisorders in the context of attention-\ndeficit/hyperactivity disorder. Nat \nCommun. 2021;12(1):576. IF:14,919. \n(Q1).\n\u2022 Martinez N, Roca N, Cozar M, \nGar\ncia N, Ovejero D, Nogu\u00e9s X et \nal. Genetics and Genomics of SOST: \nFunctional Analysis of Variants and \nGenomic  Regulation in Osteoblasts. \nInt. J. Mol. Sci. 2021;22(2):489.\nIF:5,923. (Q1).\nHuman molecular \ngenetics II\nGemma Marfany Nadal, PhD\nOur group\u2019s two main lines of \nresearch comprise, on the one hand, \nthe further development of the \ngenetic testing of rare diseases of \nthe retina, and on the other hand, \nthe generation of animal models to \nstudy the function of the genes that \ncause such diseases, together with the search for a possible precision \ntherapy. We apply NGS techniques for \ngenetic testing in retinal dystrophies \nwithin the spin-off generated as \ntransfer of knowledge, achieving a \nsuccess rate of up to 85%.\nIn order to study the molecular \nbases of hereditary blindness, we \nrecently generated model mice by \ngene editing techniques (CRISPR-\nCas9) on two genes causing retinitis \npigmentosa, cone-rod dystrophy, \nand S-cone syndrome: CERKL and \nNR2E3. In the last few months, we \nhave been conducting molecular \nstudies in greater depth with a view \nto elucidating why the mutations \nin these genes cause hereditary \nblindness. For the gene NR2E3, we \nhave identified isoforms generated \nby alternative splicing which had \nnot been previously described; at \npresent we are carrying out single-\ncell transcriptome analyses to \ncharacterise the photoreceptor \npopulations of mutant strains \nwith respect to the control group \n(collaboration with Dr Vaquerizas \nin M\u00fcnster). As concerns CERKL, \nwe have collaborated with other \ngroups of the IBUB and the IRSJD (Dr \nVillaroya and Dr Artuch) to show that \nits depletion causes changes in the \nmitochondrial morphology, dynamics \nand metabolism in retinal neurons, \nphotoreceptors, and ganglion cells \n(RGCs), as well as in retinal pigment \nepithelium cells (RPEs), opening new \nperspectives for a potential treatment \nby regulation of mitochondrial \nmetabolism. A senior postdoc of \nthe group has made stays in Naples \n(collaboration with Drs Ursini and \nTrapani) to explore potential gene \ntherapy treatments by subretinal \ninjection of adeno-associated viruses \n(AAVs). Lastly, we are investigating \nvarious genes which may contribute \nto the formation and stability of the \nsensory cilium, which means that \nthey could be candidate causes \nof ciliopathies, of which retinal \nneurodegeneration is one of the \nsymptoms.\nIn the future we plan to pursue \nin greater depth the new paths of \nresearch that have been opened \nduring this year. 2021 has been \na year of intense work, with the \nestablishment of new national and \ninternational collaborations which, \nit is hoped, will soon be coming to \nfruition.MEMBERS\nPOSTDOC ASSOCIATED RESEARCHERS\nSerena Mirra\nPHD STUDENTS\nIzarbe Aisa Marin, Elena Borrego \nDom\u00e8nech\nSELECTED PROJECTS\n\u2022 Explorando las v\u00edas de se\u00f1alizaci\u00f3n \nneur\nosensoriales en enfermedades \nhereditarias de retina como \nposible aproximaci\u00f3n a la \nterapia (PID2019-108578RB-I00). \nMinisterio de Ciencia, Innovaci\u00f3n y \nUniversidades. Convocat\u00f2ria d\u2019ajuts \ndel Programa Estatal d\u2019Investigaci\u00f3, \nDesenvolupament i Innovaci\u00f3 \nOrientada als reptes de la Societat. \nModalitat Reptes. 2020-2023. PI: \nGemma Marfany Nadal, co-PI: \nSerena Mirra.\n\u2022 Contract\nes de recerca/serveis/\ntransferencia (309710). DBGEN \nOcular Genomics, S.L. 2018-2023. \nPI: Gemma Marfany Nadal.\n\u2022 Enfermedades Rar\nas \n(CB06/07/0041). Ministerio de \nSanidad y Consumo. Convocat\u00f2ria \nd\u2019ajuts destinats a finan\u00e7ar \nestructures estables d\u2019investigaci\u00f3 \ncooperativa, a l\u2019\u00e0rea de biomedicina \ni ci\u00e8ncies de la salut, en el marc del \nPrograma Ingenio 2010, Programa \nConsolider, accions CIBER. 2006 \u2013 \n2022. PI: Gemma Marfany Nadal.\nSELECTED PUBLICATIONS\n\u2022 A\u00edsa I, Garc\u00eda R, Mirr a S, Marfany \nG. The Alter Retina: Alternative \nSplicing of Retinal Genes in \nHealth and Disease. Int J Mol Sci. \n2021;22(4):1855. IF:5,923. (Q1). \n\u2022 Garc\u00eda-Arr\noyo R, Gavalda A, \nVillarroya F, Marfany G, Mirra S. \nOverexpression of CERKL Protects \nRetinal Pigment Epithelium \nMitochondria from  Oxidative \nStress Effects. Antioxidants (Basel). \n2021;10(12):2018. IF:6,312. (Q1).\n\u2022 Mirra S, Arr\noyo RG, Dom\u00e8nech \nEB, Gavalda A, Herrera C, Oliva C \net al. CERKL, a retinal dystrophy \ngene, regulates mitochondrial \nfunction and dynamics in  the \nmammalian retina. Neurobiol Dis. \n2021;156:105405. IF:5,996. (Q1).\n\u2022 S\u00e1nchez L, Toulis V, Marf\nany G. On \nthe Wrong Track: Alterations of \nCiliary Transport in Inherited Retinal \nDystrophies. Front. Cell. Dev. Biol. \n2021;9:623734. IF:6,684. (Q1). 72 INSTITUT  DE RECERCA  \nMEDICINE AND PEDIATRIC  \nSCIENCE AREA\nPRECISSION MEDICINE  \nIN RARE DISEASES\nGenomics  \nfor the diagnosis  \nof rare diseases\nJudith Armstrong Mor\u00f3n, PhD\nThe Genomics for Diagnosis of \nRare Diseases group is a recently \norganised unit at the Sant Joan de \nD\u00e9u Barcelona Research Institute \n(IRSJD). It focuses on genomic tools \nand their potential for diagnosis, \nspecifically within the framework of \nneurological disorders but also with \nrespect to other rare diseases of \ngenetic origin. NGS technology for \nthe detection of mutations causing \nneurological pathologies began to \nbe implemented at our hospital in \n2013, and this experience has been \nextended to include the rest of the \nspecialities treated at our institution. \nThis technological knowledge and the \nknowledge of neurological disorders \nand other diseases led to creation of \nour research group. Our main goal \nis to transform clinical diagnosis \ninto genetic-molecular diagnosis \nand to achieve our aim we use mass \nsequencing technology, employing \nnot only genomic data but also \nincluding data of the transcriptome \nand proteome, taking a multi-omics \napproach. Mass sequencing generates \na large quantity of data which are \nhighly useful in the hospital sphere \nand this is why we also focus on and \nlead a research project conceived to \nallow us to strengthen inter-hospital \nnetworks that can enhance the \ninterpretation of genomic data to \nimprove the diagnostic process.\nMEMBERS\nSTAFF RESEARCHER\nN\u00faria Brandi Tarrrau, D\u00e9lia Yubero \nSiles\nPHD STUDENTS\nAinhoa Pascual Alonso, Clara Xiol \nVi\u00f1as\nTECHNICIAN\nCarlota Ros Bonaventura, Paola \nPacheco Fern\u00e1ndez\nSELECTED PROJECTS\n\u2022 Catalan Interhospital Network \nof Genetic V\nariants to Improve \nGenetic Diagnosis in Rare Diseases. (590/C/2020). Fundaci\u00f3 La Marat\u00f3 \nde TV3. 2021-2024. PI: D\u00e9lia Yubero \nSiles. \n\u2022 Estudio de pacient\nes dentro del \nEspectro Rett mediante un enfoque \nmulti\u00f3mico integrativo: delucidar la \nhuella molecular de la via funcional. \n(PI20/00389). Instituto de Salud \nCarlos III (ISCIII). 2021-2023. PI: \nJudith Silvia Armstrong Mor\u00f3n. \n\u2022 Convoc\nat\u00f2ria d\u2019ajuts per a \nla contractaci\u00f3 de personal \ninvestigador novell (FI-2020). \nBeneficiari: Ainhoa Pascual \n(co-financiado por el FSE). (2020 \nFI_B_00888). Agaur - Ag\u00e8ncia de \nGesti\u00f3 d\u2019Ajuts Universitaris i de \nRecerca. 2020-2023. PI: Judith Silvia \nArmstrong Mor\u00f3n. \n\u2022 FPU_Clara Xiol. (FPU18/02152). \nMinis\nterio Educaci\u00f3n, Cultura y \nDeporte (MECD). 2019-2023. PI: \nJudith Silvia Armstrong Mor\u00f3n.\nSELECTED PUBLICATIONS\n\u2022 Barbosa S, V\u00e1zquez ME, Gonzal ez E, \nHermida \u00c1, Valverde LL, Armstrong \nJ et al. Characterization of a Novel \nSplicing Variant in Acylglycerol \nKinase (AGK) Associated  with Fatal \nSengers Syndrome. Int. J. Mol. Sci. \n2021;22(24):13484. IF:5,923. (Q1).\n\u2022 Pascual A, Martinez T, Xiol C, \nArms\ntrong J. MECP2-Related \nDisorders in Males. Int. J. Mol. Sci. \n2021;22(17):9610. IF:5,923. (Q1).\n\u2022 Xiol C, Marina T, Pascual A, De \nOy\narzabal AL, Armstrong J. \nTechnological Improvements in the \nGenetic Diagnosis of Rett Syndrome \nSpectrum  Disorders. Int. J. Mol. \nSci. 2021;22(19):10375. IF:5,923. \n(Q1).\nDiagnostic  \nand therapeutic \nimaging\nJosep Munuera del Cerro, MD, PhD\nMEMBERS\nSTAFF RESEARCHER\nMarta G\u00f3mez Chiari, Emilio Inarejos \nClemente, M\u00f3nica Rebollo PoloSELECTED PROJECTS\n\u2022 Sistema de ayuda a la decisi\u00f3n \ncl\u00ednic\na para la evaluaci\u00f3n y \npredicci\u00f3n de enfermedad vascular \ncerebral pedi\u00e1trica: Radi\u00f3mica \na partir de RM vascular e \nInteligencia Artificial (Vascul\u00f3mica). \n(PI20/00296). Instituto de Salud \nCarlos III (ISCIII). 2021-2023. IP:Jose \nLuis Munuera del Cerro. \n\u2022 Plataf\norma ISCIII de apoyo a la I+D+I \nen Biomedicina y Ciencias de la \nSalud. Biomodelos-Impresi\u00f3n 3D. \n(PT20/00090). Instituto de Salud \nCarlos III (ISCIII). 2021-2023. IP:Jose \nLuis Munuera del Cerro. \n\u2022 Node d\u2019imatge comput\nacional \npedi\u00e0trica (PEDIATRIC_ICON). \n(PR15-019756). Departament de \nSalut - Generalitat de Catalunya. \n2020IP:Jose Luis Munuera del \nCerro.\nSELECTED PUBLICATIONS\n\u2022 Gonzalez E, Grau L, Ferrero SI, \nHernandez A, Reboll\no M, Marta \nC et al. Pessary for Management \nof Cervical Varices Complicating \nPregnancy. Obstet Gynecol. \n2021;138(3):482-486. IF:7,661. (Q1).\n\u2022 Inarejos E, Nav\narro OM, Navallas \nM, Enrique G, Colombo C, Su\u00f1ol \nM et al. Omphalomesenteric \nDuct Anomalies in Children: \nA Multimodality Overview. \nRadiographics. 2021;41(7):2090-\n2110. IF:5,333. (Q1).\n\u2022 Panwar J, T\nolend M, Redd B, \nSrinivasalu H, Colbert RA, Akikusa J \net al. Consensus-driven conceptual \ndevelopment of a standardized \nwhole body-MRI scoring  system for \nassessment of disease activity in \njuvenile idiopathic arthritis: MRI in  \nJIA OMERACT working group. Semin \nArthritis Rheum. 2021;51(6):1350-\n1359. IF:5,532. (Q1).\n\u2022 Serrano E, Zar\nco F, Gill AE, \nHawkins CM, Mac\u00edas N, Inarejos E \net al. Percutaneous cryoablation \nof chondroblastoma and \nosteoblastoma in pediatric  patients. \nInsights Imaging. 2021;12(1):106-\n106. IF:5,231. (Q1).1 FOREWORD\nGovernance and structures\nGlobal numbers 2020\nGlobal numbers 2020-2015\nInstitutional awards\n7.1\nMEDICINE  \nAND PEDIATRIC \nSCIENCE AREA\n7.1.5\nApplied clinical  \nresearch\nInfluence of the environment on child and adolescent welfare\nHospital dentistry and periodontal medicine\nPaediatric ophthalmology\nResearch in nursing74 INSTITUT  DE RECERCA  \nMEDICINE AND PEDIATRIC  \nSCIENCE AREA\nAPPLIED CLINICAL  \nRESEARCH\nInfluence of the \nenvironment \non child and \nadolescent welfare\nCarles Luaces Cubells, MD, PhD\nIn 2021, our group also took part in \ntwo non-competitive research projects \nfunded by private entities: \n\u2022 Quick determination of heart \nf\natty-acid binding protein (H-FABP) \nto rule out brain injuries in mild \ncranioencephalic trauma: a \npreliminary multi-centre study \nusing a point-of-care instrument \nin traumatology and paediatrics \nemergency services. BIOTRABIS \n(BIOmarkers of TRAumatic Brain \nInjury- Spain). Promoter: Dr Joan \nMontaner Villalonga \u2013Seville \nBiomedical Research Institute. \nFunding: Mutua Madrile\u00f1a \nFoundation. 2020-22. PI: Carles \nLuaces / V Trenchs.\n\u2022 Meningitis screening based on a \nno\nvel, non-invasive, transfontanellar \nultrasound device using machine \nlearning techniques: a proof-of-\nconcept study. Funding: New Born \nSolutions has provided funding. \nThe participation of the Rabat HER \nin the study is co-financed by the \nSpanish International Development \nCooperation Agency (2019/\nACDE/001196). PI: Carles Luaces /  \nD Mu\u00f1oz-Santanach \nIt should also be pointed out that \na significant part of the group\u2019s \nresearch has been focused on the \nimpact of the SARS-CoV 2 pandemic \non the paediatric population, placing \nspecial emphasis on its effects on \npsychological health. Moreover, \nalong the same line, we collaborated \nactively on the promotion of the \ngood handling of children and on the \nprevention of mistreatment during \nthe lockdown period, participating \nin the publication of two decalogues \nendorsed by the Spanish Paediatric \nEmergencies Society (\u201cConsejos para \nfamilias. Confinamiento saludable\u201d \n[\u201cAdvice for Families. A Healthy \nLockdown\u201d], available at: https://\nseup.org/pdf_public/gt/Cons_fam.\npdf, and \u201cDec\u00e1logo de maltrato infantil \npara profesionales\u201d [\u201cA Decalogue on \nChild Mistreatment for Healthcare \nProfessionals\u201d]).MEMBERS\nSTAFF RESEARCHER\nGemma Claret Teruel, Ana Isabel \nCurcoy Barcenilla, Lidia Mart\u00ednez \nS\u00e1nchez, Victoria Trenchs Sainz de la \nMaza\nPOSTDOC ASSOCIATED RESEARCHERS\nAndrea Aldemira Liz, Vanessa Arias \nConstant\u00ed, Eva Gargallo Burriel, \nCristina Parra Cotanda\nPHD STUDENTS\nDavid Mu\u00f1oz Santanach, Sergi Navarro \nVilarrubi, Marta Sim\u00f3 Nebot\nSELECTED PROJECTS\n\u2022 STEPS_Step by s tep standing \nup a Barnahus in Catalonia: A \nsimulation-based program to \navoid secondary victimization in \nthe assessment and treatment \nof child sexual abuse. European \nCommission. 2020-2022. IP: Marta \nSim\u00f3 Nebot. \n\u2022 Estudio pr\nospectivo observacional \nsobre la hidrataci\u00f3n y nutrici\u00f3n \nen pacientes pedi\u00e1tricos con \nenfermedad avanzada. Sociedad \nEspa\u00f1ola de cuidados paliativos \npedi\u00e1tricos (PEDPAL). 2019-2021. \nIP: Sergi Navarro Vilarrubi. \n\u2022 La experiencia de l\nos profesionales \ncomo segundas v\u00edctimas: estudio \ndescriptivo. Sociedad Espa\u00f1ola de \nUrgencias de Pediatr\u00eda. 2021. IP: \nDra. Vanessa Arias Constant\u00ed.\nSELECTED PUBLICATIONS\n\u2022 Goldman RD, McGregor S, Marneni \nSR, Katsut\na T, Griffiths MA, Hall \nJE et al. Willingness to Vaccinate \nChildren against Influenza after \nthe Coronavirus Disease  2019 \nPandemic. J Pediatr. 2021;228:87-\n93. IF:4,406. (Q1).\n\u2022 Goldman RD, Staubli G, P\narra C, \nBrown JC, Hoeffe J, Seiler M et al. \nFactors associated with parents\u2019 \nwillingness to enroll their children \nin trials for  COVID-19 vaccination. \nHum Vaccin Immunother. \n2021;17(6):1607-1611. IF:3,452. (Q2).\n\u2022 Ibrahim D, Mir\n\u00f3 \u00d2, Galicia M, \nSuperv\u00eda A, Puiguriguer J, Ortega \nJ et al. Spanish Research Network \non Drugs in Hospital Emergency \nDepartments - the REDUrHE  \nregistry: general analysis and \ncomparisons between weekend and \nweekday poisonings. Emergencias. \n2021;33(5):335-344. IF:3,881. (Q1).\n\u2022 Superv\u00eda A, Salgado E, C\u00f3rdoba F, Garc\u00eda L, Mart\u00ednez L, Moreno A et \nal. Poisoning cases in Catalonia: \ncharacteristics according to age \ngroups in the  Intox.28 study. \nEmergencias. 2021;33(2):115-120. \nIF:3,881. (Q1).\nHospital dentistry \nand periodontal \nmedicine\nAlejandro Rivera Bar\u00f3, MD, PhD\nWe have kept up our efforts along \nour group\u2019s lines of work, starting \nup three new studies, one in each \nof our research lines: odontology \n(autotransplantation of teeth), \nperiodontal medicine (gingival \nenlargement) and malformation \nmedicine (presurgical orthopaedics). \nThese studies were implemented after \nobtaining the Scientific Committee\u2019s \nendorsement and they are preparatory \nprocedures for the doctoral theses of \nthe first authors. \nMEMBERS\nSTAFF RESEARCHER\nMireia Aznar G\u00f3mez, Lluis Brunet \nLlobet, Jaume Miranda Rius, Jordi \nMoncunill Mira, Maria Llu\u00efsa Tobella \nCamps\nSELECTED PROJECTS\n\u2022 SGR 2017_Hospital Dentis try & \nPeriodontal Medicine Research \nGroup. (2017 SGR 00453). Agaur \n- Ag\u00e8ncia de Gesti\u00f3 d\u2019Ajuts \nUniversitaris i de Recerca. 2017-\n2021. IP: Lluis Brunet Llobet.\nSELECTED PUBLICATIONS\n\u2022 Moncunill J, Brunet LL, Cuadras \nD, Lor\nente N, Pascal R, Rovira C \net al. Do the clinical criteria used \nto diagnose periodontitis affect \nthe association with  prematurity? \nOdontology. 2021;109(2):455-463. \nIF:2,634. (Q2). 75 INSTITUT  DE RECERCA  \nMEDICINE AND PEDIATRIC  \nSCIENCE AREA\nAPPLIED CLINICAL  \nRESEARCH\nPaediatric \nophthalmology\nJoan Prat Bartomeu, MD, PhD\nMEMBERS\nSTAFF RESEARCHER\nElisa Carreras Bertran, Ester Casas \nGimeno, Jaume Catal\u00e0 Mora, Jes\u00fas \nD\u00edaz Cascajosa, Ana Isabel D\u00edaz \nCort\u00e9s, Carlos Fresno Ca\u00f1ada, \nCarmen Garc\u00eda de Vicu\u00f1a Mu\u00f1oz, \nEnrique Jimenez Ga\u00f1an, Ana Llorca \nCarde\u00f1osa, Marta Morales Ball\u00fas, \nN\u00faria Planas Dom\u00e8nech, M\u00aa Josep \nPlanas Tapias, Enric Puigvent\u00f3s, \nGemma Romeu Cerrillo, Alicia Serra \nCastanera, Dowon, Simone Suh, \nBegonya Yeste Mayoral\nSELECTED CLINICAL TRIALS & \nOBSERVATIONAL STUDIES\n\u2022 Ensayo cl\u00ednico fase I, unic\u00e9ntrico, \nabiert\no y de escalado de dosis, para \nevaluar la seguridad y la actividad \ndel adenovirus oncol\u00edtico VCN-01 \nen pacientes con retinoblastoma \nrefractario. (FSJD-RTB-2015). \nFundaci\u00f3 Privada per a la Recerca \ni la Doc\u00e8ncia Sant Joan de D\u00e9u - \nFSJD; VCN Biosciences S.L. 2017-. \nIP: Jaume Catal\u00e0 Mora.\n\u2022 Estudio pos\ntautorizaci\u00f3n, \nmultic\u00e9ntrico, multinacional, \nlongitudinal y observacional para \nel registro de la seguridad en \npacientes tratados con voretig\u00e9n \nneparvovec. (CLTW888A12401/\nNOV-LUX-2019-01). Novartis \nFarmac\u00e9utica, S.A. 2020-. IP: Jaume \nCatal\u00e0 Mora.\nSELECTED PUBLICATIONS\n\u2022 Fabian ID, Stacey AW, Foster A, \nKiv\nel\u00e4 TT, Munier FL, Keren N \net al. Travel burden and clinical \npresentation of retinoblastoma: \nanalysis of 1024 patients  from 43 \nAfrican countries and 518 patients \nfrom 40 European countries. Br J \nOphthalmol. 2021;105(10):1435-\n1443. IF:4,638. (Q1).\n\u2022 Liu J, Ottaviani D, Seft\na M, \nDesbrousses C, Chapeaublanc \nE, Aschero R et al. A high-risk \nretinoblastoma subtype with \nstemness features, dedifferentiated \ncone  states and neuronal/ganglion cell gene expression. Nat Commun. \n2021;12(1):5578-5578. IF:14,919. \n(Q1).\n\u2022 Stac\ney AW, Bowman R, Foster A, \nKivel\u00e4 TT, Munier FL, Cassoux N \net al. Incidence of Retinoblastoma \nHas Increased: Results from \n40 European Countries. \nOphthalmology. 2021;128(9):1369-\n1371. IF:12,079. (Q1).\n\u2022 Tomar AS, Finger PT, Gallie B, \nKiv\nel\u00e4 TT, Mallipatna A, Zhang \nC et al. Global Retinoblastoma \nTreatment Outcomes: Association \nwith National Income Level. \nOphthalmology. 2021;128(5):740-\n753. IF:12,079. (Q1).\nResearch  \nin nursing\nLaura Lahuerta Valls, RN, PhD\nMethodological support for nurse-led \nresearch projects in 2021.\n2021 was a year of transition towards \nnormalisation of the situation of \ncoexistence with the pandemic. For \nus nurses who engage in clinical \nresearch and who form part of the \nassociated clinical groups programme, \nthis transition situation has allowed \nus to conduct translational research \nprimarily focused on the areas of \ngeneral paediatrics and paediatric \noncology.\nCross-cutting projects:\n\u2022 13 communic\nations in international \ncongresses and conferences.\n\u2022 22 oral c\nommunications in national \ncongresses and conferences.\n\u2022 20 post\ners in national congresses \nand conferences.\n\u2022 7 post\ners in international \ncongresses and conferences.\n\u2022 5 publications in scientific journals.\n\u2022 2 awards.\n\u2022 2 competitiv\ne grants.\nInitiatives promoted from the research \narea:\n\u2022 #ViernesCient\u00edficosS\nJD \n(ScientificFridaysSJD): In 2021, eight \nsessions were held with project-\nleader nurses to promote evidence-\nbased knowledge and practice at \ninstitutional level. Coordination: \nJordi Mitj\u00e0.\u2022 Continuity of the proc\ness begun with \nthe graduating class of resident \nintern nurses of 2019-2021, in the \nnew approach to the final residency \nproject led by the Research Nurse:\n- The nurse r\nesidents of the \ngraduating class of 2020-2022 are \nintroduced to research skills in \nthe research lines established by \nthe Nursing Management.\n- They submit t\no the Research \nNurse the various parts of \ntheir research projects in order \nto receive assessment and \norientation, for the purpose of \nachieving the required research \nskills.\n- They ar\ne introduced to the \nprocedure for applying for the \nassessment and approval of the \nResearch Committee of the Sant \nJoan de D\u00e9u Barcelona Research \nInstitute (IRSJD), and for \nobtaining the assessment of the \nEthics Committee for Research \nwith Medicines (CEIm).\n\u2022 Methodologic\nal support for \nprojects: Effectiveness of a nursing \nstaff training intervention for \nthe handling of paediatric onco-\nhaematology patients with ASD. \nPI: Claudia Nogales Gonzalez (in \nprogress).\nMEMBERS\nSTAFF RESEARCHER\nMaribel Ferrer Orona, Concepci\u00f3n \nAgust\u00edn Mata, Silvia Cipr\u00e9s Roig, \nEncarna G\u00f3mez Gamboa, Jordi Mitj\u00e0, \nGemma P\u00e9rez Acevedo\nPOSTDOC ASSOCIATED RESEARCHERS\nM\u00aa Dolors Navarro Rubio\nPHD STUDENTS\nMarta Fajardo Samper\nASSISTANT RESEARCHER\nPau Miquel Diego, Ikram Allaoui, \nMontserrat Gutierrez Juarez, Ares \nSentenach Carb\u00f3\nCOLLABORATOR RESEARCHER\nCarmen Jerez Molina\nSELECTED PROJECTS\n\u2022 Seroprevalencia de la infecci\u00f3n por \nSARS-CO\nV-2 en los empleados del \nhospital matenor-infantil Sant Joan \nde D\u00e9u. (PR-440/2020). Fundaci\u00f3 \nInfermeria i Societat. 2021-2021. IP: \nLaura Lahuerta Valls.\n\u2022 An\u00e0lisi de l\u2019espiritualit\nat, \nreligiositat o filosofia de vida \ndels pares i mares d\u2019infants amb 76 INSTITUT  DE RECERCA  \nMEDICINE AND PEDIATRIC  \nSCIENCE AREA\nAPPLIED CLINICAL  \nRESEARCH\nnecessitats pal\u00b7liatives a Catalunya. \n(2018RELIG00008). Agaur - Ag\u00e8ncia \nde Gesti\u00f3 d\u2019Ajuts Universitaris i de \nRecerca. 2019-2021. IP: M\u00aa Dolors \nNavarro Rubio.\n\u2022 Eficacia y seguridad de l\nos \u00e1cidos \ngrasos hiperoxigenados en la \nmicrocirculaci\u00f3n de la p\u00farpura \nfulminante en pacientes pedi\u00e1tricos \ncon sepsis. (PR-242/17). Fundaci\u00f3 \nInfermeria i Societat. 2018-2021. IP: \nGemma P\u00e9rez Acevedo.\n\u2022 Pre\nvenci\u00f3n de complicaciones \nde herida quir\u00fargica en paciente \npedi\u00e1trico: efectividad de la ter\u00e0pia \nde presi\u00f3n negativa incisional en \ncirug\u00eda de escoliosis no idiop\u00e1tica \n(Estudio TePreInPed). Beca Peris \n2021-2025 (SLT017/20/000194). IP. \nGemma P\u00e9rez Acevedo.\n\u2022 Les narrativ\nes cl\u00edniques de \nla mort: una oportunitat per \nal desenvolupament \u00e8tic dels \nprofessionals? AJUT RELIG21 (Beca \nGrifols). IP: Pau Miquel i Diego.\n\u2022 An\u00e0lisi de l\u2019impact\ne de les cures infermeres en la qualitat \nassistencial i seguretat dels \npacients, segons el model de \nMitchell. Beca Enfermeria i \nSocietat. IP: Immaculada Rodr\u00edguez \nSalamanca.\nSELECTED PUBLICATIONS\n\u2022 Moreno C, Roy C, Monforte C, \nGonz\u00e1l\nez L, Navarro MD, Gallart A. \nEffectiveness of a nurse-led, face-\nto-face health coaching intervention \nin enhancing  activation and \nsecondary outcomes of primary care \nusers with chronic conditions. Res \nNurs Health. 2021;44(3):458-472. \nIF:2,228. (Q2).\n\u2022 Per\nez A, Martinez A, Negre A, \nLahuerta L. Pediatric Patient \nTransfer from a Tph Ward to \nIcu: How can we Improve our \nCommunication?. Bone Marrow \nTrasplantation. 2021;55(s1): 752-\n753. IF: 5,483 (Q1).\n1 FOREWORD\nGovernance and structures\nGlobal numbers 2020\nGlobal numbers 2020-2015\nInstitutional awards\n7.2.1\nMental health  \nand society7.2\nMENTAL HEALTH \nAREA\nEpidemiology of mental disorders and aging\nHealth technology assessment in primary care and mental health \n(PRISMA)\nPsychological research group on fibromyalgia and chronic pain \n(AGORA group)78 INSTITUT  DE RECERCA  \nMENTAL HEALTH AREA\nMENTAL HEALTH  \nAND SOCIETY\nEpidemiology of \nmental disorders \nand aging\nJosep Maria Haro Abad, MD, PhD  \n& Ai Koyanagi, MD, PhD\nIn 2021, the Epidemiology of Mental \nHealth Disorders and Ageing group \nworked on various national and \ninternational projects. It coordinates \ntwo projects funded by the European \nCommission\u2019s Horizon 2021 \nprogramme: the EMPOWER project, \nwhich has the purpose of developing \nand testing a digital platform for the \npromotion and improvement of mental \nhealth at the workplace; and the \nSYNCHROS project, whose purpose \nis to establish recommendations for \nthe standardisation of the cohort data \nharmonisation processes, and which \nwill be completed around mid-2022.\nDr Haro leads one of the 36 scientific \nresearch projects of excellence \nthat have received funds raised by \nthe 2020 telethon programme La \nMarat\u00f3  de TV3. The selected project \nis called REPICAL and its purpose is \nto achieve an understanding of the \nneeds and working conditions of the \nstaff in nursing homes with the aim of \nfavouring the well-being of the elderly \nor disabled people who live there.\nNotable among the principal results \nobtained in 2021 are the main findings \nof the \u201cAge with Health\u201d study, which \nshow that social support has an effect \non feelings of loneliness, bringing \nabout a significant reduction of the \nprobabilities of relapse or prolongation \nof major depression episodes. In the \nMINDCOVID study, research has been \nconducted on feelings of disaffection \ntowards social relations as one of \nthe main risk factors of depression, \nanxiety and suicidal ideation during \nthe pandemic. Consequently, the \nfact that young adults require more \nfrequent and varied social relations \nthan elderly persons has contributed \nto the circumstance that the former \nshow a greater prevalence of mental \nhealth problems.\nMEMBERS\nSTAFF RESEARCHER\nSantiago Palomo Conti, Jacob Louis \nEtienne Charles, Amanda Lloret \nPineda, Laura Fincias, Lydia Hanaa Faris, Gemma Riquelme Alacid, Marta \nFranch Roca, Anna Ferrer Vaquer, \nElena Condominas Casanovas, Maria \nVictoria Moneta, Ellen Vorstenbosch, \nDesire\u00e9 Guti\u00e9rrez Mar\u00edn, \u00cd\u00f1igo Chivite \nAraiz, Judit L\u00f3pez Luque\nPOSTDOC ASSOCIATED RESEARCHERS\nBeatriz Olaya Guzm\u00e1n, Iago Gin\u00e9 \nV\u00e1zquez, Mireia F\u00e9lez N\u00f3brega, \nPaula Crist\u00f3bal Narv\u00e1ez, Sara Siddi, \nStefanos Tyrovolas, Rodrigo Antunes \nLima, Joan Dom\u00e8nech Abella, Judit \nSubirana Mirete\nPHD STUDENTS\nCarlota de Miquel Bleier, Anna \nMonistrol Mula, Aina Gabarrell \nPascuet, Ivet Bayes Marin\nASSISTANT RESEARCHER\nIris Mauricio Arribas\nSELECTED PROJECTS\n\u2022 EDHEN: European Health Dat a \nand Evidence Network. European \nCommission. 2021-2022. PI: Josep \nMaria Haro Abad.\n\u2022 Xarxa d\u2019Innov\naci\u00f3 de Noves \nTecnologies en Salut Mental - \nTECSAM. (2018 XARDI 00010). \nAgaur - Ag\u00e8ncia de Gesti\u00f3 d\u2019Ajuts \nUniversitaris i de Recerca. 2020-\n2022. PI: Josep Maria Haro Abad.\n\u2022 EMPOWER_Eur\nopean platforM to \nPromOte Wellbeing and HEalth in \nthe woRkplace. (848180). European \nCommission; Fundaci\u00f3 Privada \nper a la Recerca i la Doc\u00e8ncia Sant \nJoan de D\u00e9u - FSJD. 2020-2023. PI: \nBeatriz Olaya Guzm\u00e1n.\n\u2022 SYNCHROS: S\nYNergies for Cohorts \nin Health: integrating the ROle of \nall Stakeholders. (82884). European \nCommission. 2019-2022. PI: Josep \nMaria Haro Abad.\nSELECTED PUBLICATIONS\n\u2022 Felez M, Haro JM, Stubbs B, Smith \nL, Ko\nyanagi A. Moving more, \nageing happy: findings from six \nlow- and middle-income countries. \nAge Ageing. 2021;50(2):488-497. \nIF:10,668. (Q1).\n\u2022 Fern\u00e1ndez D, Gin\u00e9 I, Liu I, Y\nucel \nR, Nai M, Morena M et al. Are \nenvironmental pollution and \nbiodiversity levels associated to the \nspread and mortality of COVID-19? A \nfour-month global analysis. Environ \nPollut. 2021;271:116326-116326. \nIF:8,071. (Q1).\n\u2022 Jacob L, Smith L, McDermott D, \nHar\no JM, Stickley A, Koyanagi A. Relationship between sexual \norientation and psychotic \nexperiences in the general \npopulation in England. Psychol Med. \n2021;51(1):138-146. IF:7,723. (Q1).\n\u2022 Smith L, Shin JI, Ghayda RA, Hijaz \nA, Sheyn D, P\nope R et al. Physical \nmultimorbidity and incident urinary \nincontinence among community-\ndwelling adults aged =50 years: \nfindings from a prospective \nanalysis of the Irish Longitudinal \nStudy on Ageing. Age Ageing. \n2021;50(6):2038-2046. IF:10,668. \n(Q1).\nHealth technology \nassessment in \nprimary care and \nmental health \n(PRISMA)\nMaria Rubio Valera, PhD  \n& Antoni Serrano Blanco, MD, PhD\nIn 2021, the PRISMA group carried \nout over 30 projects. Additionally, it \nbegan to prepare a database of unit \ncosts at national level to inform health \neconomy studies, and it started up two \nEuropean projects. \nOne of these European projects is \nfunded by a starting grant from the \nEuropean Research Council (ERC). \nIts purpose is to carry out a cluster \nclinical trial of an intervention to \nreduce initial medication non-\nadherence. All the preparations \nrequired to carry out the intervention \nhave been performed during the year. \nThe other project with European \nfunding is focused on the performance \nof a study of the implementation cost \nand of the cost-effectiveness of an \nintervention to reduce the cancer \ndiagnosis time in three Latin American \ncountries.\nAs concerns our principal results in \n2021, we demonstrated the efficiency \nof an intervention to improve healthy \nlifestyles, which was carried out in 8 \nautonomous regions in Spain. This \nstudy involved a major process of \nharmonisation of data from different \nhealthcare systems. 79 INSTITUT  DE RECERCA  \nMENTAL HEALTH AREA\nMENTAL HEALTH  \nAND SOCIETY\nLikewise, we demonstrated in a \npilot study that the intervention \nabout shared decision-making on \nIMA (Initial Medication Adherence) \nis accepted by patients and primary \ncare professionals. Before conducting \nthe study, we explored the reasons \nfor which professionals thought \nthat patients decided not to begin \nmedication. We also established that \nan estimated 9% of the treatments \nprescribed to the paediatric population \nin Catalonia are not begun. We \nobserved that the prevalence of initial \nmedication non-adherence differed \naccording to the age of the boys or \ngirls concerned. Specifically, younger \nchildren and adolescents showed \nhigher figures of initial medication \nnon-adherence, while children \nbetween 5 and 11 years of age showed \nthe lowest initial medication non-\nadherence figures.\nA study carried out using qualitative \nmethodology assessed the Mental \nHealth Primary Care Support \nProgramme in Catalonia based on the \nexperience of primary care physicians \nand mental health professionals.\nWe also carried out the project \ncalled \u201cDesign of an action plan for \nimproving the quality of services and \nmental health in the Baix Llobregat \nRegion\u201d, which was commissioned \nby the Barcelona Provincial Council, \nusing a participative action research \nmethodology.\nLastly, in 2021 we worked with Banc \nFarmac\u00e8utic (the Pharmaceutics \nBank, an NGO whose purpose is to \ncover the price of medication for \ncitizens who cannot afford it), to \nidentify the profile of the beneficiaries \nof this organisation, and to determine \nthe pattern of use of the covered \nmedications and healthcare products.\nMEMBERS\nSTAFF RESEARCHER\nV\u00edctor Chavarr\u00eda Romero, Salvatore \nFabrizio Contaldo, Luisa Balad\u00f3n \nHiguera, Vanessa Barneda, Laura \nGonz\u00e1lez Su\u00f1er, Maria Iglesias \nGonz\u00e1lez, Cristina L\u00f3pez Ortiz, Carlos \nPe\u00f1a Salazar, S\u00edlvia Ram\u00edrez Perdomo, \nEnric Vicens Pons\nPOSTDOC ASSOCIATED RESEARCHERS \nIgnacio Aznar-Lou, M\u00aaMontserrat Gil \nGirbau, Alexandra Dima and Merc\u00e8 \nSoler Font\nPHD STUDENTS\nPaula Arroyo Uriarte, Ana Mar\u00eda \nBesoa\u00edn Cornejo, Cristina Carbonell Duacastella, Marina Fuente Moreno, \nCarmen Corral Partearroyo, Alba \nS\u00e1nchez Vi\u00f1as\nTECHNICIAN\nMarcos Antonio Catalan Vega\nCOLLABORATOR RESEARCHER\nMar\u00eda del Carmen Gallardo Gonz\u00e1lez, \nMontserrat Iracheta Tod\u00f3, Ana \nFern\u00e1ndez S\u00e1nchez, Ana Maria Jov\u00e9 \nMass\u00f3, Maria Antonia March Pujol, \nJuan Manuel Mendive Arbeloa, Mar\u00eda \ndel Carmen Olmo, Maria Teresa \nPe\u00f1arrubia Mar\u00eda, Ramon Sab\u00e9s \nFiguera, Lu\u00eds Salvador Carulla, Carles \nVilaplana Carnerero\nSELECTED PROJECTS\n\u2022 EquityCancer-LA_Impr oving equity \nin access to early diagnosis of \ncancer: implementation research \nin different healthcare systems of \nLatin America. (965226). European \nCommission. 2021-2025. PI: Maria \nRubio Valera. \n\u2022 Evaluaci\u00f3n de la adher\nencia a \nantipsic\u00f3ticos a partir de datos de la \npr\u00e1ctica cl\u00ednical real. (PI19/00111). \nInstituto de Salud Carlos III (ISCIII). \n2020-2022. PI: Antoni Serrano \nBlanco. \n\u2022 El probl\nema de la no iniciaci\u00f3n \npedi\u00e1trica: Evaluaci\u00f3n con m\u00e9todos \nmixtos. (PI19/00108). Instituto de \nSalud Carlos III (ISCIII). 2020-2022. \nPI: Maria Rubio Valera. \n\u2022 IMA-cRCT_Eff\nectiveness and \ncost-effectiveness of the Initial \nMedication Adherence intervention: \ncluster randomized controlled trial \nand economic model. (948973). \nEuropean Commission. 2021-2025. \nPI: Maria Rubio Valera.\nSELECTED PUBLICATIONS\n\u2022 Arias J, Vilagut G, Ronaldson A, \nSerrano A, Mart\u00edn V, P\neters M et al. \nPrevalence and variability of current \ndepressive disorder in 27 European \ncountries: a population-based study. \nLancet Public Health. 2021;6(10)\nIF:21,648. (Q1).\n\u2022 Aznar I, Zabalet\na E, Casajuana M, \nS\u00e1nchez A, Parody E, Bol\u00edbar B \net al. Cost-effectiveness analysis \nof a multiple health behaviour \nchange intervention in people \naged between 45 and 75 years: a \ncluster randomized controlled trial \nin primary care (EIRA study). Int J \nBehav Nutr Phys Act. 2021;18(1):88-\n88. IF:6,457. (Q1).\u2022 Iglesias M, Gil M, Pe\u00f1arrubia MT, \nBlanc\no E, Fern\u00e1ndez R, Serrano A \net al. Barriers and opportunities for \nthe treatment of mild-to-moderate \ndepression with a watchful waiting \napproach. Patient Educ Couns. \n2021;104(3):611-619. IF:2,940. (Q1).\n\u2022 Rubio M, Marqu\u00e9s S, P\ne\u00f1arrubia \nMT, Urbanos RM, Borrell C, \nBosch J et al. Who Suffers \nFrom Pharmaceutical Poverty \nand What Are Their Needs? \nEvidence From a Spanish \nRegion. FRONTPHARMACOL. \n2021;12:617687-617687. IF:5,810. \n(Q1).\nPsychological \nresearch group \non fibromyalgia \nand chronic pain \n(AGORA group)\nJuan Vicente Luaciano Devis, PhD\nIn 2021, the most important \ndevelopment for our team was \nthe establishment of a double \naffiliation agreement of our PI to the \nAutonomous University of Barcelona \n(UAB) and the Sant Joan de D\u00e9u \nBarcelona Research Foundation \n(FSJD) thanks to the understanding \nreached between these two \ninstitutions. Since September 2021, \nDr Luciano has been a teacher in \nthe Clinical Psychology and Health \nDepartment of the UAB.\nOver the course of the year, our group \nhas mainly focused its efforts on two \nclinical trials: one on psychological \ntherapies for patients with chronic \nlow-back pain and depression \n(IMPACT Project), and the other on \na new pharmacological therapy for \nfibromyalgia (INNOVA Project).\nMEMBERS\nSTAFF RESEARCHER\nLlu\u00eds Torruella Barraquer, Eugenia \nCarde\u00f1osa Valera, Antoni Rozadilla \nSacanell\nPOSTDOC ASSOCIATED RESEARCHERS\nAdri\u00e1n P\u00e9rez Aranda80 INSTITUT  DE RECERCA  \nMENTAL HEALTH AREA\nMENTAL HEALTH  \nAND SOCIETY\nPHD STUDENTS\nJuan Pablo Sanabria Mazo, Ariadna \nColomer Carbonell\nASSISTANT RESEARCHER\nJaime Navarrete Hidalgo\nCOLLABORATOR RESEARCHER\nAlbert Feliu Soler, Xavier Borr\u00e0s \nHern\u00e1ndez \nSELECTED PROJECTS\n\u2022 Convocat\u00f2ria d\u2019ajuts per a \nla c\nontractaci\u00f3 de personal \ninvestigador novell (FI-2021). \nBeneficiari: Ariadna Colomer \nCarbonell. (2021_FI_B_00216). \nAgaur - Ag\u00e8ncia de Gesti\u00f3 d\u2019Ajuts \nUniversitaris i de Recerca. 2021-\n2024. PI: Juan Vicente Luciano \nDevis. \n\u2022 Contrat\nos predoctorales de \nformaci\u00f3n en investigaci\u00f3n en \nsalud (PFIS). Beneficiari: Juan \nPablo Sanabria. (FI20/00034). \nInstituto de Salud Carlos III (ISCIII). \n2021-2024. PI: Juan Vicente \nLuciano Devis. \n\u2022 Effectiv\neness, cost-utility and \nneurobiological effects of low-\ndose naltrexone in patients with \nfibromyalgia (INNOVA project). \n(ICI20/00080). Instituto de Salud \nCarlos III (ISCIII). 2021-2024. PI: \nJuan Vicente Luciano Devis. \n\u2022 Cost\ne-utilidad y efectos fisiol\u00f3gicos \nde la Terapia de Acept\u00e1ci\u00f3n y \nCompromiso y la Activaci\u00f3n \nConductual en pacientes con \ndolor cr\u00f3nico y depresi\u00f3n mayor com\u00f3rbida (Proyecto IMPACT). \n(PI19/00112). Instituto de Salud \nCarlos III (ISCIII). 2020-2022. PI: \nJuan Vicente Luciano Devis.\nSELECTED CLINICAL TRIALS & \nOBSERVATIONAL STUDIES\n\u2022 Pacientes con espondiloartritis \naxial: Regis\ntro multinacional de \ncaracter\u00edsticas cl\u00ednicas, incluida la \nprogresi\u00f3n radiol\u00f3gica, y carga de \nla enfermedad durante 5 a\u00f1os en \ncontextos de la vida real. Estudio \nPROOF. (10297). Abbvie Spain, S.L.U. \n2014PI:Antoni Rozadilla Sacanell.\nSELECTED PUBLICATIONS\n\u2022 P\u00e9rez Aranda A, Garc\u00eda J, Gude \nF, Luciano JV, F\neliu A, Gonz\u00e1lez A \net al. Impact of mindfulness and \nself-compassion on anxiety and \ndepression: The mediating role of \nresilience. Int J Clin Health Psychol. \n2021;21(2):100229-100229. IF:5,350. \n(Q1).\n\u2022 Collado C, Navarr\no M, Adri\u00e1n \nA, L\u00f3pez Y, Garcia J, Montero J. \nEffectiveness of mindfulness-based \nstress reduction and attachment-\nbased compassion therapy for the \ntreatment of depressive, anxious, \nand adjustment disorders in mental \nhealth settings: A randomized \ncontrolled trial. Depress Anxiety. \n2021;38(11):1138-1151. IF:6,505. \n(Q1).\u2022 Mart\u00ednez D, Mart\u00ednez C, Monreal \nA, Bar\ncel\u00f3 A, Campos D, P\u00e9rez \nAranda A et al. Protective role of \nmindfulness, self-compassion \nand psychological flexibility on the \nburnout subtypes among psychology \nand nursing undergraduate \nstudents. J ADV NURS. \n2021;77(8):3398-3411. IF:3,187. (Q1).\n\u2022 Modrego M, L\u00f3pez Y, Gar\nc\u00eda J, P\u00e9rez \nAranda A, Navarro M, Beltr\u00e1n M et \nal. Efficacy of a mindfulness-based \nprogramme with and without virtual \nreality support to reduce stress in \nuniversity students: A randomized \ncontrolled trial. Behav Res Ther. \n2021;142:103866-103866. IF:4,473. \n(Q1).\n\u2022 Serrat M, Juan P\nablo Sanabria \nM, Almirall M, Must\u00e9 M, Feliu A, \nM\u00e9ndez JL et al. Effectiveness \nof a Multicomponent Treatment \nBased on Pain Neuroscience \nEducation, Therapeutic Exercise, \nCognitive Behavioral Therapy, \nand Mindfulness in Patients with \nFibromyalgia (FIBROWALK Study): A \nRandomized Controlled Trial. Phys \nTher. 2021;101(12)IF:3,021. (Q1).\n1 FOREWORD\nGovernance and structures\nGlobal numbers 2020\nGlobal numbers 2020-2015\nInstitutional awards\n7.2.2\nScientific bases  \nand approach  \nto mental disorders7.2\nMENTAL HEALTH \nAREA\nEtiopathogenesis and treatment of severe mental disorders (MERITT)\nCerebral imprints of gender, development and pathology82 INSTITUT  DE RECERCA  \nMENTAL HEALTH AREA\nSCIENTIFIC BASES  \nAND APPROACH  \nTO MENTAL DISORDERS\nEtiopathogenesis \nand treatment  \nof severe mental \ndisorders (MERITT)\nSusana Ochoa G\u00fcerre, MD, PhD  \n& Judith Usall i Rodi\u00e9, MD, PhD\nIn 2021, our group participated actively \nin various financed research projects, \npublished articles with a high impact \nfactor, and collaborated with other \ncentres. Moreover, we are leading \ndifferent multi-centre projects in each \nof our research lines, the progress \nof which is reported in the resulting \npublications. The impact factor of our \ngroup grew with respect to previous \nyears and the number of publications \nwith the participation of other centres \nhas increased as well.\nWith respect to new grants, it may be \npointed out that we obtained three \nresearch projects in the call of the \nCarlos III Health Institute, which are \naddressed to the study of traumatic \nexperiences, the effectiveness of a \nfamily metacognitive intervention, and \nthe inflammatory effect of COVID on \ncognition. \nA project of collaboration with an \nenterprise has been obtained to \nvalidate the potentiating effect of \naquatic activities on psychological \ntreatment.\nThe post-residence grant was awarded \nto a member of our group to allow \ncontinued training in research and the \npreparation of a doctoral thesis.\nLikewise, two other grants were \nawarded to two pre-doctoral members \nof our team so that they may make \nstays at other research centres \nabroad.\nMEMBERS\nSTAFF RESEARCHER\nNoem\u00ed del Prado S\u00e1nchez, Jos\u00e9 \nManuel Fern\u00e1ndez Rodr\u00edguez, \nJaume Mart\u00ednez Mas, Alvaro Muro \nAlvarez, Aitor-Eneko Oliv\u00e9 Albiztur, \nJes\u00fas P\u00e9rez Pazos, Mar\u00eda Ribas \nSi\u00f1ol, Vicente Tort Herrando, Maria \nLuisa Barrigon Estevez, Mar\u00eda Jos\u00e9 \nEscandell Morcillo, Belen Ramos \nJoseMaria, Antonio Manuel Alba \nMu\u00f1oz, Hilari Andres Mora, Belen \nArranz Mart\u00ed, Adela Berrozpe \nBlasco, Emma Casas Anguera, Marta Coromina Sadurn\u00ed, Jorge \nCuevas Esteban, Ruth Cunill Clotet, \nGemma Escartin Martin, Gemma \nEscuder Romeva, Alexandrina Foix \nSanjuan, Mar Garc\u00eda Franco, Marcia \nIraz\u00e1bal Gim\u00e9nez, Francisco Mart\u00ednez \nZambrano, Eva Miquel Fernandez, \nMar\u00eda Trinidad Pel\u00e1ez Mart\u00ednez, Elena \nRubio Abadal, Luis San Molina, Sonia \nVilamala Anton\nPOSTDOC ASSOCIATED RESEARCHERS\nAmerica Jennifer Vera Montecinos, \nHelena Garc\u00eda Mieres\nPHD STUDENTS\nDesir\u00e9 Traver Edo, Luciana Beatriz \nDiaz Cutraro, Silvia Marc\u00f3 Garcia, Elia \nVila Andreu\nASSISTANT RESEARCHER\nManuel Abella Villena, Jordi Galiano \nLandeira, Marta Dom\u00ednguez del \nCampo, Clara Serra Arum\u00ed, Marina \nVerdaguer Rodriguez, Marta Ferrer \nQuintero, Anna Butjosa Molines, \nGabriel Ledesma Iparraguirre, Regina \nVila Badia\nCOLLABORATOR RESEARCHER\nJoan Costa Escol\u00e0, Maria Elena Huerta \nRamos, Raquel L\u00f3pez Carrilero, \nAlfonso Monje Hern\u00e1ndez\nSELECTED PROJECTS\n\u2022 Autoestigma i funcionament \nper\nsonal i social en persones \namb primers episodis psic\u00f2tics. \nBeneficiari: Manu Abella. (AFR \n2021). Parc Sanitari de Sant Joan de \nD\u00e9u -Serveis de Salut Mental. 2021-\n2022. IP: Judith Usall i Rodi\u00e9.\n\u2022 Influencia del estil\no de apego en la \ncognici\u00f3n social y sesgos cognitivos \nen personas con primeros episodios \npsic\u00f3ticos, esquizofrenia cr\u00f3nica \ny controles sanos. (PI18/00212). \nInstituto de Salud Carlos III (ISCIII). \n2019-2023. IP: Susana Ochoa \nG\u00fcerre.\n\u2022 Reguladores de la e\nxpresi\u00f3n g\u00e9nica \ncomo predictores de diagn\u00f3stico y \nbiomarcadores de d\u00e9ficits cognitivos \ny cambios en el grosor cortical \nen psicosis de inicio reciente. \n(PI18/00213). Instituto de Salud \nCarlos III (ISCIII). 2019-2023. IP:\n\u2022 Belen Ramos JoseMaria.\nSELECTED PUBLICATIONS\n\u2022 Afia AB, Vila \u00c8, MacDow ell KS, \nOrmazabal A, Leza JC, Haro JM \net al. Kynurenine pathway in \npost-mortem prefrontal cortex \nand cerebellum in schizophrenia:  relationship with monoamines \nand symptomatology. J \nNeuroinflammation. 2021;18(1):198. \nIF:8,322. (Q1). \n\u2022 Tr\naver-Edo D, Escuder-Romeva \nG, Talavera-Valverde MA, Moruno-\nMiralles P. Women in Forensic \nMental Health Services: Lived \nExperiences and Meanings \nAttributed to Activities in \nRehabilitation Programs. Study \nProtocol. INT J QUAL METH. 2021. \nIF:2,767. (Q2). \n\u2022 Ferr\ner-Quintero M, Fern\u00e1ndez D, \nL\u00f3pez-Carrilero R, Birul\u00e9s I, Barajas \nA, Lorente-Rovira E et al. Persons \nwith first episode psychosis have \ndistinct profiles of social cognition \nand  metacognition. NPJ Schizophr. \n2021;7(1):61. IF:5,200. (Q1). \n\u2022 Vila-Badia R, Butjosa A, del Cacho \nN, Serra-Arum\u00ed C, Es\nteban-Sanjusto \nM, Ochoa S et al. Types, prevalence \nand gender differences of childhood \ntrauma in first-episode  psychosis. \nWhat is the evidence that childhood \ntrauma is related to symptoms and  \nfunctional outcomes in first episode \npsychosis? A systematic review. \nSchizophr Res. 2021;228:159-179. \nIF:4,939. (Q1).\nCerebral imprints \nof gender , \ndevelopment  \nand pathology\nChristian Stephan-Otto Attolini, PhD\nOur group continues its interaction \nwith clinical personnel in different \nfields. For example, the joint research \nline with Dr Alfredo Garc\u00eda-Alix and Dr \nThais Agut has allowed us to produce \ntwo scientific papers, one of which has \nalready been accepted for publication \nin Archives of Disease in Childhood , \nwhile the other is currently under \npeer review. For its part, the research \nline on psychosis has produced a \nnotable article, which reports various \npatterns of cognitive impairment in \nwomen, who are more susceptible to \ndepression, and in men, who are more \nsusceptible to anxiety. Other projects \nof interest are the joint analysis of 83 INSTITUT  DE RECERCA  \nMENTAL HEALTH AREA\nSCIENTIFIC BASES  \nAND APPROACH  \nTO MENTAL DISORDERS\ndatabases on neuroimaging in the \npsychiatric population, with the \npsychiatry research group of Hospital \nSant Pau, and the collaboration with \nDr Giovanni Frisoni (Fatebenefratelli, \nItaly) on the use of a database of brain \ndata on Alzheimer\u2019s patients.\nMEMBERS\nSTAFF RESEARCHER\nAntonio Callen Soto, Maria Rosa \nCambra Mart\u00ed, Christian N\u00fa\u00f1ez \nLe\u00e1nez\nASSISTANT RESEARCHER\nFederica Lombardini \nCOLLABORATOR RESEARCHER\nGildas Yanin Guillaume Brebion\nSELECTED PROJECTS\n\u2022 Identificaci\u00f3 dels principals trets \nc\nerebrals associats a les etapes \nm\u00e9s primerenques de diversos \ntrastorns psiqui\u00e0trics i neurol\u00f2gics. \n(05_2020). Parc Sanitari de Sant \nJoan de D\u00e9u -Serveis de Salut Mental. 2021-2022. PI:Maria Rosa \nCambra Mart\u00ed. \n\u2022 COGNIVITRA: COGNItive VIt\nality \nTRAining at home. (AC18/00015). \nInstituto de Salud Carlos III (ISCIII). \n2019-2022. PI:Antonio Callen Soto. \n\u2022 SGR 2017: Cerebr\nal imprints of \ngender, development and pathology. \n(2017 SGR 1297). Agaur - Ag\u00e8ncia \nde Gesti\u00f3 d\u2019Ajuts Universitaris i de \nRecerca. 2017-2021. PI: Christian \nStephan-Otto Attolini. \nSELECTED CLINICAL TRIALS  \n& OBSERVATIONAL STUDIES\n\u2022 ACSF2004 - RGS@Home. (RGS@\nHome). F\nundaci\u00f3 Privada per a la \nRecerca i la Doc\u00e8ncia Sant Joan de \nD\u00e9u - FSJD. 2020PI:Antonio Callen \nSoto. \n\u2022 Estudio Pr\nospectivo No \nIntervencionista De Pacientes Con \nEnfermedad De Alzheimer Leve \nA Moderada Y Sus Cuidadores \nEn Cuatro Pa\u00edses Europeos. \n(MER-ALZ-2016-01). Merck, Sharp & Dohme de Espa\u00f1a. S.A. \n2016PI:Antonio Callen Soto.\nSELECTED PUBLICATIONS\n\u2022 Brebion G, Nu\u00f1ez C, Lombardini F, \nCarl S, S\u00e1nchez AM, Sar\na S et al. \nSubclinical depression and anxiety \nimpact verbal memory functioning \ndifferently in men and women \n-an fMRI study. J Psychiatr Res. \n2021;140:308-315. IF:4,791. (Q1).\n\u2022 Mart\u00edn Bejarano M, Ruiz B, Zamor\na \nB, Mart\u00ednez de Arag\u00f3n A, Garc\u00eda C, \nJim\u00e9nez S et al. Actividad cerebral \nen j\u00f3venes infectados por el virus de \nla inmunodeficiencia humana por \ntransmisi\u00f3n vertical: estudio piloto \nde resonancia magn\u00e9tica funcional. \nRev Neurol. 2021;72(10):343-351. \nIF:0,870. (Q4).\n\u2022 Quintas J, P\nais J, Martins AI, \nSantos H, Neves L, Sousa S et al. \nCogniViTra, a Digital Solution to \nSupport Dual-Task Rehabilitation \nTraining. Electronics. 2021;10(11)\nIF:2,397. (Q3).\n1 FOREWORD\nGovernance and structures\nGlobal numbers 2020\nGlobal numbers 2020-2015\nInstitutional awards\n7.3.1\nHealth technologies \nand innovation7.3\nTRANSVERSAL \nPROGRAM\nMedical technologies: bioinformatics and biomedical signals\nMedical technologies: computer graphics: serious games and gamification\nMedical technologies: biomaterials and tissue engineering\nMedical technologies: analysis for rehabilitation\nMedical technologies: instrumentation and eHealth\nMedical technologies: robotics and vision\nMedical technologies: biomechanics\nPatients engagement in research\nInnovation in health technologies85 INSTITUT  DE RECERCA  \nTRANSVERSAL PROGRAM\nHEALTH TECHNOLOGIES  \nAND INNOVATION\nMedical \ntechnologies: \nbioinformatics  \nand biomedical \nsignals\nAlexandre Perera Lluna, PhD\nMEMBERS\nSTAFF RESEARCHER\nJordi Fonollosa, Jon Garrido Aguirre, \nJes\u00fas Escriv\u00e1 Mu\u00f1oz, Giovana \nElizabeth Gavidia Bovadilla, Pedro \nGomis Rom\u00e1n, Alexander Vallmitjana \nLees, Montserrat Vallverd\u00fa Ferre\nPOSTDOC ASSOCIATED RESEARCHERS\nSamir Kanaan Izquierdo\nPHD STUDENTS\nPol Canal Noguer, Flavio Palmieri, \nMaria Barranco Altirriba, Angela \nLopez del Rio, Xavier Marimon Serra, \nSergi Picart Armada\nASSISTANT RESEARCHER\nPol Gil Figuerola, Joshua Llano Viles, \nPol Sola de los Santos, Laura Fincias \nMarin\nTECHNICIAN\nJoana Pal\u00e9s Huix, Enrico Manzini, \nMaria Maqueda\nSELECTED PROJECTS\n\u2022 CAIXAIMPULSE VALIDATE CI21-\n00186 Vinc\ner. AI. Fundaci\u00f3 La Caixa. \n2021-2024. PI: Alexandre Perera \nLluna.\n\u2022 Dev\nelopment of new algorithms \nfor analgesia management during \ngeneral anesthesia (2020 DI \n080). Ag\u00e8ncia De Gesti\u00f3 D\u2019ajuts \nUniversitaris I De Recerca (agaur). \n2021-2024. PI: Montserrat Vallverd\u00fa.\n\u2022 Dev\nelopment of an advisory \nsystem for the administration of \nanaesthetics and analgesics (2020 \nDI 102). Ag\u00e8ncia De Gesti\u00f3 D\u2019ajuts \nUniversitaris I De Recerca (agaur). \n2021-2024. PI: Montserrat Vallverd\u00fa.\n\u2022 \u00das de la intel\u00b7lig\u00e8ncia artificial \ni la biol\nogia de sistemes per a \nla diagnosi i l\u2019avaluaci\u00f3 de risc \npersonalitzat per a les malalties \nrenals heredit\u00e0ries, centrat en la \ns\u00edndrome d\u2019Alport (IA&biologia per \ns\u00edndrome d\u2019Alport). La Fundaci\u00f3 \nLa Marat\u00f3 de TV3. 2021-2024. PI: \nMontserrat Vallverd\u00fa.SELECTED PUBLICATIONS\n\u2022 Barranco M, Sol\u00e0 P, Picart S, \nKanaan S, F\nonollosa J, Perera \nA. mWISE: An Algorithm for \nContext-Based Annotation of \nLiquid Chromatography-Mass  \nSpectrometry Features through \nDiffusion in Graphs. Anal Chem. \n2021;93(31):10772-10778. IF:6,986. \n(Q1).\n\u2022 Lopez A, Picart S, P\nerera A. \nBalancing Data on Deep Learning-\nBased Proteochemometric Activity \nClassification. J Chem Inf Model. \n2021;61(4):1657-1669. IF:4,956. (Q1).\n\u2022 Picart S, Thompson WK, Buil A, \nP\nerera A. The effect of statistical \nnormalization on network \npropagation scores. Bioinformatics. \n2021;37(6):845-852. IF:6,937. (Q1).\n\u2022 Wei J, Y\nao J, Belke D, Guo W, \nZhong X, Sun B et al. Ca(2+)-CaM \nDependent Inactivation of RyR2 \nUnderlies Ca(2+) Alternans in Intact  \nHeart. Circ Res. 2021;128(4):63-83. \nIF:17,367. (Q1).\nMedical \ntechnologies: \ncomputer graphics: \nserious games  \nand gamification\nRa\u00fcl Ben\u00edtez Iglesias, PhD\nOur group has been granted a \nnational project for the study of \nheart fibrillation phenomena at the \ncellular and molecular levels, a \nproject in which we will be applying \npattern recognition and deep learning \ntools to analyse fluorescence \nmicroscopy images. We have signed \na collaboration agreement with Dr \nTha\u00efs Agut\u2019s Neonatal Brain research \ngroup at Sant Joan de D\u00e9u Barcelona \nChildren\u2019s Hospital, and as a result \nof our collaboration a final master\u2019s \ndegree project has been carried out. \nWe participated actively in the 3rd \nedition of the course \u201cTransversal \nProgramme in Medical Image \nPostprocess. Training Professionals: \n3D Printing to Research\u201d, financed \nby EIT Health. Additionally, we published two articles in journals \nof acknowledged prestige in \ncollaboration with the Neurogenetics \nand Molecular Medicine research \ngroup of the Sant Joan de D\u00e9u \nBarcelona Research Institute (IRSJD), \ncoordinated by Dr Francesc Palau \nand Dr Janet Hoenicka. Lastly, a \ncollaboration began with researchers \nof Amrita University (India) to develop \nnew tools for interpretation of deep \nlearning models.\nMEMBERS\nSTAFF RESEARCHER\nDolors Ayala Vallesp\u00ed, Maria Amor \nDuch Guillen, Jose Luis Egu\u00eda G\u00f3mez, \nMerc\u00e8 Ginjaume Egido, Robert Joan \nAriny\u00f3, N\u00faria Pla Garc\u00eda, Josep \nSempau Roma, Llu\u00eds Solano Albages, \nDaniela Tost Pardell, Marc Vigo \nAnglada\nPHD STUDENTS\nN\u00faria Bonet Codina, Ariel von \nBarnekow\nSELECTED PROJECTS\n\u2022 Analisis automatic o de datos \nexperimentales en fisiologia \ncardiaca. SAF2017-88019-C3-\n3-R. MINECO. 2018-2021. PI: Ra\u00fcl \nBen\u00edtez\n\u2022 An\u00e1lisis comput\nacional del impacto \nde riesgos gen\u00e9ticos y cl\u00ednicos \nen la se\u00f1alizaci\u00f3n molecular y \ndisfunciones electrofisiol\u00f3gicas \nen fibrilaci\u00f3n auricular. (PID2020-\n116927RB-C22). Ministerio de \nCiencia e Innovaci\u00f3n (MICINN). \n2021-2024. PI: Blas Echebarr\u00eda, \nRa\u00fcl Ben\u00edtez.\n\u2022 Implications of Medic\nal Low Dose \nRadiation Exposure.  (MEDIRAD). \n(H2020-755523). H2020. 2017-2022. \nPI: Merc\u00e8 Ginjaume.\n\u2022 Estimaciones de dosis \nocupacional\nes en cristalino en \ninstalaciones sanitarias y de \ninvestigaci\u00f3n (EDOCI). Propuestas \nde vigilancia radiol\u00f3gica individual. \nConsejo de Seguridad Nacional. \n2019-2022. PI: Merc\u00e8 Ginjaume. \nSELECTED PUBLICATIONS\n\u2022 Bonet N, von Barnek ow A, Mata \nMT, Gomar C, Tost D. Three-\nDimensional Game-Based \nCardiopulmonary Bypass Training. \nClin Simul Nurs. 2021;50:81. \nIF:2,391. (Q1).86 INSTITUT  DE RECERCA  \nTRANSVERSAL PROGRAM\nHEALTH TECHNOLOGIES  \nAND INNOVATION\n\u2022 Cantarero L, Ju\u00e1rez E, Civera A, \nRodriguez M, Roldan M, Ben\u00edt\nez \nR et al. Mitochondria-lysosome \nmembrane contacts are defective \nin GDAP1-related  Charcot-Marie-\nTooth disease. Hum. Mol. Genet. \n2021;29(22):3589-3605. IF:6,150. \n(Q1).\n\u2022 Civer\na A, Dominguez L, Mart\u00ednez P, \nSerrano C, Vallmitjana A, Ben\u00edtez \nR et al. Mitochondria and calcium \ndefects correlate with axonal \ndysfunction in GDAP1-related  \nCharcot-Marie-Tooth mouse model. \nNeurobiol Dis. 2021;152:105300. \nIF:5,996. (Q1).\n\u2022 Pijuan J, Rodr\u00edguez M, Nater\na \nD, Ortez CI, Altimir A, Osuna M \net al. Translational Diagnostics: \nAn In-House Pipeline to Validate \nGenetic Variants in  Children with \nUndiagnosed and Rare Diseases. \nJ Mol Diagn. 2021;23(1):71-90. \nIF:5,568. (Q1).\nMedical \ntechnologies: \nbiomaterials and \ntissue engineering\nCristina Canal Barnils, PhD\nWe were granted 3 European projects \nin 2021, as coordinators in one case, \nas well as one AEI (Spanish Research \nAgency) project. Likewise, our group \nhas an ERC Starting Grant, two  \nH2020 projects and four projects \nfrom the AEI. We published a total of \n38 articles in JCR indexed journals \nand 2 book chapters, in addition to \npresenting 11 guest lectures and 20 \npapers in international conferences. \nOur doctoral students presented a \ntotal of five theses, one in the form of \nindustrial doctorate. All five theses \nwere graded Excellent Cum Laude.\nLikewise, Dr Cristina Canal obtained \nan ICREA Academia Prize for her \nresearch career, and Dr Carles \nMas-Moruno obtained the Marcial \nMoreno-Ma\u00f1as 2020 Prize, awarded \nby the Catalan Section of the Spanish \nRoyal Society of Chemistry (RSEQ). \nSeveral of our doctoral students \nalso obtained prizes: J. M. Sadowska received the Julia Polak European \nDoctorate Award 2020 from the \nEuropean Society of Biomaterials \n(ESB) (Portugal, 06/09/2022); Llu\u00eds \nOliver won the Audience Award in the \ncompetition \u201cPresent Your Thesis in 4 \nMinutes\u201d, of the Catalan Foundation \nfor Research and Innovation (FCRI) \n(Barcelona, 22/06/2021); and Miguel \nMateu obtained the prize for the \u201cBest \nThesis Presentation\u201d at the 3rd IRSJD \nScientific Conference (Barcelona, \n28/10/2021).\nLastly, our group has two University-\nBusiness Chairs with Soadco/\nKlockner and AMES Group, as well \nas a large number of agreements \nwith companies of the biohealth and \nrelated sectors.\nMEMBERS\nSTAFF RESEARCHER\nAndrea Malandrino, Albert Espona \nNoguera, Jos\u00e9 Manuel Garc\u00eda Torres, \nMontserrat Espa\u00f1ol Pons, Francesc \nXavier Gil Mur, Jordi Guillem Mart\u00ed, \nJose Mar\u00eda Manero Planella, Carles \nMas Moruno, Marta Pegueroles Neyra, \nDaniel Rodr\u00edguez Rius\nPOSTDOC ASSOCIATED RESEARCHERS\nIrene Lodoso Torrecilla, Francesco \nTampieri, C\u00e9dric Labay, Juan Tornin \nCavielles\nPHD STUDENTS\nDavid Pi\u00f1era Avellaneda, Laura del \nMazo Barbara, Victor Chausse Calbet, \nClaudia Garc\u00eda Mintegui, Xavier Sol\u00e9 \nMart\u00ed, Mar Bonany Mari\u00f1osa, Judit \nBuxadera Palomero, Miguel Mateu \nSanz,  Konka, Joanna Magdalena, \nLlu\u00eds Oliver Cervell\u00f3, Yago Raymond \nLlorens, Elisa Rup\u00e9rez de Gracia\nTECHNICIAN\nMeritxell S\u00e1nchez Herv\u00e1s, Noelia \nAparicio B\u00e1denas, Meritxell Molmeneu \nTrias, Miquel Punset Fust\u00e9\nSELECTED PROJECTS\n\u2022 ICREA Academia. ICREA. 2021-2025. \nPI: Cris\ntina Canal.\n\u2022 PlasTHER: Therapeutic\nal \nApplications of Cold Plasmas \n(COST Action CA20114). European \nCommission. 2021-2025. PI: Cristina \nCanal.\n\u2022 SMARTGEL: Bioactiv\ne and \nmultifunctional peptide-based \nhydrogels obtained by bottom-\nup self-assembly for advanced \nbiomedical applications (PID2020-\n114019RB-I00). Agencia Estatal de Investigaci\u00f3n, Ministerio de Ciencia, \nInnovaci\u00f3n y Universidades. 2021-\n2024. PI: Carles Mas-Moruno.\nSELECTED PUBLICATIONS\n\u2022 Garc\u00eda C, C\u00f3rdoba LC, Buxadera \nJ, Mar\nquina A, Jim\u00e9nez E, Ginebra \nMP et al. Zn-Mg and Zn-Cu \nalloys for stenting applications: \nFrom nanoscale mechanical  \ncharacterization to in vitro \ndegradation and biocompatibility. \nBioact Mater. 2021;6(12):4430-4446. \nIF:14,593. (Q1).\n\u2022 Oliver L, Martin H, Re\nyes L, \nNoureddine F, Ada Cavalcanti E, \nGinebra MP et al. An Engineered \nBiomimetic Peptide Regulates Cell \nBehavior by Synergistic Integrin \nand  Growth Factor Signaling. \nAdv Healthc Mater. 2021;10(7): \ne2001757. IF:9,933. (Q1).\n\u2022 Raymond Y, Thorel E, Liv\nersain \nM, Riveiro A, Pou J, Ginebra \nM. 3D printing non-cylindrical \nstrands: Morphological and \nstructural implications. Additive \nManufacturing. 2021;46: 102129. \nIF:10,998. (Q1).\n\u2022 Tornin J, Labay C, T\nampieri F, \nGinebra MP, Canal C. Evaluation \nof the effects of cold atmospheric \nplasma and plasma-treated liquids \nin  cancer cell cultures. Nat Protoc. \n2021;16(6):2826-2850. IF:13,491. \n(Q1).\nMedical \ntechnologies: \nanalysis for \nrehabilitation\nMiquel \u00c1ngel Ma\u00f1anas Villanueva, \nPhD\nThe BIOsignal Analysis for \nRehabilitation and Therapy Research \nGroup (BIOART) has been officially \nrecognised by the Government of \nCatalonia since 2008. It is formed by \nfour professors, three post-doctoral \nresearchers, four PhD students, and \nmedical specialists in motor and \ncognitive rehabilitation, respiratory 87 INSTITUT  DE RECERCA  \nTRANSVERSAL PROGRAM\nHEALTH TECHNOLOGIES  \nAND INNOVATION\nsystem, and internal medicine. The \ngroup belongs to the Biomedical \nEngineering Research Centre (CREB, \nfrom the Catalan) of the Polytechnic \nUniversity of Catalonia (UPC).\nBetween 2020 and 2022, our group \nhas received financing from various \ncompetitive projects that has \nallowed us to strengthen our three \nresearch lines on motor, cognitive and \nrespiratory system rehabilitation, and \nto launch a new line of research on \nartificial intelligence for the support \nof decision-making in the diagnosis, \ntreatment and rehabilitation of high-\nimpact disorders. Of special note \nare a concept test of the national \nR&D&I programme addressed to \nthe challenges of society (Spanish \nMinistry of Science and Innovation), a \nTecnioSpring Industry project financed \nby the Marie Sklodowska-Curie \nActions programme (Horizon Europe), \nand a Beatriu de Pin\u00f3s post-doctoral \ngrant, all three of which were obtained \nin 2021. Our group also receives \nfunding from other projects such as \nLlavor i Producte (Seed and Product) \n(AGAUR- Government of Catalonia), \nCaixaImpulse (La Caixa Foundation), \nINNOTEC (ACCI\u00d3; Government of \nCatalonia), and the National Plan for \nScientific and Technical Research and \nfor Innovation (MINECO/MICINN).\nDuring the past year, nine articles \nwere published in JCR indexed \njournals (six in the first quartile) and \none patent was registered. Our group \nalso received the Prize for the Best \nInnovation Patent for Its Application \nto the Market, awarded by the UPC\u2019s \nSocial Council.\nMEMBERS\nSTAFF RESEARCHER\nJoan Francesc Alonso Lopez, Sergio \nRomero Lafuent\nSELECTED PROJECTS\n\u2022 Caixaimpulse validat e CI21-00242 \nMV-Optimizer (CAIXAIMPULSE \nVALIDATE CI21-00242). Fundaci\u00f3 La \nCaixa. 2021-2023. PI: Miquel \u00c1ngel \nMa\u00f1anas.\n\u2022 MYO\nARM: tecnolog\u00eda inteligente \npara la rehabilitaci\u00f3n motora \n(PDC2021-120818-I00). Agencia \nEstatal De Investigaci\u00f3n. 2021-2023. \nPI: Miquel \u00c1ngel Ma\u00f1anas.\n\u2022 Tecnol\nog\u00edas innovadoras para \nmonitorizar y personalizar la rehabilitaci\u00f3n interdisciplinar de \npacientes de cuidado intensivo \n(PID2020-117751RB-I00). Agencia \nEstatal De Investigacion. 2021-2024. \nPI: Miquel \u00c1ngel Ma\u00f1anas.\nSELECTED PUBLICATIONS\n\u2022 Marateb HR, Ziaie F, Mohebian \nMR, Sami R, Haghjoo\ny S, Dehghan \nF et al. Automatic Classification \nBetween COVID-19 and Non-\nCOVID-19 Pneumonia Using \nSymptoms,  Comorbidities, and \nLaboratory Findings: The Khorshid \nCOVID Cohort Study. Front Med \n(Lausanne). 2021;8:768467-768467. \nIF:5,091. (Q1).\n\u2022 Migliorelli C, Romer\no S, Bachiller \nA, Aparicio J, Alonso JF, Ma\u00f1anas \nMA et al. Improving the ripple \nclassification in focal pediatric \nepilepsy: identifying  pathological \nhigh-frequency oscillations by \nGaussian mixture model clustering. \nJ Neural Eng. 2021;18(4): 0460f2. \nIF:5,379. (Q1).\n\u2022 Sarmiento C\nA, Hernandez AM, \nSerna LY, Ma\u00f1anas MA. An \nintegrated mathematical model of \nthe cardiovascular and respiratory \nresponse to  exercise: model-\nbuilding and comparison with \nreported models. Am J Physiol \nHeart Circ Physiol. 2021;320(4): \nH1235-H1260. IF:4,733. (Q1).\n\u2022 Tos\nt A, Migliorelli C, Bachiller A, \nMedina IF, Romero S, Garcia A et \nal. Choosing Strategies to Deal with \nArtifactual EEG Data in Children \nwith Cognitive  Impairment. Entropy \n(Basel). 2021;23(8):1030. IF:2,524. \n(Q2).\nMedical \ntechnologies: \ninstrumentation \nand eHealth\nXavier Rosell Ferrer, PhD\nMEMBERS\nSTAFF RESEARCHER\nRamon Brag\u00f3s Badia, Mireya \nFern\u00e1ndez Chimeno, Miguel Angel Garc\u00eda Gonzalez, Miguel J Garc\u00eda \nHernandez, Lexa Nescolarde Selva, \nJuan Ramos Castro, Pere Joan Riu \nCost\nSELECTED PROJECTS\n\u2022 Integrating CARTo and multi-\nfr\nequency impedance system. \nBiosenseWebster. 2019-2022. PI: \nXavier Rosell.\n\u2022 Electr\nonic biopsy of in-vivo \nlung tissue based on electrical \nimpedance spectroscopy (RTI2018-\n098116-B-C21). Agencia Eestatal de \nInvestigaci\u00f3n. 2019-2021. PI: Ramon \nBragos Bardia.\nSELECTED PUBLICATIONS\n\u2022 Hern\u00e1ndez JA, Nesc olarde L, \nRoca E, Revuelta E, Ara J, Bayes \nA. Marathon Running Increases \nSynthesis and Decreases \nCatabolism of Joint Cartilage \nType II Collagen Accompanied by \nHigh-Energy Demands and an \nInflamatory Reaction. Front Physiol. \n2021;12:722718-722718. IF:4,566. \n(Q1). \n\u2022 Mateu M, Guede F, Rodriguez N,\n \nGarc\u00eda MA, Ramos J, Fern\u00e1ndez \nC. A non-contact camera-based \nmethod for respiratory rhythm \nextraction. Biomed. Signal Process. \nControl. 2021;66: 102443. IF:3,880. \n(Q2). \n\u2022 Rom\u00e1n E, Poc\na M, Amor\u00f3s G, \nRosell X, Gely C, Nieto JC et \nal. Phase angle by electrical \nbioimpedance is a predictive \nfactor of hospitalisation,  falls and \nmortality in patients with cirrhosis. \nSci Rep. 2021;11(1):20415-20415. \nIF:4,379. (Q1). \nMedical \ntechnologies: \nrobotics and vision\nAlicia Casals Gelpi, PhD\nIn 2021m we successfully completed \nthe SARAS project, which has \nentailed an important step forward 88 INSTITUT  DE RECERCA  \nTRANSVERSAL PROGRAM\nHEALTH TECHNOLOGIES  \nAND INNOVATION\nin the process of providing a certain \nautonomy to two robotic assistance \narms for laparoscopic surgery \nthat is carried out either manually \n(laparoscopy) or by telesurgery \n(robotics). This work has provided an \nadvance in cognitive aspects which, \nwith the knowledge of the steps of a \nspecific surgical procedure and the \ncapacity to perceive and to interpret \nthe evolution in real time, allows the \nsurgical assisting robots to carry \nout cooperatively auxiliary tasks \nthat would otherwise need to be \nperformed by one or more assistant \nsurgeons.\nIn the field of intraluminal surgery, \nexperimentation has already been \nconducted with teams of physicians \non the interface resulting from the \nstudies. We have studied the effect \non the improvement achieved as \na result of both the type of device \nused (endoscope) and the form of \npresentation of the information to the \nintervening professionals, as well as \nthe effect of each type of assistance, \neither of perception or of provision of \nautonomy to the exploratory robotic \ndevice. Work was carried out on a \ncolon simulator, which has been \ndeveloped to allow progress in this \nline, and results on a significant \nsample of specialists are now \navailable.\n2021 began with a new project in \nthe field of disability assistance, \nspecifically involving the design of \na robotised chair with the twofold \nfunction of providing mobility and \nassistance for the user\u2019s action \nas well as operativity in his or her \nsurroundings. The project comprises \ntwo different parts. On the one hand, \nthe design of the chair-exoskeleton \nitself, providing mobility, posture, \nand assistance for the action of \nthe user\u2019s arms. This entails the \nchallenge of making the human \nanatomy compatible with an external \nstructure. And on the other hand, \nthe project involves the design of \nan intelligent interface that will \nallow users with motor limitations \nto control their movement from one \nplace to another, their posture, and \ntheir arm actions in an intuitive way \nthat is adapted to their physical \nconstraints.\nLikewise, negotiations have been \nresumed to reach an understanding \non our cooperation with the \nNorwegian company Topro, after the \npostponement of the new agreement on this second phase of the process \ndue to the pandemic. Now that the \nfeasibility has been demonstrated \nof our systems for user monitoring \nsupport and walker control, which \nhave already been produced and \nassessed, this agreement will allow \nour group to carry out the robotisation \nof Topro\u2019s walkers. We have also \nbegun to work on the creation of the \ncompany that is to implement this \nproject, on the development of its \nbusiness plan, and on the process of \nits founding.\nMEMBERS\nSTAFF RESEARCHER\nJoan Aranda L\u00f3pez, Josep Fern\u00e1ndez \nRuzafa, Manel Frigola Bourlon, Enric \nXavier Mart\u00edn Rull, Antonio Benito \nMart\u00ednez Velasco\nPOSTDOC ASSOCIATED RESEARCHERS\nAlbert Hernansanz Prats\nPHD STUDENTS\nNarc\u00eds Sayols Baixeras\nTECHNICIAN\nOriol Escot\u00e9 Llu\u00eds\nCOLLABORATOR RESEARCHER\nAntonio Benedico Blanes, Carlos \nMorata, Laureano Tinoco\nSELECTED PROJECTS\n\u2022 Plataforma h\u00edbrida cadira \nr\nodes-exoesquelet (PID2020-\n116091RB-I00). Ministerio \nde Econom\u00eda, Industria y \nCompetitividad. 2021-2024. PI: Alicia \nCasals.\n\u2022 Smart . Autonomous \nRoboticAs\nsistant Surgeon (SARAS) \n(H2020-ICT-2017 Ref 77981). H2020. \n2018-2021. PI: Alicia Casals.\n\u2022 Autonomous  Intr\naluminal Surgery \n(ATLAS) (H2020-ITN 2018 REF: \n813782). H2020. 2019-2023. PI. \nAlicia Casals.\n\u2022 Caminadors el\n\u00e8ctrics. TOPRO \nIndustry. 2018-2022. PI: Antonio B \nMart\u00ednez.\nSELECTED PUBLICATIONS\n\u2022 Finocchiaro M, Cortegoso P, \nHernansanz A, Marino N, Amr\nam D, \nCasals A et al. Training Simulators \nfor Gastrointestinal Endoscopy: \nCurrent and Future Perspectives. \nCancers (Basel). 2021;13(6):1427. \nIF:6,639. (Q1).Medical \ntechnologies: \nbiomechanics\nJosep Maria Font Llagunes, PhD\nIn 2021, the BIOMEC group received \nfunding for a project of the telethon \nprogramme La Marat\u00f3  de TV3, in \ncollaboration with Sant Joan de D\u00e9u \nBarcelona Children\u2019s Hospital, and we \nwere also granted a TECNIOSpring \nIndustry project, financed by the Marie \nSklodowska-Curie Actions (Horizon \nEurope) programme. Likewise, during \nthis period, our group led projects \nin progress financed by Spanish \nResearch Agency (AEI) (Research \nChallenges), AGAUR (Product), and \nthe European Institute of Innovation \nand Technology (EIT Health). Six \narticles were published in JCR indexed \njournals in this period, 10 papers were \npresented in scientific conferences, \nand a doctoral thesis co-directed \nby a researcher of our group was \npresented at Rice University (United \nStates).\nAdditionally, our group coordinated \nthe National Network of Excellence \nin Biomechanics Research, financed \nby Spanish Research Agency (AEI) \nand formed by 10 Spanish groups in \nthe biomechanics field. We are also \nan active member of the innovation \nnetworks Xartec Salut and i4KIDS, \nled by CREB (Research Centre for \nBiomedical Engineering) and Sant \nJoan de D\u00e9u Barcelona Children\u2019s \nHospital, respectively. Lastly, Dr Josep \nMaria Font has chaired the Technical \nCommittee for Multibody Dynamics of \nthe International Federation for the \nPromotion of Mechanism and Machine \nScience (IFToMM).\nIn 2021, our research group received \nthe Polytechnic University of Catalonia \n(UPC) Prize for Social Commitment in \nthe Field of Inclusion, and a mention \nin the UPC Prize for Valorisation of \nResearch, both of which are granted \nby the UPC\u2019s Social Council.\nMEMBERS\nSTAFF RESEARCHER\nOriol Al\u00eds Gonz\u00e1lez, Ana Barjau \nCondomines, Daniel Clos Costa, Rosa \nP\u00e0mies Vil\u00e0\nPOSTDOC ASSOCIATED RESEARCHERS\nMassimo Cenciarini, Albert Peiret 89 INSTITUT  DE RECERCA  \nTRANSVERSAL PROGRAM\nHEALTH TECHNOLOGIES  \nAND INNOVATION\nGim\u00e9nez, Joan Lobo Prat\nPHD STUDENTS\nJes\u00fas de Miguel Fern\u00e1ndez, Michael \nRay Epke, Antonio Rodr\u00edguez \nFern\u00e1ndez, M\u00edriam Febrer Nafr\u00eda\nSELECTED PROJECTS\n\u2022 ArmTracker: Un sistema portable \nper av\naluar la funci\u00f3 motora de les \nextremitats superiors durant la vida \ndi\u00e0ria per a pacients amb distr\u00f2fia \nmuscular de Duchenne i atr\u00f2fia \nmuscular espinal (202023-32). La \nFundaci\u00f3 La Marat\u00f3 de TV3. 2021-\n2024. PI: Josep Maria Font.\n\u2022 ABLE Exosk\neleton (EIT_HEALTH-\n20121-ABLE). EIT Health Innovation \nProgramme (H2020, EU Comission). \n2020-2022. PI: Josep Maria Font.\n\u2022 ABLE: Exoesquel\net rob\u00f2tic que \npermet tornar a caminar de forma \nnatural i intu\u00eftiva despr\u00e9s de patir \nuna lesi\u00f3 medul\u00b7lar (2018-PROD-\n00059). AGAUR. 2019-2021. PI: \nJosep Maria Font.\n\u2022 Design of personalized r\nobotic \nand neuroprosthetic wearable \nsystems for walking assistance \nusing a predictive simulation \nframework (TAILOR) (RTI2018-\n097290-B-C33). Spanish Ministry of \nScience, Innovation and Universities \n(MICINN).  2020-2022. PI: Josep \nMaria Font.\nSELECTED PUBLICATIONS\n\u2022 Febrer-Nafr\u00eda M, Pallar\u00e8s-L\u00f3pez \nR, F\nregly BJ, Font-Llagunes JM. \nPrediction of three-dimensional \ncrutch walking patterns using a \ntorque-driven model. Multibody Syst \nDyn. 2021;51(1):1-19. IF:3,109. (Q2).\n\u2022 G\u00f3mez-P\u00e9r\nez C, Martori JC, Puig \nA, Medina J, Vidal J, Font-Llagunes \nJM. Gait event detection using \nkinematic data in children with \nbilateral spastic cerebral palsy. \nClin Biomech (Bristol, Avon). \n2021;90:105492. IF:2,063. (Q3).\n\u2022 Koch MA, Font-Llagunes JM. Lo\nwer-\nLimb Exosuits for Rehabilitation or \nAssistance of Human Movement: A \nSystematic Review. Appl Sci-Basel. \n2021;11(18): 105.492. IF:2,679. (Q2).\n\u2022 Rodr\u00edguez-Fern\u00e1ndez A, Lobo-Pr\nat \nJ, Font-Llagunes JM. Systematic \nreview on wearable lower-limb \nexoskeletons for gait training in  \nneuromuscular impairments. J \nNeuroeng Rehabil. 2021;18(1):22. \nIF:4,262. (Q1).Patients \nengagement  \nin research\nJoana Claverol Torres, MSc  \n& Begonya Nafria Escalera, MSc\nIn 2021, the Patient Participation in \nResearch Area carried out its research \nactivity in the framework of competitive \nprojects with public financing as well \nas in projects conducted with our own \nfunds, which have a direct impact on \nour institution. Notable among these \nactivities was the development of the \nPatient Participation Plan, which will \nbe implementing its first strategic plan \nin the period 2022-2024. This plan will \nallow the preparation and orientation \nof our institution\u2019s research activity \ntowards a model centred on patients\u2019 \nneeds. To this end, it will be essential \nto have patients\u2019 close involvement \nfrom the earliest phases of research \nto the final moment when the results \nof the projects are fed back to patients \nand disseminated.\nAnother initiative of note is the start \nof the Science Agora project, which \nhas the primary goal of making our \ninstitution\u2019s research initiatives \nknown, taking special care to highlight \nthe importance of involving society \nin these initiatives and to present \nthe results of the projects in clearly \nunderstandable language. \nThe scientific output of the Patient \nParticipation Area was focused in 2021 \non disseminating the results of projects \nfinanced by the European Commission \nin the field of collaborative research \nwith patients and their families in \nrelation to rare diseases (Share4Rare \nProject), the study of paediatric \npatient\u2019s preferences with respect \nto the oral formulation of medicines \n(EPTRI Project), the analysis of the \nimpact of the quarantine on Spanish \nfamilies (Kids Corona Project), the \nconceptualisation of a pan-European \nnetwork of paediatric clinical trials \n(Conect4children Project), and the \nanalysis of the needs of the various \nagents participating in research on new \nmedicines (Paradigm Project).\nMEMBERS\nSTAFF RESEARCHER\nNuria Noel Palacio, Estibaliz Urarte \nRodr\u00edguezTECHNICIAN\nElisa Mora de Checa\nSELECTED PROJECTS\n\u2022 \u00c1gora de la Ciencia. (FCT-20-16045). \nF\nundaci\u00f3n Espa\u00f1ola para la Ciencia \ny la Tecnolog\u00eda. 2021-2022. IP: \nBego\u00f1a Nafria Escalera. \n\u2022 YEAH: Youngs\nters EngAgement in \nHealth science (20624). EIT Health \ne.V. CAMPUS Citizens. 2020-2021. \nIP: Bego\u00f1a Nafria Escalera.\n\u2022 EJP RD: Eur\nopean Joint \nProgramme on Rare Diseases. \n(825575). European Commission. \n2019-2023. IP: Joana Claverol \nTorres. \n\u2022 c4c_conect4childr\nen (Collaborative \nNetwork for European Clinical Trials \nFor Children). (777389). European \nCommission. 2018-2024. IP: Joana \nClaverol Torres.\n\u2022 SHARE4RARE: Social media \nplatf\norm dedicated to rare \ndiseases, using collective \nintelligence for the generation \nof awareness and advanced \nknowledge on this large group of \ndiseases. European Commision. \n2018-2021. IP: Bego\u00f1a Nafria \nEscalera.\nSELECTED PUBLICATIONS\n\u2022 Ajanovic S, Jon A, Baro B, Balanza \nN, V\naro R, Millat P et al. How Did \nthe COVID-19 Lockdown Affect \nChildren and Adolescent\u2019s Well-\nBeing: Spanish  Parents, Children, \nand Adolescents Respond. Front \nPublic Health. 2021;9:746052. IF: \n3,709. (Q1).\n\u2022 Ales\nsandrini E, Brako F, Scarpa \nM, Lupo M, Bonifazi D, Pignataro \nV et al. Children\u2019s Preferences \nfor Oral Dosage Forms and Their \nInvolvement in Formulation  \nResearch via EPTRI (European \nPaediatric Translational Research \nInfrastructure). Pharmaceutics. \n2021;13(5):730. IF: 6,321. (Q1).\n\u2022 Faulkner SD, Sayuri S, P\nakarinen \nC, Somers F, Jose Vicente Edo \nM, Prieto L et al. Understanding \nmulti-stakeholder needs, \npreferences and expectations to \ndefine  effective practices and \nprocesses of patient engagement in \nmedicine development: A  mixed-\nmethods study. Health Expect. \n2021;24(2):601-616. IF:3,377. (Q1).90 INSTITUT  DE RECERCA  \nTRANSVERSAL PROGRAM\nHEALTH TECHNOLOGIES  \nAND INNOVATION\nInnovation  \nin health \ntechnologies\nJaume P\u00e9rez Payarols, MD, PhD\nOur group\u2019s activity in 2021 notably \nincluded the inauguration of the \nPediatric Innovation Hub (i4KIDS), \nwhich is formed by 26 institutions of \nexcellence. They are all focused on \nstrengthening paediatric research \nand innovation, and include hospitals, \nuniversities, biomedical research \ncentres and technology centres. \nLikewise, we should point out \nthe success achieved in terms of \nparticipation in the first edition of the \nPediatric Innovation Day (PID). \nIn order to comply with the new \nlegislation, HSJD\u2019s 3D Unit (3D4H) \nhas obtained the required operating \nlicence to manufacture made-to-\nmeasure orthopaedic products \nfrom the competent authority of the \nAutonomous Region, which in our \ncase is the Government of Catalonia \n(General Directorate for Health \nPlanning and Regulation). This licence \nis valid for 5 years.\nThis year Sant Joan de D\u00e9u Barcelona \nChildren\u2019s Hospital received the prize \nfor the Best Innovating Hospital at \nthe BHHSummit 2021 held by the \nBarcelona Health Hub on 28th October.\nLastly, mention should also be made \nof our new spin-off Ephion Health \nS.l., a pioneer in the use of artificial \nintelligence to monitor the evolution of \npatients with disorders affecting their \nmobility, in cooperation with Eurecat \nTechnology Centre and the Collider, \nthe Mobile World Capital Barcelona \n(MWCapital) innovation programme. \nMEMBERS\nSTAFF RESEARCHER\nMarta Ayats Soler, Carmen De la Gala \nOtero, Jos\u00e9 M. Quintill\u00e1 Mart\u00ednez, \nJosep Rubio Palau, Arian Tarbal \nRoquer, Arnau Valls Esteve \nASSISTANT RESEARCHER\nAlba Clavero Ros, Nuria Adell G\u00f3mez, \nSofia Ferreira Quartino\nTECHNICIAN\nMerc\u00e8 Francisco Bordas, Xavier Pu\u00f1et \nOrtiz, Ariadna Ballesteros Herruzo, \nPaula Ca\u00f1al VegaSELECTED PROJECTS\n\u2022 Hub d\u2019Innov aci\u00f3 Pedi\u00e0trica. (2018 \nXARDI 00011). Agaur - Ag\u00e8ncia de \nGesti\u00f3 d\u2019Ajuts Universitaris i de \nRecerca. 2020-2022. IP: Jaume \nP\u00e9rez Payarols. \n\u2022 Ecosis\ntema d\u2019 R+D+i per la \nimplementaci\u00f3 i adopci\u00f3 de la \nFabricaci\u00f3 Additiva / Impressi\u00f3 \n3D a la ind\u00fastria de Salut \n(QuirofAM). (COMRDI16-1-0011-06). \nDepartament de Salut - Generalitat \nde Catalunya. 2018-2021. IP: Arnau \nValls Esteve. \n\u2022 AC\nADOM_Assegurant la continu\u00eftat \nassistencial domicili\u00e0ria. \n(COMRDI15-1-0026). Departament \nde Salut - Generalitat de Catalunya. \n2016-2021. IP: Arnau Valls Esteve.\n\u2022 Perfil t\n\u00e9cnico en las Unidades 3D \nsanitarias. El binomio Imagen \npara el Diagn\u00f3stico y Fabricaci\u00f3n \nMec\u00e1nica, hibridaci\u00f3n de futuro en \nFP. (AFP21/00052). Ministerio de \neducaci\u00f3n. 2021-2023. IP: Arnau \nValls Esteve.\n\u2022 Families4Health (F4H), un \npr\noyecto para la formaci\u00f3n en \nh\u00e1bitos saludables para familias \ndesfavorecidas. Fundaci\u00f3n Ramon \nPrado i Pint\u00f3. 2020-2022. IP:Arian \nTarbal Roquer.\nSELECTED PUBLICATIONS\n\u2022 COVIDSurg C, Dajti I, Valenzuela \nJI, Boc\ncalatte LA, Gemelli NA, \nSmith DE et al. Machine learning \nrisk prediction of mortality for \npatients undergoing surgery with  \nperioperative SARS-CoV-2: the \nCOVIDSurg mortality score. Br \nJ Surg. 2021;108(11):1274-1292. \nIF:6,939. (Q1).\n\u2022 Quiroz MJ, Gonz\u00e1l\nez H, Palaz\u00f3n A, \nRubio J, Prat J. Amblyopia due a \ndentigerous cyst. Case report and \nliterature review. J FR OPHTALMOL. \n2021;44(8):1249-1255. IF:0,818. (Q4).\n\u2022 Vanesa V, Ir\nene MP, Ayats M, Parri \nFerrandis F, Miguel S, Mireia RM \net al. Accuracy of virtually planned \nmandibular distraction in a pediatric \ncase series. J Craniomaxillofac \nSurg. 2021;49(2):154-165. IF:2,078. \n(Q3).\n\u2022 Ver\ncruysse HJR, Rubio J, Van de \nCasteele E, Nadjmi N, De Praeter \nM, Dunaway D. Virtual planning in \nLe Fort III distraction osteogenesis: \nA case series. J Craniomaxillofac \nSurg. 2021;49(5):341-346. IF:2,078. \n(Q3).Santa Rosa, 39-57\n08950 Esplugues de Llobregat \u00b7 Barcelona\nT. 936 00 97 51\ninfo@fsjd.org\nwww.irsjd.org\n", "language": "PDF", "image": "PDF", "pagetype": "PDF", "links": "PDF"}